{"PMC7403031": [["IntroductionDecades of progress in behavioral science have led to a realization of the next steps that are needed to evolve societies in which an increasing proportion of people live productive and caring lives (O'Connell, Boat, & Warner, 2009).", [["people", "ORGANISM", 171, 177], ["people", "SPECIES", 171, 177]]], ["We argue that the accumulated evidence in the human sciences converges to show both the environmental conditions and the behavioral repertoires that maximize human well-being.", [["human", "ORGANISM", 46, 51], ["human", "ORGANISM", 158, 163], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 158, 163], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 158, 163]]], ["Progress is being made in disseminating interventions so that an increasing, albeit small, proportion of the population is being reached.", [["disseminating interventions", "TREATMENT", 26, 53], ["increasing", "OBSERVATION_MODIFIER", 65, 75], ["small", "OBSERVATION_MODIFIER", 84, 89]]], ["However, evolving societies whose goal is to support everyone's well-being will require more than the dissemination of existing interventions.", [["existing interventions", "TREATMENT", 119, 141]]], ["Evolutionary theory shows us that we can understand the change over time in all living things in terms of variation, selection, and some form of reproduction or retention.", [["retention", "PROBLEM", 161, 170]]], ["This is as true for changes in the behavior of individuals and organizations as it is for changes in the physical characteristics of organism.", [["organism", "PROBLEM", 133, 141]]], ["It explains the change over time in genetic, epigenetic, behavioral, and symbolic/verbal processes (Jablonka & Lamb, 2014; Wilson et al., 2014).", [["epigenetic, behavioral, and symbolic/verbal processes", "PROBLEM", 45, 98], ["change", "OBSERVATION_MODIFIER", 16, 22]]], ["An applied example is the long-term epigenetic changes in the intervention group receiving the Good Behavior Game that were observed in the brain-derived neurotrophic factor gene, which is related to impulsivity and aggression (Musci et al., 2014).Evolutionary theory ::: The nurture consilienceAt the same time, selection can occur at multiple levels (Henrich, 2004; Turchin, 2015; Wilson & Wilson, 2007).", [["brain", "ANATOMY", 140, 145], ["impulsivity", "DISEASE", 200, 211], ["aggression", "DISEASE", 216, 226], ["brain-derived neurotrophic factor", "GENE_OR_GENE_PRODUCT", 140, 173], ["brain-derived neurotrophic factor gene", "DNA", 140, 178], ["the intervention group", "TREATMENT", 58, 80], ["long-term epigenetic", "OBSERVATION_MODIFIER", 26, 46], ["brain", "ANATOMY", 140, 145]]], ["The cooperative tendencies of humans are thus seen as the result of the greater likelihood of survival of cooperative groups as compared to less cooperative groups (Wilson, 2019).", [["humans", "ORGANISM", 30, 36], ["humans", "SPECIES", 30, 36], ["humans", "SPECIES", 30, 36], ["cooperative", "OBSERVATION_MODIFIER", 4, 15], ["tendencies", "OBSERVATION", 16, 26]]], ["Virtually everything that we take for granted in the modern world\u2014from airplanes to medicine\u2014is the result of cooperation among unrelated individuals, and effective cooperation requires nurturing behavior among group members.Evolutionary theory ::: The nurture consilienceWhat we have learned about the psychological, behavioral, and physical health of humans can all be understood in terms of evolution.", [["humans", "ORGANISM", 353, 359], ["humans", "SPECIES", 353, 359], ["humans", "SPECIES", 353, 359]]], ["An evolutionary framework can organize our thinking about the human condition in ways that not only reduce individual suffering but also lay the foundation for the evolution of a society that does a better job of ensuring the well-being of all of its members.Coercion and fast and slow development ::: The nurture consilienceWe can explain differences in developmental trajectories as a function of the quality of the young person's social environment (Ellis et al., 2012; Ellis & Bjorklund, 2012).", [["human", "ORGANISM", 62, 67], ["human", "SPECIES", 62, 67], ["person", "SPECIES", 424, 430], ["human", "SPECIES", 62, 67]]], ["\u201cFast life\u201d versus \u201cslow life\u201d outcomes among humans are evolutionary adaptions of humans to two distinct social and ecological contexts.", [["humans", "ORGANISM", 46, 52], ["humans", "ORGANISM", 83, 89], ["humans", "SPECIES", 46, 52], ["humans", "SPECIES", 83, 89], ["humans", "SPECIES", 46, 52], ["humans", "SPECIES", 83, 89]]], ["Environments with high levels of conflict and stress promote a \u201cfast life\u201d trajectory that involves a lack of self-regulation, a high level of risk-taking, the development of antisocial and violent behavior, academic failure, and a greater likelihood of depression, as well as the development of inflammatory processes that contribute to metabolic syndrome, diabetes, cardiovascular disease, and ultimately premature death (Ellis et al., 2012; Ellis & Bjorklund, 2012; Miller, Chen, & Parker, 2011).Coercion and fast and slow development ::: The nurture consilienceBehavior analysis has provided an in-depth understanding of the nature of the environments that lead to \u201cfast life\u201d developmental trajectories (Patterson, Reid, & Dishion, 1992; Sidman, 1989).", [["cardiovascular", "ANATOMY", 368, 382], ["antisocial and violent behavior", "DISEASE", 175, 206], ["depression", "DISEASE", 254, 264], ["metabolic syndrome", "DISEASE", 338, 356], ["diabetes", "DISEASE", 358, 366], ["cardiovascular disease", "DISEASE", 368, 390], ["premature death", "DISEASE", 407, 422], ["cardiovascular", "ANATOMICAL_SYSTEM", 368, 382], ["antisocial and violent behavior", "PROBLEM", 175, 206], ["academic failure", "PROBLEM", 208, 224], ["depression", "PROBLEM", 254, 264], ["inflammatory processes", "PROBLEM", 296, 318], ["metabolic syndrome", "PROBLEM", 338, 356], ["diabetes", "PROBLEM", 358, 366], ["cardiovascular disease", "PROBLEM", 368, 390], ["ultimately premature death", "PROBLEM", 396, 422], ["depression", "OBSERVATION", 254, 264], ["inflammatory", "OBSERVATION", 296, 308], ["metabolic syndrome", "OBSERVATION", 338, 356], ["cardiovascular", "ANATOMY", 368, 382]]], ["Each person's aversive behavior is reinforced by the cessation of the other's aversive behavior, reinforcing the use of this behavior as a means to resolve conflicts.", [["person", "SPECIES", 5, 11]]], ["Research has shown that chronically coercive interactions in families predict the development of the just-mentioned constellation of psychological, behavioral, and health problems (Dishion, Patterson, & Kavanagh, 1992; Granic & Patterson, 2006; Miller et al., 2011; Van Ryzin & Dishion, 2013).", [["psychological, behavioral, and health problems", "DISEASE", 133, 179], ["chronically", "OBSERVATION_MODIFIER", 24, 35], ["coercive", "OBSERVATION", 36, 44]]], ["The consilience of this analysis with evolutionary theory is further shown by the fact that children on this trajectory are more likely to have children at an early age (Ellis et al., 2012).", [["children", "ORGANISM", 92, 100], ["children", "ORGANISM", 144, 152], ["children", "SPECIES", 92, 100], ["children", "SPECIES", 144, 152], ["this analysis", "TEST", 19, 32]]], ["Apparently, the fast life strategy has had value in our evolutionary history; in a threatening world, you should have your babies early or you may not have them at all.Coercion and fast and slow development ::: The nurture consilienceOn the other hand, nurturing environments, as defined above, promote a \u201cslow life\u201d developmental pathway in which children develop skills in self-regulation, cooperation, and resilience, all of which enable children to learn and contribute to the well-being of society.", [["children", "ORGANISM", 348, 356], ["children", "ORGANISM", 441, 449], ["children", "SPECIES", 348, 356], ["children", "SPECIES", 441, 449]]], ["This pathway has been labeled \u201cslow\u201d because it involves a longer period of time for the person to develop the prosocial skills needed to function as cooperative member of society.", [["person", "SPECIES", 89, 95]]], ["Nurturing environments provide numerous occasions in which children are reinforced for delaying immediate gratification or inhibiting impulsive behavior (Murray, Rosanbalm, Christopoulos, & Meyer, 2019).", [["children", "ORGANISM", 59, 67], ["children", "SPECIES", 59, 67]]], ["A more detailed description of these terms is outside the scope of this paper, but noting the overlap is important for the broad implications of interventions that can improve self-regulatory skills.", [["interventions", "TREATMENT", 145, 158]]], ["Psychological flexibility and delay discounting have both been shown to be related to well-being, more effective functioning, and lower levels of a wide variety of psychological and behavioral problems and diagnoses (Amlung et al., 2019; Bickel, Jarmolowicz, Mueller, Koffarnus, & Gatchalian, 2012; Gloster, Meyer, & Lieb, 2017; Kashdan & Rottenberg, 2010; Lempert, Steinglass, Pinto, Kable, & Simpson, 2019; Levin et al., 2014; Levin, Haeger, Ong, & Twohig, 2018).Clinical psychology ::: The nurture consilienceIn many ways, research in clinical psychology has been foundational for understanding the basis of nurturance.", [["Psychological flexibility", "PROBLEM", 0, 25], ["psychological and behavioral problems", "PROBLEM", 164, 201]]], ["Some of the earliest work in psychotherapy showed the beneficial effects of the therapists' empathy, genuiness and warmth (Carkhuff & Truax, 1965).", [["genuiness", "PROBLEM", 101, 110], ["warmth", "PROBLEM", 115, 121], ["warmth", "OBSERVATION_MODIFIER", 115, 121]]], ["Systematic desensitization (Wolpe, 1963) was a matter of creating conditions in which people could increase their comfort enough to approach stimuli they had been fearful of.", [["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92], ["Systematic desensitization", "TREATMENT", 0, 26], ["creating conditions", "PROBLEM", 57, 76]]], ["Lewinsohn's work on depression (Lewinsohn, Biglan, & Zeiss, 1976) showed that depression could be alleviated by increasing a person's contact with positively reinforcing contingencies.Clinical psychology ::: The nurture consilienceMore recently, evidence has accumulated that psychological \u201cdisorders\u201d can be largely understood in terms of efforts to avoid threatening or aversive experiences (Hayes, Strosahl, & Wilson, 2016).", [["depression", "DISEASE", 20, 30], ["depression", "DISEASE", 78, 88], ["person", "SPECIES", 125, 131], ["depression", "PROBLEM", 20, 30], ["depression", "PROBLEM", 78, 88], ["psychological \u201cdisorders", "PROBLEM", 276, 300], ["depression", "OBSERVATION", 78, 88]]], ["Clinical research on the treatment of diverse disorders shows that when people are helped to become willing to experience, rather than avoid, psychological or physical aversive sensations and to pursue a set of chosen values, their pain diminishes and the meaning and joy in their lives is enhanced (A-Tjak et al., 2015; Atkins et al., 2017; Jim\u00e9nez, 2012).", [["pain", "DISEASE", 232, 236], ["people", "ORGANISM", 72, 78], ["people", "SPECIES", 72, 78], ["diverse disorders", "PROBLEM", 38, 55], ["psychological or physical aversive sensations", "PROBLEM", 142, 187], ["their pain", "PROBLEM", 226, 236]]], ["Moreover, it appears that when people are encouraged to freely choose their values rather than adopt the values that they perceive others demand that they live by, they typically choose a set of prosocial values that involve caring relationships with others (Gagn\u00e9, 2003; Sheldon, Arndt, & Houser-Marko, 2003).Prevention science ::: The nurture consilienceThe importance of nurturance for human well-being is further supported by evidence from prevention science.", [["people", "ORGANISM", 31, 37], ["human", "ORGANISM", 389, 394], ["people", "SPECIES", 31, 37], ["human", "SPECIES", 389, 394], ["human", "SPECIES", 389, 394]]], ["Over the past forty years, a large body of evidence has accumulated about the family, school, and community interventions that can prevent the \u201cfast life\u201d developmental trajectory (Biglan, 2015; Biglan, Van Ryzin, & Hawkins, 2017; Biglan, Van Ryzin, Moore, Mauricci, & Mannan, 2019; Van Ryzin, Fishbein, & Biglan, 2018).Prevention science ::: The nurture consiliencePreventive family interventions grew out of clinical work with children with behavioral disorders (e.g., Patterson, 1974).", [["behavioral disorders", "DISEASE", 443, 463], ["children", "ORGANISM", 429, 437], ["children", "SPECIES", 429, 437], ["community interventions", "TREATMENT", 98, 121], ["Preventive family interventions", "TREATMENT", 366, 397], ["behavioral disorders", "PROBLEM", 443, 463], ["large", "OBSERVATION_MODIFIER", 29, 34]]], ["Parental behavior is important in affecting the intergenerational transmission of self-regulatory skills or deficits (Bridgett, Burt, Edwards, & Deater-Deckard, 2015).", [["deficits", "PROBLEM", 108, 116]]], ["Leslie et al. (2016) describe sixteen family interventions that have been shown to prevent most of the common and costly psychological and behavioral problems.", [["sixteen family interventions", "TREATMENT", 30, 58], ["behavioral problems", "PROBLEM", 139, 158]]], ["This is especially true for the children exposed to the highest levels of neighborhood violence and victimization (Vazsonyi, Belliston, & Flannery, 2004).Prevention science ::: The nurture consilienceAll of these interventions reduce the use of aversive or punitive behavior, limit opportunities and influences for problem behavior, and increase positive reinforcement for diverse forms of prosocial behavior (Biglan et al., 2012).Social psychology ::: The nurture consilienceResearch in social psychology lines up with this observation.", [["children", "ORGANISM", 32, 40], ["children", "SPECIES", 32, 40], ["these interventions", "TREATMENT", 207, 226], ["punitive behavior", "PROBLEM", 257, 274], ["problem behavior", "PROBLEM", 315, 331], ["increase positive reinforcement", "TREATMENT", 337, 368], ["this observation", "TEST", 520, 536]]], ["Kasser (2006), Kasser, 2016; Sheldon & Kasser, 2008) has summarized extensive evidence that people generally embrace one of two sets of values.", [["people", "ORGANISM", 92, 98], ["people", "SPECIES", 92, 98]]], ["Consistent with the previously described analysis of fast and slow developmental pathways, values having to do with materialism\u2014\u201cI want to be rich, I want to be famous\u201d\u2014are more likely to be endorsed when people are living in threatening circumstances, where having wealth and fame may contribute to survival.", [["people", "ORGANISM", 205, 211], ["people", "SPECIES", 205, 211], ["fast and slow developmental pathways", "PROBLEM", 53, 89]]], ["However, people who adopt this constellation of wealth and status values have greater psychological and behavioral distress.", [["psychological and behavioral distress", "DISEASE", 86, 123], ["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15], ["behavioral distress", "PROBLEM", 104, 123]]], ["On the other hand, in more nurturing circumstances, people are likely to endorse prosocial values that involve contributing to the well-being of others (Kasser, Ryan, Zax, & Sameroff, 1995).Public health ::: The nurture consiliencePublic health is a system for enhancing the well-being of entire populations.", [["people", "ORGANISM", 52, 58], ["people", "SPECIES", 52, 58]]], ["It evolved out of efforts to control epidemic diseases like polio but has expanded to address the incidence and prevalence of psychological and behavioral problems as well as physical health.", [["polio", "DISEASE", 60, 65], ["epidemic diseases", "PROBLEM", 37, 54], ["polio", "PROBLEM", 60, 65], ["psychological and behavioral problems", "PROBLEM", 126, 163]]], ["Moreover, it focuses on the prevalence of any environmental condition that affects the incidence or prevalence of human problems, which can include the marketing of tobacco, alcohol, and unhealthful foods, poverty, or discrimination against groups (Biglan, Van Ryzin, & Westling, 2019).Public health ::: The nurture consilienceAs our recent experience with the novel coronavirus COVID-19 has shown, the public health framework is vital to any effort to improve human well-being because it demands that we monitor and affect the incidence and prevalence of problems in entire populations, rather than simply focusing on the well-being of individuals (Biglan, 2015).Economics ::: The nurture consilienceIt will be impossible to increase the prevalence of nurturing environments if we do not understand the evolution of economic conditions and their impact on human well-being.", [["alcohol", "CHEMICAL", 174, 181], ["alcohol", "CHEMICAL", 174, 181], ["human", "ORGANISM", 114, 119], ["tobacco", "ORGANISM", 165, 172], ["alcohol", "SIMPLE_CHEMICAL", 174, 181], ["coronavirus", "ORGANISM", 367, 378], ["human", "ORGANISM", 461, 466], ["individuals", "ORGANISM", 637, 648], ["human", "ORGANISM", 857, 862], ["coronavirus COVID-19", "DNA", 367, 387], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 461, 466], ["human", "SPECIES", 857, 862], ["human", "SPECIES", 114, 119], ["tobacco", "SPECIES", 165, 172], ["human", "SPECIES", 461, 466], ["human", "SPECIES", 857, 862], ["human problems", "PROBLEM", 114, 128], ["the novel coronavirus COVID", "TEST", 357, 384], ["economic conditions", "PROBLEM", 817, 836]]], ["In the United States, and increasingly around the world, we have evolved a form of capitalism that makes the maximization of profits the singular goal of business enterprises (Biglan, 2020a).", [["capitalism", "OBSERVATION", 83, 93]]], ["This is the result of extensive and stealthy advocacy for the theory that the individual and corporate pursuit of economic gain will necessarily benefit others (Mayer, 2016).", [["extensive", "OBSERVATION_MODIFIER", 22, 31]]], ["Our ability to evolve societies that nurture the well-being of every person will be limited if we do not reform the values and priorities of each sector of society (Kasser, Cohn, Kanner, & Ryan, 2007).A word about terminology ::: The nurture consilienceAlthough there are many other terms that might be used to communicate the vast, interdisciplinary network of findings that help us understand what humans need to thrive, we have labeled this synthesis the \u201cNurture Consilience\u201d based on our own work on this issue (Biglan, 2015; Biglan et al., 2012; Komro et al., 2011).", [["humans", "ORGANISM", 400, 406], ["person", "SPECIES", 69, 75], ["humans", "SPECIES", 400, 406], ["humans", "SPECIES", 400, 406]]], ["There is a strong need to bring diverse disciplines together around a shared understanding of what humans need to thrive and how we can evolve societies that support their well-being.", [["humans", "ORGANISM", 99, 105], ["humans", "SPECIES", 99, 105], ["humans", "SPECIES", 99, 105]]], ["If the scientific community intends to make use of this knowledge to evolve societies in nurturing directions, it will be important to get not only the scientific community, but societies as a whole to understand and embrace this analysis.", [["this analysis", "TEST", 225, 238]]], ["Thus, a first step in advancing this understanding would be to settle on a label for this effort.Scaling up and scaling outAlthough it has not been defined with precision, prevention science has developed a concept known as scaling up that refers to the process of moving from an individually focused intervention to the application or dissemination of that intervention to affect an entire population.", [["the application", "TREATMENT", 317, 332], ["that intervention", "TREATMENT", 353, 370], ["scaling", "OBSERVATION_MODIFIER", 112, 119]]], ["As prevention science has accumulated a large array of tested and effective interventions, the field has increasingly turned to the question of how those interventions could be so widely applied that they affect entire populations.", [["effective interventions", "TREATMENT", 66, 89], ["large", "OBSERVATION_MODIFIER", 40, 45], ["array", "OBSERVATION_MODIFIER", 46, 51]]], ["Examples of these efforts include (a) the implementation of the PAX Good Behavior Game in more than 40,000 elementary school classrooms worldwide that grew out of the studies by Sheppard Kellam and colleagues (Kellam et al., 2012), which showed the long term benefit of the Good Behavior Game; (b) the efforts of Wilson, Atkins, and Hayes to disseminate the Ostrom Principles (Wilson, Ostrom, & Cox, 2013) by integrating behavior change techniques from clinical psychology (Polk & Schoendorff, 2014), to help small groups function more effectively (Atkins, Wilson, & Hayes, 2019); (c) the extensive work that is being done to disseminate clinical interventions derived from Acceptance and Commitment Therapy (Hayes et al., 2016) that focus on promoting psychological flexibility (Brown, Glendenning, Hoon, & John, 2016; Hayes, 2019; Tol et al, 2020); and (d) our own efforts to increase the prevalence of nurturing environments by enhancing the developmental contexts of children and youth (Biglan, 2020a; Biglan, Van Ryzin, Moore, et al., 2019; Biglan, Van Ryzin, & Westling, 2019; Van Ryzin et al., 2020; Van Ryzin, Roseth, Fosco, Lee, & Chen, 2016).Scaling up and scaling outAlthough the emphasis in this work has generally been on scaling up to affect an increasing proportion of the population via a single channel (e.g., schools, the health care system, the mental health system, the criminal justice system), there is another facet of dissemination that might be labeled scaling out.", [["children", "ORGANISM", 971, 979], ["children", "SPECIES", 971, 979], ["the studies", "TEST", 163, 174], ["another facet of dissemination", "PROBLEM", 1425, 1455], ["long term", "OBSERVATION_MODIFIER", 249, 258], ["scaling", "OBSERVATION_MODIFIER", 1167, 1174], ["facet", "OBSERVATION_MODIFIER", 1433, 1438], ["dissemination", "OBSERVATION", 1442, 1455]]], ["This involves creating an impact in sectors of society other than the one in which the intervention or practice originated.", [["the intervention", "TREATMENT", 83, 99], ["impact", "OBSERVATION_MODIFIER", 26, 32]]], ["Aarons, Sklar, Mustanski, Benbow, and Brown (2017) suggest three variants of scaling out; (a) targeting the same population as the intervention was developed for, but using a different delivery method; (b) targeting a different population, using the same delivery method; (c) changing both target population and delivery method.", [["a different delivery method", "TREATMENT", 173, 200], ["a different population", "TREATMENT", 216, 238], ["the same delivery method", "TREATMENT", 246, 270], ["delivery method", "TREATMENT", 312, 327], ["Sklar", "ANATOMY", 8, 13], ["Mustanski", "ANATOMY", 15, 24]]], ["Our use of the term \u201cscaling out\u201d is clearly related, but also more general in that we advocate spreading practices that lead to similar outcomes - increased levels of nurturance - across all sectors of society.Scaling up and scaling outFor example, the rapid expansion of the PAX Good Behavior Game to elementary schools around the USA and around the world has recently begun to be accompanied by attention to how the generic practices of PAX could be useful in families, the criminal justice system, and business (Johansson, Biglan, & Embry, in press).", [["PAX", "GENE_OR_GENE_PRODUCT", 440, 443], ["PAX", "PROTEIN", 440, 443], ["increased levels of nurturance", "PROBLEM", 148, 178], ["rapid", "OBSERVATION_MODIFIER", 254, 259], ["expansion", "OBSERVATION_MODIFIER", 260, 269]]], ["The same evidence-based kernels that work in the classroom, for example, may also work in families, after-school settings, and community settings serving children (Embry & Biglan, 2008; E. P. Smith, Faulk, & Sizer, 2016; Smith, Osgood, Oh, & Caldwell, 2018; E. P. Smith & Bradshaw, 2017; Szabo, Richling, Embry, Biglan, & Wilson, 2020).Scaling up and scaling outEvolving societies in which the vast majority of people are experiencing nurturing conditions requires both types of scaling.", [["children", "ORGANISM", 154, 162], ["people", "ORGANISM", 411, 417], ["children", "SPECIES", 154, 162], ["people", "SPECIES", 411, 417], ["E. P. Smith, Faulk, & Sizer, 2016; Smith, Osgood, Oh, & Caldwell, 2018; E. P. Smith & Bradshaw, 2017", "SPECIES", 186, 286], ["scaling", "OBSERVATION_MODIFIER", 351, 358], ["societies", "OBSERVATION", 371, 380]]], ["Because the need for scaling up is increasingly understood and is progressing, we will focus here on the issue of scaling out.Business ::: The impact of free market advocacy on societyJane Mayer provides an excellent historical overview of the fifty-year advocacy for free-market economics that was conducted by a network of wealthy business people primarily in the U.S. (Mayer, 2016).", [["people", "ORGANISM", 342, 348], ["people", "SPECIES", 342, 348], ["free", "OBSERVATION_MODIFIER", 153, 157]]], ["By 1997, the Business Roundtable, which includes the largest American corporations, formally adopted this principle (The Business Roundtable, 1997).Business ::: The impact of free market advocacy on societyAdvocates for free-market ideology called for minimum regulation of business and reduction in the size of government.", [["largest", "OBSERVATION_MODIFIER", 53, 60], ["free", "OBSERVATION_MODIFIER", 175, 179], ["reduction", "OBSERVATION_MODIFIER", 287, 296], ["size", "OBSERVATION_MODIFIER", 304, 308]]], ["They include 480,000 people a year who die of smoking-related illness (Biglan, 2020e; Centers for Disease Control and Prevention, 2018), the opioid epidemic that has killed more than 350,000 people (Biglan, 2020b; National Institute on Drug Abuse, 2019), the marketing of unhealthful food that has created an epidemic of obesity and diabetes (Biglan, 2020c; Moss, 2013) and is shortening the life expectancy of children (Olshansky et al., 2005), the practices of the financial industry that resulted in the 2008 Great Recession (Lewis, 2010), and the failure to reduce greenhouse gas emissions in the face of scientific consensus on the dangers of climate change (Biglan, 2020a, Biglan, 2020c).The healthcare system ::: The impact of free market advocacy on societyDuring the time in which free-market advocacy came to dominate society, we have experienced a dramatic increase in health care expenses and a reduction in American's health.", [["smoking", "CHEMICAL", 46, 53], ["illness", "DISEASE", 62, 69], ["obesity", "DISEASE", 321, 328], ["diabetes", "DISEASE", 333, 341], ["people", "ORGANISM", 21, 27], ["children", "ORGANISM", 411, 419], ["people", "SPECIES", 21, 27], ["people", "SPECIES", 191, 197], ["children", "SPECIES", 411, 419], ["Disease Control", "TREATMENT", 98, 113], ["obesity", "PROBLEM", 321, 328], ["diabetes", "PROBLEM", 333, 341], ["the failure", "PROBLEM", 547, 558], ["greenhouse gas emissions", "PROBLEM", 569, 593], ["epidemic", "OBSERVATION_MODIFIER", 309, 317], ["obesity", "OBSERVATION", 321, 328], ["diabetes", "OBSERVATION", 333, 341], ["free", "OBSERVATION_MODIFIER", 734, 738], ["dramatic", "OBSERVATION_MODIFIER", 859, 867], ["increase", "OBSERVATION_MODIFIER", 868, 876]]], ["In the U.S., salaries of physicians have risen faster than inflation and are higher than in any other country (Daggett, 2017; Rampell, 2009).", [["higher", "OBSERVATION_MODIFIER", 77, 83]]], ["Health insurance company profits and executive salaries have increased dramatically in recent years (Herman, 2017; Small, 2017).", [["increased", "OBSERVATION_MODIFIER", 61, 70], ["dramatically", "OBSERVATION_MODIFIER", 71, 83]]], ["The same is true of the pharmaceutical industry (Krantz, 2016).", [["true", "OBSERVATION_MODIFIER", 12, 16], ["pharmaceutical", "OBSERVATION_MODIFIER", 24, 38]]], ["The over-prescription of opioids, anti-depressive medication, psychostimulants for children, and antibiotics has increased even as research documented the harm of such practices (Gotzsche, 2013).The healthcare system ::: The impact of free market advocacy on societyPresently, the contingencies of reinforcement do not favor the actual health of the patients or the larger community.", [["opioids", "SIMPLE_CHEMICAL", 25, 32], ["children", "ORGANISM", 83, 91], ["patients", "ORGANISM", 350, 358], ["children", "SPECIES", 83, 91], ["patients", "SPECIES", 350, 358], ["opioids", "TREATMENT", 25, 32], ["anti-depressive medication", "TREATMENT", 34, 60], ["psychostimulants", "TREATMENT", 62, 78], ["antibiotics", "TREATMENT", 97, 108], ["free", "OBSERVATION_MODIFIER", 235, 239]]], ["Fig. 1shows how a huge bureaucracy has evolved during the ascendancy of free-market advocacy and the accompanying reduction in American longevity.", [["huge", "OBSERVATION_MODIFIER", 18, 22], ["bureaucracy", "OBSERVATION", 23, 34], ["reduction", "OBSERVATION_MODIFIER", 114, 123]]], ["In short, the players in the health care system have selected practices that benefit them, but have ignored their impact on the nation's health (Reinhardt, 2019).Higher education ::: The impact of free market advocacy on societyColleges and universities are not acting in light of their impact on the prevalence of well-being.", [["short", "OBSERVATION_MODIFIER", 3, 8], ["free", "OBSERVATION_MODIFIER", 197, 201]]], ["In addition, the contingencies of many private enterprise higher-education entities were deliberately designed to take advantage of students.Higher education ::: The impact of free market advocacy on societyMore generally, higher education is not educating the workforce that is needed to help communities and sectors of society advance nurturance (Grant, 2016).", [["free", "OBSERVATION_MODIFIER", 176, 180]]], ["However, the problems we face now will not be solved by new technologies, but by the broad application of the science of human behavior.", [["human", "ORGANISM", 121, 126], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126]]], ["The behavioral sciences receive less than 10% of federal funding for research (Biglan, 2020a), yet it is the science of human behavior that has the knowledge to educate a generation of young people to acquire the skills and competencies to evolve more nurturing societies.Criminal justice ::: The impact of free market advocacy on societyThe U.S. has the highest level of incarceration of any country in the world (\u201cList of countries by incarceration rate,\u201d, 2019).", [["human", "ORGANISM", 120, 125], ["people", "ORGANISM", 191, 197], ["human", "SPECIES", 120, 125], ["people", "SPECIES", 191, 197], ["human", "SPECIES", 120, 125], ["free", "OBSERVATION_MODIFIER", 307, 311], ["incarceration", "OBSERVATION", 372, 385]]], ["Incarceration has intergenerational effects.", [["Incarceration", "DISEASE", 0, 13], ["Incarceration", "PROBLEM", 0, 13]]], ["Our punitive system undermines family well-being by incarcerating people who could be breadwinners for their family and by traumatizing the children of adults caught up in the system (Morsy & Rothstein, 2016).", [["people", "ORGANISM", 66, 72], ["children", "ORGANISM", 140, 148], ["people", "SPECIES", 66, 72], ["children", "SPECIES", 140, 148]]], ["The punitive system results in high levels of recidivism, and this system remains in place despite the fact that more nurturing practices have been found to be far more effective (Lipsey, Wilson, & Cothern, 2000).Criminal justice ::: The impact of free market advocacy on societyThis situation is not entirely due to free-market advocacy.", [["The punitive system", "TEST", 0, 19], ["high levels of recidivism", "PROBLEM", 31, 56], ["this system", "TREATMENT", 62, 73], ["high levels", "OBSERVATION_MODIFIER", 31, 42], ["free", "OBSERVATION_MODIFIER", 248, 252]]], ["Moreover, economic policy has increased poverty, which contributes to crime.The political system ::: The impact of free market advocacy on societyBehavioral scientists have traditionally been loath to get involved in politics, at least in their role as scientists.", [["increased", "OBSERVATION_MODIFIER", 30, 39], ["free", "OBSERVATION_MODIFIER", 115, 119]]], ["However, our political system consists of a set of cultural practices whose evolution can be understood in the same way that other aspects of society can.", [["cultural practices", "TREATMENT", 51, 69]]], ["That their investment has reaped benefits is documented by Fig. 2, which shows the increase in income of the top 1% of households (Alvaredo, Chancel, Piketty, Saez, & Zucman, 2017) compared to the bottom 50%.", [["increase", "OBSERVATION_MODIFIER", 83, 91]]], ["Advocacy for policies that benefit the wealthy has been richly rewarded and it is undermining our democratic system.The political system ::: The impact of free market advocacy on societyThe impact of public policy on general well-being needs to be routinely scrutinized and widely reported.", [["free", "OBSERVATION_MODIFIER", 155, 159]]], ["We also need to articulate the contingencies that have allowed a small group of the very wealthy to have such influence on policymaking, and we need to support research and practical action on how we can change those contingencies.The promotion of prosocial values ::: Evolving more nurturing societiesAn airline passenger does not need to know anything about the science of aviation in order to enjoy the benefits of that science.", [["airline", "OBSERVATION", 305, 312]]], ["The beneficiaries of effective clinical and preventive interventions adopt an orientation that is consistent with that scientific consensus.", [["preventive interventions", "TREATMENT", 44, 68], ["consistent with", "UNCERTAINTY", 98, 113]]], ["Much of the spread of these values and behaviors is resulting from the scaling up of these interventions.", [["these interventions", "TREATMENT", 85, 104], ["spread", "OBSERVATION_MODIFIER", 12, 18]]], ["We can learn from the free-market advocates who funded programs promoting their views in major universities and through the cultivation of careers in academia, business, and the media of people who were skilled at promoting business-friendly views (Mayer, 2016).", [["people", "ORGANISM", 187, 193], ["people", "SPECIES", 187, 193]]], ["Similarly, behavioral scientists and practitioners need to educate a generation of people who understand and can advocate for the science of human well-being and its implications for every sector of society.", [["people", "ORGANISM", 83, 89], ["human", "ORGANISM", 141, 146], ["people", "SPECIES", 83, 89], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 141, 146]]], ["In other words, we are not saying that prosocial values are the one TRUE set of values.", [["prosocial values", "TEST", 39, 55]]], ["You might explain to a person the benefit to the general well-being of prosocial values, but that person would be free to respond that they understand that prosociality, as opposed to self-centered values, will benefit a larger proportion of society, but they still want to have a society in which some people are able to amass huge wealth, even if others' well-being is diminished.The promotion of prosocial values ::: Evolving more nurturing societiesAlthough we cannot claim that science proves that prosocial values are the one true set of values, we can advance these values by educating people about their benefit.", [["prosociality", "DISEASE", 156, 168], ["people", "ORGANISM", 303, 309], ["people", "ORGANISM", 593, 599], ["person", "SPECIES", 23, 29], ["person", "SPECIES", 98, 104], ["people", "SPECIES", 303, 309], ["people", "SPECIES", 593, 599], ["diminished", "PROBLEM", 371, 381], ["prosocial values", "TEST", 503, 519], ["diminished", "OBSERVATION", 371, 381]]], ["As American society has become more secular, a gulf between religious and secular communities has arisen (Putnam & Campbell, 2012).", [["more secular", "OBSERVATION_MODIFIER", 31, 43]]], ["In sum, we believe that scaling up and scaling out the framework of the Nurture Consilience across all sectors of society will contribute to the wealth, safety, health, freedom, and political stability of any nation that makes use of this knowledge.Monitoring the impact of each sector on wellbeing ::: Evolving more nurturing societiesUsing public health practices, we can readily measure the degree to which any given practice is (or is not) harming people.", [["people", "ORGANISM", 452, 458], ["people", "SPECIES", 452, 458]]], ["We already do this for cigarettes, guns, alcohol, unhealthful foods, and some aspects of economic policy.", [["alcohol", "CHEMICAL", 41, 48], ["alcohol", "CHEMICAL", 41, 48], ["alcohol", "SIMPLE_CHEMICAL", 41, 48]]], ["We have systems for monitoring psychological, behavioral, and physical health as well, but they are generally not available at the level of communities and are not linked to the impact of public policy and organizational practices to the extent that they need to be.Monitoring the impact of each sector on wellbeing ::: Evolving more nurturing societiesConsider what could happen if every sector of society examined how its practices were affecting well-being.", [["organizational practices", "TREATMENT", 206, 230]]], ["Careful monitoring of the well-being of the population would enable a business to identify which of its practices affect population well-being; examples include the degree of well-being of its employees, the marketing of unhealthful products, and support of the business community for the private and public sector efforts to make effective preventive interventions widely available.", [["Careful monitoring", "TEST", 0, 18], ["unhealthful products", "TREATMENT", 221, 241], ["effective preventive interventions", "TREATMENT", 331, 365]]], ["The criminal justice system could be charged with monitoring the rate of juvenile and adult crime, the rate of recidivism, as well as the harm to children who are affected by parental involvement in the system.", [["juvenile and adult crime", "DISEASE", 73, 97], ["children", "ORGANISM", 146, 154], ["children", "SPECIES", 146, 154], ["criminal justice", "OBSERVATION", 4, 20]]], ["Such data would direct their attention to these issues and lay the groundwork for selecting strategies to move these numbers in the right direction.Monitoring the impact of each sector on wellbeing ::: Evolving more nurturing societiesSchools are already tracking the academic and, to a lesser extent, the social development of students.", [["selecting strategies", "TREATMENT", 82, 102], ["right", "ANATOMY_MODIFIER", 132, 137], ["lesser extent", "OBSERVATION_MODIFIER", 287, 300]]], ["Higher education could pay greater attention to whether it is training people who have the skills to promote the evolution of greater nurturance.", [["people", "ORGANISM", 71, 77], ["people", "SPECIES", 71, 77]]], ["We can also assess the degree to which news and entertainment media are contributing to the promotion of nurturance or are increasing division, hate crimes, and false beliefs.Monitoring the impact of each sector on wellbeing ::: Evolving more nurturing societiesFinally, there is government.", [["false beliefs", "OBSERVATION", 161, 174]]], ["One of the most important things government can do is increase the use of effective monitoring systems.", [["effective monitoring systems", "TREATMENT", 74, 102]]], ["Why should we not have similar data on the well-being of the people in our communities?Creating contingencies that select beneficial practices ::: Evolving more nurturing societiesAs people in each sector come to understand the Nurture Consilience, they can begin to advocate for practices in each sector that improve the general well-being.", [["people", "ORGANISM", 61, 67], ["people", "ORGANISM", 183, 189], ["people", "SPECIES", 61, 67], ["people", "SPECIES", 183, 189]]], ["In every case, it will be a matter of creating consequences that select beneficial practices and eliminate harmful ones.Creating contingencies that select beneficial practices ::: Evolving more nurturing societiesLet's start with some business practices that are clearly harmful to a large proportion of the population\u2014the marketing of unhealthful food and substances.", [["beneficial practices", "TREATMENT", 72, 92]]], ["Progress has been made in curtailing the marketing of tobacco to young people, but alcohol and unhealthful food continue to be widely marketed to young people (Biglan, Van Ryzin, & Westling, 2019).", [["alcohol", "CHEMICAL", 83, 90], ["alcohol", "CHEMICAL", 83, 90], ["tobacco", "ORGANISM", 54, 61], ["people", "ORGANISM", 71, 77], ["alcohol", "SIMPLE_CHEMICAL", 83, 90], ["people", "ORGANISM", 152, 158], ["people", "SPECIES", 71, 77], ["people", "SPECIES", 152, 158], ["tobacco", "SPECIES", 54, 61]]], ["Moreover, the public health system has failed to prevent the marketing of vaping products to young people.Creating contingencies that select beneficial practices ::: Evolving more nurturing societiesMany of the efforts to prevent these harms have focused on stopping specific forms of marketing such as the use of billboards to promote tobacco use.", [["people", "ORGANISM", 99, 105], ["tobacco", "ORGANISM", 336, 343], ["people", "SPECIES", 99, 105], ["tobacco", "SPECIES", 336, 343]]], ["However, a much more effective strategy would be to simply tie the success of companies in marketing harmful products to young people to the companies' profits.", [["people", "ORGANISM", 127, 133], ["people", "SPECIES", 127, 133]]], ["We can assess the proportion of young people who begin using any specific product\u2014a brand of cigarettes, alcohol, or sugar-sweetened beverages for example.", [["alcohol", "CHEMICAL", 105, 112], ["alcohol", "CHEMICAL", 105, 112], ["sugar", "CHEMICAL", 117, 122], ["people", "ORGANISM", 38, 44], ["alcohol", "SIMPLE_CHEMICAL", 105, 112], ["sugar", "SIMPLE_CHEMICAL", 117, 122], ["people", "SPECIES", 38, 44]]], ["Indeed, Pierce, Gilpin, and Choi (1999) were able to estimate the percent of youth who would begin smoking Camel cigarettes or Marlboro cigarettes.", [["Marlboro", "CHEMICAL", 127, 135]]], ["They were also able to estimate the number of those youth who would eventually die of smoking-related illness due to each of these brands.", [["smoking", "CHEMICAL", 86, 93], ["illness", "DISEASE", 102, 109]]], ["Using such methods, it would be possible to fine a company for every percent of the youth population that is using a specific product.", [["such methods", "TREATMENT", 6, 18]]], ["Even the Business Roundtable has abandoned its position that the only goal of a corporation should be to maximize profits.", [["a corporation", "TREATMENT", 78, 91]]], ["Instead, it recently articulated the principle that businesses should benefit all of these constituencies (Gelles & Yaffe-Bellany, 2019).Creating contingencies that select beneficial practices ::: Evolving more nurturing societiesIn health care, practices would increasingly be selected by their impact in improving health, rather than only curing illness.", [["illness", "DISEASE", 348, 355]]], ["Policy could be adopted that makes system funding contingent on reductions in the incidence and prevalence of psychological, behavioral, and physical health disorders.", [["psychological, behavioral, and physical health disorders", "PROBLEM", 110, 166]]], ["This would motivate these organizations to fund the kind of family and school preventive interventions that we described above.", [["preventive interventions", "TREATMENT", 78, 102]]], ["It is already the case that a number of accountable care organizations and state Medicaid authorities are investing in school-based interventions such as the Good Behavior Game because of its proven benefit in preventing substance use, depression, and other expensive conditions.Creating contingencies that select beneficial practices ::: Evolving more nurturing societiesHigher education needs to train MBAs and lawyers who understand and promote the importance of nurturing conditions for health and societal well-being.", [["depression", "DISEASE", 236, 246], ["depression", "PROBLEM", 236, 246]]], ["We need more people who are trained to disseminate and implement the treatment and prevention programs that can significantly improve health.", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19], ["the treatment", "TREATMENT", 65, 78], ["prevention programs", "TREATMENT", 83, 102]]], ["To the extent that an increasing proportion of the leaders of each sector are focused on advancing well-being, they will implement contingencies to increase the preparation of a new generation of people who are committed to advance nurturance.Creating contingencies that select beneficial practices ::: Evolving more nurturing societiesThe criminal justice system needs to select practices such as prosecution, incarceration, and probation on the basis of their impact on crime and recidivism.", [["people", "ORGANISM", 196, 202], ["people", "SPECIES", 196, 202], ["incarceration", "PROBLEM", 411, 424], ["increasing", "OBSERVATION_MODIFIER", 22, 32], ["proportion", "OBSERVATION_MODIFIER", 33, 43], ["incarceration", "OBSERVATION", 411, 424]]], ["Law enforcement will need to work with health care, human services, and education to support and promote practices in those areas that have proven benefit in preventing crime (Biglan, 2015).Advocacy by behavioral scientists ::: The need for a grand coalitionThis last point is a good example of why behavioral scientists need to play a leadership role in the scaling up and scaling out of the framework for the Nurture Consilience.", [["human", "ORGANISM", 52, 57], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57]]], ["However, it has become clear that changing practice in society itself requires research and action.", [["clear", "OBSERVATION", 23, 28]]], ["To the extent that opinion leaders and policymakers throughout society come to believe that human well-being is fostered by nurturing conditions, there will be greater support for the policies and programs that are needed.", [["human", "ORGANISM", 92, 97], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97]]], ["The recent work of the National Prevention Science Coalition to Improve Lives in conducting Congressional briefings and writing op-eds is a good example (National Prevention Science Coalition to Improve Lives, 2019).The implications of this analysis for other countriesAdmittedly our analysis has been U.S.-centric.", [["this analysis", "TEST", 236, 249], ["our analysis", "TEST", 280, 292]]], ["For example, Sweden, a country known for its success in nurturing the well-being of most people (Lakey, 2016), has since the early 1990s quite rapidly moved from a welfare system almost completely predominated by the public sector, to allow for the establishment of private for-profit providers and privatization of public operations, funded by taxes and pre-set rates of reimbursement.", [["people", "ORGANISM", 89, 95], ["people", "SPECIES", 89, 95], ["public operations", "TREATMENT", 316, 333]]], ["Several welfare areas were opened up for market competition in a similar manner.", [["Several welfare areas", "PROBLEM", 0, 21], ["welfare", "OBSERVATION_MODIFIER", 8, 15], ["areas", "OBSERVATION_MODIFIER", 16, 21]]], ["These reforms originated from the 1980s emerging Swedish right-wing think tanks, inspired by the governments of Reagan and Thatcher (Svallfors & Tyllstr\u00f6m, 2017).", [["right", "ANATOMY_MODIFIER", 57, 62]]], ["The Swedish right-wing political parties are all in favor of the current system with unregulated profits in the welfare sector, even though most of their voters don't agree with this position (Svallfors & Tyllstr\u00f6m, 2017).The implications of this analysis for other countriesEvaluations of the changes in Swedish school systems have shown increased segregation between schools in terms of students' socio-economic status, ethnicity and performance (B\u00f6hlmark, Holmlund, & Lindahl, 2016; Holmlund et al., 2014), while average performance has not increased (Hennerdal, Malmberg, & Andersson, 2018; Hinnerich & Vlachos, 2017).", [["this analysis", "TEST", 242, 255], ["right", "ANATOMY_MODIFIER", 12, 17], ["increased", "OBSERVATION_MODIFIER", 339, 348], ["segregation", "OBSERVATION_MODIFIER", 349, 360], ["increased", "OBSERVATION_MODIFIER", 544, 553]]], ["Access to health care and medication has increased in geographical areas with denser population and higher income where patients usually have simpler issues, while it has decreased in low-populated areas and for more complex cases (Burstr\u00f6m et al., 2017).The spread of evidence-based programs and policies ::: Evidence of cultural evolutionA recent report from the National Academies of Sciences, Engineering, and Medicine (2019) enumerated examples of progress that has been made in promoting programs and policies that improve family, schools, and community support of child and adolescent development.", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["health care", "TREATMENT", 10, 21], ["medication", "TREATMENT", 26, 36], ["simpler issues", "PROBLEM", 142, 156], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["geographical", "OBSERVATION_MODIFIER", 54, 66], ["areas", "OBSERVATION_MODIFIER", 67, 72], ["denser", "OBSERVATION_MODIFIER", 78, 84], ["decreased", "OBSERVATION_MODIFIER", 171, 180], ["low", "OBSERVATION_MODIFIER", 184, 187]]], ["Among the examples of progress being made in this area were\u2022Eleven federal efforts that range from pregnancy prevention to workforce development.\u2022Efforts in six states to systematically implement evidence-based family, school, and community interventions to prevent the development of child and adolescent problems.\u2022The growing field of research on the dissemination and implementation of evidence-based preventive interventions.\u2022Numerous evidence-based programs that have reached a significant portion of the population\u2014beyond those receiving the programs in the context of a randomized trial.", [["pregnancy prevention", "TREATMENT", 99, 119], ["community interventions", "TREATMENT", 231, 254], ["adolescent problems", "PROBLEM", 295, 314], ["preventive interventions", "TREATMENT", 404, 428], ["a randomized trial", "TREATMENT", 575, 593], ["growing", "OBSERVATION_MODIFIER", 320, 327], ["field", "OBSERVATION_MODIFIER", 328, 333], ["significant", "OBSERVATION_MODIFIER", 483, 494], ["portion", "OBSERVATION_MODIFIER", 495, 502]]], ["These included:oPositive Behavioral Intervention and Support, a schoolwide system for promoting prosocial behavior, is used to some degree in more than 25,000 schools.oThe Nurse Family Partnership, a program proven to support positive development during pregnancy and the first to years of life, has reached 283,000 families (Nurse-Family Partnership NationalSymposium, 2019).", [["prosocial behavior", "DISEASE", 96, 114], ["Behavioral Intervention", "TREATMENT", 25, 48]]]], "fb2c5a27759bb6fa552df0338e7a0becf0e1bda5": [["IntroductionSurveillance of infectious animal diseases constitutes an important part of the prevention of animal disease and can have several specific purposes, e.g. early detection, declaration of freedom or evaluation of control strategies.", [["infectious animal diseases", "DISEASE", 28, 54], ["animal disease", "DISEASE", 106, 120], ["infectious animal diseases", "PROBLEM", 28, 54], ["animal disease", "PROBLEM", 106, 120], ["evaluation", "TEST", 209, 219], ["control strategies", "TREATMENT", 223, 241], ["infectious", "OBSERVATION_MODIFIER", 28, 38], ["disease", "OBSERVATION", 113, 120]]], ["However, financial resources may limit the number of samples that can be collected and analysed, and a riskbased approach is then one alternative for increasing the case-finding capacity of the surveillance system.", [["a riskbased approach", "TREATMENT", 101, 121]]], ["Infectious diseases are seldom homogeneously spread within the population and the benefits of searching \"in the most likely place\" when monitoring disease, in contrast to overall random sampling, have been previously discussed, e.g. by Cannon (2009) and St\u00e4rk et al. (2006) .IntroductionMany livestock diseases can spread through direct contact between animals, and thus between herds through movements of animals.", [["Infectious diseases", "DISEASE", 0, 19], ["livestock diseases", "DISEASE", 292, 310], ["Infectious diseases", "PROBLEM", 0, 19], ["monitoring disease", "PROBLEM", 136, 154], ["homogeneously", "OBSERVATION_MODIFIER", 31, 44], ["spread", "OBSERVATION_MODIFIER", 45, 51], ["livestock diseases", "OBSERVATION", 292, 310]]], ["When the aim of surveillance is detection (eradication context, emergence of an exotic disease, 0167-5877/$ -see front matter \u00a9 2011 Elsevier B.V. All rights reserved. doi:10.1016/j.prevetmed.2011.12.011 etc.), and when the disease is expected to spread through live animal contacts, animal movement data could be used in the selection of herds to be included in surveillance activities.", [["surveillance", "TEST", 16, 28], ["an exotic disease", "PROBLEM", 77, 94], ["the disease", "PROBLEM", 220, 231], ["animal movement data", "TEST", 284, 304], ["exotic disease", "OBSERVATION", 80, 94], ["disease", "OBSERVATION", 224, 231]]], ["In such cases, herds with many live animal contacts can be assumed to have a higher probability of infection, and sampling of these would therefore increase surveillance sensitivity.IntroductionLately there has been an increasing number of publications analysing livestock movements (Dub\u00e9 et al., 2009; Martinez-Lopez et al., 2009) .", [["infection", "DISEASE", 99, 108], ["livestock movements", "DISEASE", 263, 282], ["infection", "PROBLEM", 99, 108], ["surveillance sensitivity", "TEST", 157, 181], ["infection", "OBSERVATION", 99, 108], ["increasing", "OBSERVATION_MODIFIER", 219, 229], ["number", "OBSERVATION_MODIFIER", 230, 236], ["livestock movements", "OBSERVATION", 263, 282]]], ["For instance, the outbreak of foot-and-mouth disease in the United Kingdom in 2001 was the starting point for a number of studies within this field of research (e.g. see Ortiz-Pelaez et al., 2006) .", [["foot-and-mouth disease", "DISEASE", 30, 52], ["foot", "ORGANISM_SUBDIVISION", 30, 34], ["mouth", "ORGAN", 39, 44], ["foot-and-mouth", "SPECIES", 30, 44], ["mouth disease", "PROBLEM", 39, 52], ["foot", "ANATOMY", 30, 34], ["mouth", "ANATOMY", 39, 44], ["disease", "OBSERVATION", 45, 52]]], ["However, although analysis of animal contact patterns has already been suggested for targeting the surveillance of diseases (Christley et al., 2005; Martinez-Lopez et al., 2009; Blickenstorfer et al., 2011; N\u00f6remark et al., 2011) , to our knowledge there have been almost no published applications of the use of cattle movement network analysis for implementing a risk-based surveillance so far.", [["cattle", "SPECIES", 312, 318], ["diseases", "PROBLEM", 115, 123]]], ["There are many different network measures of centrality and, in 1979 in the context of social network analysis, Freeman discussed the importance of using meaningful and intuitively interpretable measures (Freeman, 1979) .", [["many", "OBSERVATION_MODIFIER", 10, 14], ["different", "OBSERVATION_MODIFIER", 15, 24], ["network", "OBSERVATION_MODIFIER", 25, 32]]], ["For surveillance activities that target herds with an increased risk of disease due to ingoing live animal contacts, an intuitive focus would be measures of contacts that have actually occurred, rather than measures describing the relative role of the herd in connecting the entire network (e.g. different measures of betweenness).", [["surveillance activities", "TEST", 4, 27], ["disease", "PROBLEM", 72, 79], ["disease", "OBSERVATION", 72, 79]]], ["Inclusion of measures of betweenness may, on the other hand, be more applicable in models simulating spread of disease.", [["disease", "PROBLEM", 111, 118], ["spread", "OBSERVATION_MODIFIER", 101, 107], ["disease", "OBSERVATION", 111, 118]]], ["There are different network analysis parameters describing incoming contacts that may be applied for risk-based surveillance purposes.", [["surveillance purposes", "TEST", 112, 133]]], ["In addition, N\u00f6remark (2010) and N\u00f6remark et al. (2011) described the 'ingoing infection chain', which includes secondary contacts in sequences, taking into account the temporal aspect and the order in which these contacts have occurred (Fig. 1) .IntroductionBovine respiratory syncytial virus (BRSV) and bovine coronavirus (BCV) are examples of pathogens that can spread through live animal contacts and also indirectly, e.g. through visitors and equipment (Elvander et al., 1998; H\u00e4gglund et al., 2006; Valarcher and Taylor, 2007; Bidokhti et al., 2009; Ohlson et al., 2010) .", [["infection", "DISEASE", 79, 88], ["respiratory syncytial virus (BRSV) and bovine coronavirus", "DISEASE", 266, 323], ["IntroductionBovine respiratory syncytial virus", "ORGANISM", 247, 293], ["BRSV", "ORGANISM", 295, 299], ["bovine coronavirus", "ORGANISM", 305, 323], ["BCV", "ORGANISM", 325, 328], ["respiratory syncytial virus", "SPECIES", 266, 293], ["BRSV", "SPECIES", 295, 299], ["bovine", "SPECIES", 305, 311], ["coronavirus", "SPECIES", 312, 323], ["respiratory syncytial virus", "SPECIES", 266, 293], ["BRSV", "SPECIES", 295, 299], ["bovine coronavirus", "SPECIES", 305, 323], ["BCV", "SPECIES", 325, 328], ["the 'ingoing infection chain'", "PROBLEM", 66, 95], ["secondary contacts in sequences", "PROBLEM", 112, 143], ["IntroductionBovine respiratory syncytial virus", "PROBLEM", 247, 293], ["BRSV", "PROBLEM", 295, 299], ["bovine coronavirus", "PROBLEM", 305, 323], ["pathogens", "PROBLEM", 346, 355], ["infection", "OBSERVATION", 79, 88], ["syncytial virus", "OBSERVATION", 278, 293]]], ["Identified risk factors for BRSV and BCV infection in Sweden include large herd size (Tr\u00e5v\u00e9n et al., 1999; Norstr\u00f6m et al., 2000; Ohlson et al., 2010) and being located in southern Sweden (Elvander, 1996; Beaudeau et al., 2010) where the herd density is higher compared to northern parts.", [["BCV infection", "DISEASE", 37, 50], ["BRSV", "ORGANISM", 28, 32], ["BCV", "ORGANISM", 37, 40], ["BRSV", "SPECIES", 28, 32], ["BRSV", "SPECIES", 28, 32], ["BCV", "SPECIES", 37, 40], ["BRSV", "PROBLEM", 28, 32], ["BCV infection", "PROBLEM", 37, 50], ["BCV", "ANATOMY", 37, 40], ["infection", "OBSERVATION", 41, 50], ["large", "OBSERVATION_MODIFIER", 69, 74], ["herd", "OBSERVATION_MODIFIER", 75, 79], ["size", "OBSERVATION_MODIFIER", 80, 84], ["density", "OBSERVATION", 243, 250], ["higher", "OBSERVATION_MODIFIER", 254, 260]]], ["Both diseases are distributed worldwide, causing enteric and respiratory disease in beef and dairy cattle (Clark, 1993; Valarcher and Taylor, 2007) .IntroductionThe aim of this study was to elaborate on the potential usefulness of including network analysis measures of animal movements in the design of surveillance programmes aimed at the detection of exotic diseases.", [["respiratory", "ANATOMY", 61, 72], ["enteric and respiratory disease", "DISEASE", 49, 80], ["exotic diseases", "DISEASE", 354, 369], ["beef", "ORGANISM_SUBDIVISION", 84, 88], ["beef", "SPECIES", 84, 88], ["cattle", "SPECIES", 99, 105], ["beef", "SPECIES", 84, 88], ["cattle", "SPECIES", 99, 105], ["Both diseases", "PROBLEM", 0, 13], ["enteric and respiratory disease", "PROBLEM", 49, 80], ["this study", "TEST", 172, 182], ["network analysis", "TEST", 241, 257], ["surveillance programmes", "TEST", 304, 327], ["exotic diseases", "PROBLEM", 354, 369], ["diseases", "OBSERVATION", 5, 13], ["distributed", "OBSERVATION_MODIFIER", 18, 29], ["worldwide", "OBSERVATION_MODIFIER", 30, 39], ["enteric", "OBSERVATION_MODIFIER", 49, 56], ["respiratory disease", "OBSERVATION", 61, 80], ["exotic diseases", "OBSERVATION", 354, 369]]], ["In order to investigate potential association between network analysis parameters and the presence of disease, results from a serological survey of BRSV and BCV in Swedish cattle were combined with data of reported animal movements.", [["BRSV", "ORGANISM", 148, 152], ["BCV", "ORGANISM", 157, 160], ["cattle", "ORGANISM", 172, 178], ["BRSV", "SPECIES", 148, 152], ["cattle", "SPECIES", 172, 178], ["BRSV", "SPECIES", 148, 152], ["BCV", "SPECIES", 157, 160], ["cattle", "SPECIES", 172, 178], ["network analysis parameters", "TEST", 54, 81], ["disease", "PROBLEM", 102, 109], ["a serological survey", "TEST", 124, 144], ["BRSV", "PROBLEM", 148, 152], ["disease", "OBSERVATION", 102, 109]]], ["BRSV and BCV were used as a proxy for exotic diseases, or other serious infections under surveillance, with similar contagiousness and routes of transmission.", [["exotic diseases", "DISEASE", 38, 53], ["infections", "DISEASE", 72, 82], ["BRSV", "ORGANISM", 0, 4], ["BCV", "ORGANISM", 9, 12], ["BRSV", "SPECIES", 0, 4], ["BRSV", "SPECIES", 0, 4], ["BCV", "SPECIES", 9, 12], ["BRSV", "PROBLEM", 0, 4], ["exotic diseases", "PROBLEM", 38, 53], ["other serious infections", "PROBLEM", 58, 82], ["BCV", "ANATOMY", 9, 12], ["serious", "OBSERVATION_MODIFIER", 64, 71], ["infections", "OBSERVATION", 72, 82]]], ["In other words, the study was not designed to investigate risk factors for these specific diseases.", [["the study", "TEST", 16, 25], ["risk factors", "PROBLEM", 58, 70], ["these specific diseases", "PROBLEM", 75, 98]]], ["Simulated sampling from the study material was used to visualise and compare riskbased approaches to a random selection strategy.DataInformation about movements of individual cattle in Sweden 2006 was retrieved from the database of the Swedish Board of Agriculture (described in more detail by N\u00f6remark (2010) and N\u00f6remark et al. (2011) ).", [["cattle", "ORGANISM", 175, 181], ["cattle", "SPECIES", 175, 181], ["cattle", "SPECIES", 175, 181], ["Simulated sampling from the study material", "TEST", 0, 42], ["a random selection strategy", "TREATMENT", 101, 128]]], ["Information about herd size, i.e. the number of cattle >1 year of age, and about the geographic location of herds was also included in that database.", [["herd", "ORGANISM_SUBDIVISION", 18, 22], ["cattle", "SPECIES", 48, 54], ["cattle", "SPECIES", 48, 54], ["size", "OBSERVATION_MODIFIER", 23, 27]]], ["The regional cattle herd density was calculated for all herds in the study sample by dividing the total number of cattle herds by the total area of their three-digit postal code area.DataIn addition, results from a cross-sectional serological study investigating spatial patterns of BRSV and BCV in Swedish cattle were used.", [["cattle", "ORGANISM", 13, 19], ["herd", "ORGANISM_SUBDIVISION", 20, 24], ["BRSV", "ORGANISM", 283, 287], ["BCV", "ORGANISM", 292, 295], ["cattle", "ORGANISM", 307, 313], ["cattle", "SPECIES", 13, 19], ["BRSV", "SPECIES", 283, 287], ["cattle", "SPECIES", 307, 313], ["cattle", "SPECIES", 13, 19], ["cattle", "SPECIES", 114, 120], ["BRSV", "SPECIES", 283, 287], ["BCV", "SPECIES", 292, 295], ["cattle", "SPECIES", 307, 313], ["The regional cattle herd density", "PROBLEM", 0, 32], ["the study sample", "TEST", 65, 81], ["cattle herds", "TREATMENT", 114, 126], ["a cross-sectional serological study", "TEST", 213, 248], ["BRSV", "PROBLEM", 283, 287], ["regional", "OBSERVATION_MODIFIER", 4, 12], ["cattle", "OBSERVATION_MODIFIER", 13, 19], ["herd density", "OBSERVATION", 20, 32], ["BCV", "ANATOMY", 292, 295]]], ["The design of the cross-sectional study and the analytical methods used are described in detail by Beaudeau et al. (2010) .", [["the cross-sectional study", "TEST", 14, 39]]], ["In short, a randomised subset of blood samples collected within the Swedish Bovine Viral Diarrhoea control programme was used.", [["blood samples", "ANATOMY", 33, 46], ["Viral Diarrhoea", "DISEASE", 83, 98], ["blood samples", "ORGANISM_SUBSTANCE", 33, 46], ["Bovine", "ORGANISM", 76, 82], ["Bovine", "SPECIES", 76, 82], ["Bovine", "SPECIES", 76, 82], ["blood samples", "TEST", 33, 46], ["the Swedish Bovine Viral Diarrhoea control programme", "TREATMENT", 64, 116], ["short", "OBSERVATION_MODIFIER", 3, 8]]], ["In the original study a total of 2763 samples from young stock >12 months of age in 2137 herds were collected between The 'in-degree' for the recipient herd is 3 (herds included within the solid line), and assuming that t1 and t2 occur before t3, that t4 occurs before t5 and that t5 occurs before t6, the 'ingoing infection chain' for the recipient herd is 7 (herds included within the dotted line).DataNovember 2006 and May 2007.", [["samples", "ANATOMY", 38, 45], ["infection", "DISEASE", 315, 324], ["samples", "CANCER", 38, 45], ["t4", "DNA", 252, 254], ["t5", "ANATOMY", 281, 283]]], ["The samples were analyzed for presence of immunoglobulin G antibodies to BRSV and BCV by commercially available indirect enzyme-linked immunosorbent assays (ELISA; SVANOVA Biotech, Uppsala, Sweden).", [["samples", "ANATOMY", 4, 11], ["immunoglobulin G antibodies", "GENE_OR_GENE_PRODUCT", 42, 69], ["BRSV", "ORGANISM", 73, 77], ["BCV", "ORGANISM", 82, 85], ["immunoglobulin G antibodies", "PROTEIN", 42, 69], ["BRSV", "SPECIES", 73, 77], ["BRSV", "SPECIES", 73, 77], ["BCV", "SPECIES", 82, 85], ["The samples", "TEST", 0, 11], ["immunoglobulin G antibodies", "TREATMENT", 42, 69], ["BRSV", "TEST", 73, 77], ["indirect enzyme", "TEST", 112, 127], ["immunosorbent assays", "TEST", 135, 155], ["ELISA", "TEST", 157, 162]]], ["Cut-off was set to a corrected OD of 0.20, which is recommended by the manufacturer for individual samples.", [["samples", "ANATOMY", 99, 106], ["individual samples", "TEST", 88, 106]]], ["At this cut-off, the sensitivity is estimated as 94.6% for BRSV and 84.6% for BCV and specificity to 100% for both tests (SVANOVA manual).", [["BRSV", "ORGANISM", 59, 63], ["BRSV", "SPECIES", 59, 63], ["BCV", "SPECIES", 78, 81], ["the sensitivity", "TEST", 17, 32], ["BRSV", "TEST", 59, 63], ["BCV", "TEST", 78, 81], ["specificity", "TEST", 86, 97], ["both tests", "TEST", 110, 120]]], ["In order to get a balanced number of results per herd for the present study, one result was randomly selected from each herd, giving a total of 2137 animals and herds.", [["the present study", "TEST", 58, 75]]], ["Of these, 859 (40%) and 899 (42%) had tested positive for BRSV and BCV, respectively.Statistical analysesNetwork analysis of the cattle movement data was performed, including calculation of 'in-degree' and 'ingoing infection chain' for all herds in the study sample.", [["infection", "DISEASE", 215, 224], ["BRSV", "ORGANISM", 58, 62], ["BCV", "ORGANISM", 67, 70], ["cattle", "ORGANISM", 129, 135], ["BRSV", "SPECIES", 58, 62], ["BRSV", "SPECIES", 58, 62], ["BCV", "SPECIES", 67, 70], ["cattle", "SPECIES", 129, 135], ["BRSV", "PROBLEM", 58, 62], ["Statistical analyses", "TEST", 85, 105], ["the cattle movement data", "TEST", 125, 149], ["the study sample", "TEST", 249, 265], ["BCV", "ANATOMY", 67, 70]]], ["Both measures were set to reflect all reported movements of cattle during 2006, excluding transports for slaughter (N\u00f6remark et al., 2011) .", [["cattle", "ORGANISM", 60, 66], ["cattle", "SPECIES", 60, 66], ["cattle", "SPECIES", 60, 66]]], ["In addition, possible associations between animals testing positive for BRSV or BCV antibodies and the measures based on network analysis were investigated using logistic regression.", [["animals", "ORGANISM", 43, 50], ["BRSV", "ORGANISM", 72, 76], ["BCV", "ORGANISM", 80, 83], ["BCV antibodies", "PROTEIN", 80, 94], ["BRSV", "SPECIES", 72, 76], ["BRSV", "SPECIES", 72, 76], ["BCV", "SPECIES", 80, 83], ["animals testing", "TEST", 43, 58], ["BRSV", "PROBLEM", 72, 76], ["BCV antibodies", "TREATMENT", 80, 94], ["network analysis", "TEST", 121, 137]]], ["In the regression models, the outcome was the dichotomized test result (0 = negative, 1 = positive) as regards BRSV and BCV.", [["BRSV", "ORGANISM", 111, 115], ["BCV", "ORGANISM", 120, 123], ["BRSV", "SPECIES", 111, 115], ["BRSV", "SPECIES", 111, 115], ["BCV", "SPECIES", 120, 123], ["the dichotomized test result", "TEST", 42, 70], ["BRSV", "PROBLEM", 111, 115], ["BCV", "ANATOMY", 120, 123]]], ["In addition to the in-degree and ingoing infection chain measures, herd size and regional cattle herd density were explanatory variables that were also investigated.", [["infection", "DISEASE", 41, 50], ["cattle", "SPECIES", 90, 96], ["cattle", "SPECIES", 90, 96], ["ingoing infection chain measures", "PROBLEM", 33, 65], ["herd size and regional cattle herd density", "PROBLEM", 67, 109], ["infection", "OBSERVATION", 41, 50], ["chain", "OBSERVATION_MODIFIER", 51, 56], ["size", "OBSERVATION_MODIFIER", 72, 76], ["regional", "OBSERVATION_MODIFIER", 81, 89], ["cattle", "OBSERVATION_MODIFIER", 90, 96], ["herd density", "OBSERVATION", 97, 109]]], ["The main effects models were decided based on univariable regression of each variable followed by a check of the correlation between explanatory variables, and multivariable regression with backward elimination of non-significant variables.", [["explanatory variables", "TEST", 133, 154], ["backward elimination of non-significant variables", "PROBLEM", 190, 239], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["The network analysis parameters were investigated separately in different models.", [["The network analysis parameters", "TEST", 0, 31]]], ["For best fit of the models, both 'in-degree' and 'ingoing infection chain' were included in categorized form.", [["infection", "DISEASE", 58, 67], ["'ingoing infection chain'", "PROBLEM", 49, 74]]], ["The categories were 0, >0 to <5 and \u22655 for 'in-degree', and 0, >0 to <25 and \u226525 for 'ingoing infection chain'.", [["infection", "DISEASE", 94, 103], ["The categories", "TEST", 0, 14], ["'ingoing infection chain'", "PROBLEM", 85, 110], ["infection", "OBSERVATION", 94, 103]]], ["Fifty-six herds had missing information about live animal contacts and these were included in categories 'in-degree' \u22655 and 'ingoing infection chain' \u226525.", [["infection", "DISEASE", 133, 142], ["herds", "ORGANISM", 10, 15]]], ["Model fit was assessed by applying the Hosmer-Lemeshow goodness-of-fit test and investigation of the influence of covariate patterns (Hosmer and Lemeshow, 2000) .", [["fit test", "TEST", 67, 75]]], ["Thirty observations were excluded from these analyses due to missing values for one or more variables.Statistical analysesFor comparison of different strategies of sample selection, different approaches were used to select 100 results from the total of 2137 in the study sample.", [["Thirty observations", "TEST", 0, 19], ["these analyses", "TEST", 39, 53], ["missing values", "PROBLEM", 61, 75], ["Statistical analyses", "TEST", 102, 122], ["sample selection", "TEST", 164, 180], ["the study sample", "TEST", 261, 277]]], ["First, a total random sample was selected.", [["a total random sample", "TEST", 7, 28]]], ["Second, random samples amongst herds with certain levels of 'in-degree' or 'ingoing infection chain' were selected.", [["samples", "ANATOMY", 15, 22], ["infection", "DISEASE", 84, 93], ["random samples", "TEST", 8, 22], ["certain levels", "TEST", 42, 56], ["'ingoing infection chain", "TREATMENT", 75, 99]]], ["The categories were >0 (n = 1134), and \u22655 for 'in-degree' (n = 172), and \u226525 for 'ingoing infection chain' (n = 178).", [["infection", "DISEASE", 90, 99], ["The categories", "TEST", 0, 14], ["'ingoing infection chain'", "PROBLEM", 81, 106], ["infection", "OBSERVATION", 90, 99]]], ["Each of these sampling strategies was simulated with 10,000 repetitions, and the median, and the 5th and 95th percentiles, were calculated from the output distribution of the number of positives for BRSV or BCV from these simulations.", [["BRSV", "ORGANISM", 199, 203], ["BRSV", "SPECIES", 199, 203], ["BRSV", "PROBLEM", 199, 203], ["these simulations", "TEST", 216, 233], ["output", "OBSERVATION_MODIFIER", 148, 154], ["distribution", "OBSERVATION_MODIFIER", 155, 167]]], ["In addition, the number of positive results in the 100 herds with the highest 'in-degree' and the highest 'ingoing infection chain' was assessed.", [["infection", "DISEASE", 115, 124], ["the highest 'in-degree'", "PROBLEM", 66, 89], ["infection", "OBSERVATION", 115, 124]]], ["The number of test-positive results included in the samples from the risk-based approaches was compared to the random selection approach.SoftwareData management, random selection, simulations and statistical analyses were performed using STATA/SE 11.1 (Stata Co., College Station, TX, USA).", [["test", "TEST", 14, 18], ["SoftwareData management", "TREATMENT", 137, 160], ["random selection", "TEST", 162, 178], ["statistical analyses", "TEST", 196, 216], ["STATA/SE", "TEST", 238, 246]]], ["Network analysis was performed using the Python module NetworkX 0.99, and Perl 5.8.7, as described by N\u00f6remark et al. (2011) .", [["Network analysis", "TEST", 0, 16]]], ["Input to the calculation of regional densities was managed through the use of Arc GIS 9.2 (ESRI Co., Redlands, CA, USA) and a digitized map 'Sverige 1000 plus' version 5/2004 (Statistics Sweden).ResultsBased on univariable regression analysis (see Table 1 for detailed results), all potential explanatory variables were significantly associated (P < 0.001) with the outcomes (i.e. testing positive for BRSV or BCV).", [["BRSV", "ORGANISM", 402, 406], ["BRSV", "SPECIES", 402, 406], ["BCV", "SPECIES", 410, 413], ["Arc GIS", "TEST", 78, 85], ["a digitized map 'Sverige", "TREATMENT", 124, 148], ["univariable regression analysis", "TEST", 211, 242], ["testing", "TEST", 381, 388], ["BRSV", "PROBLEM", 402, 406], ["regional", "OBSERVATION_MODIFIER", 28, 36], ["densities", "OBSERVATION", 37, 46]]], ["In the multivariable models (see Table 2 for detailed results), only 'herd size' and 'regional cattle density' were significantly associated with testing positive for BRSV.", [["cattle", "ORGANISM", 95, 101], ["BRSV", "ORGANISM", 167, 171], ["BRSV", "SPECIES", 167, 171], ["cattle", "SPECIES", 95, 101], ["BRSV", "SPECIES", 167, 171], ["'regional cattle density'", "PROBLEM", 85, 110], ["testing", "TEST", 146, 153], ["BRSV", "PROBLEM", 167, 171], ["size", "OBSERVATION_MODIFIER", 75, 79], ["regional", "OBSERVATION_MODIFIER", 86, 94], ["cattle density", "OBSERVATION", 95, 109]]], ["In other words, when adjusting for these covariates, neither 'in-degree' nor 'ingoing infection chain' could be shown to be associated to testing positive for BRSV.", [["infection", "DISEASE", 86, 95], ["BRSV", "ORGANISM", 159, 163], ["BRSV", "SPECIES", 159, 163], ["BRSV", "SPECIES", 159, 163], ["neither 'in-degree'", "PROBLEM", 53, 72], ["'ingoing infection chain", "PROBLEM", 77, 101], ["BRSV", "PROBLEM", 159, 163]]], ["For the outcome testing positive to BCV, the significant covariates kept in the final models were 'herd size', 'regional cattle density' and also 'in-degree' or 'ingoing infection chain'.", [["infection", "DISEASE", 170, 179], ["BCV", "ORGANISM", 36, 39], ["cattle", "SPECIES", 121, 127], ["the outcome testing", "TEST", 4, 23], ["BCV", "TEST", 36, 39], ["'regional cattle density'", "PROBLEM", 111, 136], ["'ingoing infection chain'", "PROBLEM", 161, 186], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["size", "OBSERVATION_MODIFIER", 104, 108], ["cattle density", "OBSERVATION", 121, 135], ["in-degree", "OBSERVATION_MODIFIER", 147, 156], ["infection", "OBSERVATION", 170, 179]]], ["No interactions between main effects were significant and these were therefore excluded from the final models.ResultsIn the comparison of selection strategies, all risk-based approaches detected more positive cases compared to total random sampling.", [["selection strategies", "TREATMENT", 138, 158], ["total random sampling", "TEST", 227, 248]]], ["However, for BRSV, the only strategies where the median values or number of detected positives were above the 95% percentile of the random sampling distribution were the sampling strategies based on 'indegree' (Fig. 2) .", [["BRSV", "ORGANISM", 13, 17], ["BRSV", "SPECIES", 13, 17], ["BRSV", "SPECIES", 13, 17], ["BRSV", "PROBLEM", 13, 17], ["the median values", "TEST", 45, 62], ["the sampling strategies", "TREATMENT", 166, 189]]], ["For BCV on the other hand, all risk-based approaches except random sampling of herds with >0 contacts (i.e. 'in-degree' >0 and 'ingoing infection chain' >0), had median numbers of detected positives above the 95% percentile of the random sampling distribution (Fig. 3) .", [["infection", "DISEASE", 136, 145], ["BCV", "SPECIES", 4, 7], ["median numbers", "TEST", 162, 176]]], ["Notice that the more narrow distributions for the selections strategies 'in-degree' \u22655 and 'ingoing infection chain' \u226525, compared to total random sampling, is a result of the smaller number of herds in these categories (relative to the sample size of 100).DiscussionResults from this study show that network analysis parameters representing animal purchase can be associated with the presence of infectious diseases (such as BCV or BRSV) in cattle.", [["infection", "DISEASE", 100, 109], ["infectious diseases (such as BCV or BRSV)", "DISEASE", 397, 438], ["BRSV", "ORGANISM", 433, 437], ["cattle", "ORGANISM", 442, 448], ["BRSV", "SPECIES", 433, 437], ["cattle", "SPECIES", 442, 448], ["BCV", "SPECIES", 426, 429], ["BRSV", "SPECIES", 433, 437], ["cattle", "SPECIES", 442, 448], ["the selections strategies", "TREATMENT", 46, 71], ["'ingoing infection chain", "PROBLEM", 91, 115], ["total random sampling", "TEST", 134, 155], ["the sample size", "TEST", 233, 248], ["this study", "TEST", 280, 290], ["network analysis parameters", "TEST", 301, 328], ["infectious diseases", "PROBLEM", 397, 416], ["BRSV", "PROBLEM", 433, 437], ["more", "OBSERVATION_MODIFIER", 16, 20], ["narrow", "OBSERVATION_MODIFIER", 21, 27], ["infection", "OBSERVATION", 100, 109], ["smaller", "OBSERVATION_MODIFIER", 176, 183], ["number", "OBSERVATION_MODIFIER", 184, 190], ["size", "OBSERVATION_MODIFIER", 244, 248], ["infectious", "OBSERVATION", 397, 407]]], ["The 'in-degree' measure, which takes only direct contacts into account, was slightly more strongly associated with testing positive to BCV, compared Table 1 Results from univariable logistic regression analyses of the combined data from a cross-sectional study for bovine coronavirus (BCV) and bovine respiratory syncytial virus (BRSV) with network analysis measures of animal movements in 2137 Swedish dairy herds. to the 'ingoing infection chain' measure, where secondary contacts through sequence of movements are also incorporated.", [["bovine coronavirus", "DISEASE", 265, 283], ["respiratory syncytial virus", "DISEASE", 301, 328], ["infection", "DISEASE", 432, 441], ["bovine coronavirus", "ORGANISM", 265, 283], ["BCV", "ORGANISM", 285, 288], ["bovine", "ORGANISM", 294, 300], ["respiratory syncytial virus", "ORGANISM", 301, 328], ["BRSV", "ORGANISM", 330, 334], ["bovine", "SPECIES", 265, 271], ["bovine", "SPECIES", 294, 300], ["respiratory syncytial virus", "SPECIES", 301, 328], ["BRSV", "SPECIES", 330, 334], ["bovine coronavirus", "SPECIES", 265, 283], ["BCV", "SPECIES", 285, 288], ["bovine respiratory syncytial virus", "SPECIES", 294, 328], ["BRSV", "SPECIES", 330, 334], ["a cross-sectional study", "TEST", 237, 260], ["bovine coronavirus", "PROBLEM", 265, 283], ["bovine respiratory syncytial virus", "PROBLEM", 294, 328], ["network analysis", "TEST", 341, 357], ["respiratory syncytial", "ANATOMY", 301, 322], ["infection", "OBSERVATION", 432, 441]]], ["However, when comparing the exact values of influence of the two network analysis measures, it should be kept in mind that results can be expected to be highly dependent on the cut-offs used in the categorization of these parameters.", [["the cut-offs", "TEST", 173, 185]]], ["For BRSV, none of the network analysis parameters were found to be significantly associated when herd size and regional cattle density were accounted for.", [["BRSV", "ORGANISM", 4, 8], ["herd", "ORGANISM_SUBDIVISION", 97, 101], ["BRSV", "SPECIES", 4, 8], ["BRSV", "SPECIES", 4, 8], ["cattle", "SPECIES", 120, 126], ["BRSV", "PROBLEM", 4, 8], ["the network analysis parameters", "TEST", 18, 49], ["regional cattle density", "PROBLEM", 111, 134], ["size", "OBSERVATION_MODIFIER", 102, 106], ["regional", "OBSERVATION_MODIFIER", 111, 119], ["cattle density", "OBSERVATION", 120, 134]]], ["Nevertheless, these measures could still be useful for risk-based sampling because buying animals can be a risk regardless of whether a herd also has other characteristics associated with disease introduction.", [["disease introduction", "PROBLEM", 188, 208]]], ["This was illustrated in the comparison of selection strategies, where sampling strategies based on 'in-degree' detected more BRSV positives compared to random sampling.", [["BRSV", "ORGANISM", 125, 129], ["BRSV", "SPECIES", 125, 129], ["selection strategies", "TREATMENT", 42, 62], ["sampling strategies", "TEST", 70, 89], ["more BRSV positives", "PROBLEM", 120, 139], ["random sampling", "TEST", 152, 167], ["BRSV positives", "OBSERVATION", 125, 139]]], ["In a recent study, live animal contacts were recognized as a major risk for the spread of emerging infectious animal diseases and an increased need for Table 2 Results from multivariable logistic regression analyses of combined data from a cross-sectional study for bovine coronavirus (BCV) and bovine respiratory syncytial virus (BRSV) and network analysis measures of animal movements in 2137 Swedish dairy herds.VariableOdds surveillance was also identified (Wentholt et al., 2012) .", [["infectious animal diseases", "DISEASE", 99, 125], ["respiratory syncytial virus", "DISEASE", 302, 329], ["bovine coronavirus", "ORGANISM", 266, 284], ["BCV", "ORGANISM", 286, 289], ["bovine respiratory syncytial virus", "ORGANISM", 295, 329], ["BRSV", "ORGANISM", 331, 335], ["bovine", "SPECIES", 266, 272], ["bovine", "SPECIES", 295, 301], ["respiratory syncytial virus", "SPECIES", 302, 329], ["BRSV", "SPECIES", 331, 335], ["bovine coronavirus", "SPECIES", 266, 284], ["BCV", "SPECIES", 286, 289], ["bovine respiratory syncytial virus", "SPECIES", 295, 329], ["BRSV", "SPECIES", 331, 335], ["a recent study", "TEST", 3, 17], ["emerging infectious animal diseases", "PROBLEM", 90, 125], ["a cross-sectional study", "TEST", 238, 261], ["bovine coronavirus", "PROBLEM", 266, 284], ["bovine respiratory syncytial virus", "PROBLEM", 295, 329], ["network analysis", "TEST", 341, 357], ["infectious", "OBSERVATION", 99, 109], ["increased", "OBSERVATION_MODIFIER", 133, 142], ["respiratory syncytial", "ANATOMY", 302, 323]]], ["Especially in the first stages of an outbreak, or for diseases where animals do not show clear clinical symptoms, we see benefits from targeting herds with high measures of live animal contacts.", [["diseases", "PROBLEM", 54, 62], ["clear clinical symptoms", "PROBLEM", 89, 112]]], ["Although BCV and BRSV were primarily used as general examples of contagious diseases, some of the findings in this study can be worthwhile mentioning in specific relation to BCV and BRSV.", [["BCV", "ORGANISM", 9, 12], ["BRSV", "ORGANISM", 17, 21], ["BCV", "ORGANISM", 174, 177], ["BRSV", "ORGANISM", 182, 186], ["BRSV", "SPECIES", 17, 21], ["BRSV", "SPECIES", 182, 186], ["BCV", "SPECIES", 9, 12], ["BRSV", "SPECIES", 17, 21], ["BCV", "SPECIES", 174, 177], ["BRSV", "SPECIES", 182, 186], ["BCV", "PROBLEM", 9, 12], ["BRSV", "PROBLEM", 17, 21], ["contagious diseases", "PROBLEM", 65, 84], ["this study", "TEST", 110, 120], ["BRSV", "PROBLEM", 182, 186], ["BCV", "ANATOMY", 9, 12], ["BRSV", "OBSERVATION", 17, 21], ["contagious", "OBSERVATION", 65, 75]]], ["Both diseases can spread through other types of contacts, e.g. visitors such as veterinarians; and the relative importance of animal trade and farm visits has not been investigated in relation to these infections in Swedish beef cattle.", [["infections", "DISEASE", 202, 212], ["beef", "SPECIES", 224, 228], ["cattle", "SPECIES", 229, 235], ["beef", "SPECIES", 224, 228], ["cattle", "SPECIES", 229, 235], ["Both diseases", "PROBLEM", 0, 13], ["these infections", "PROBLEM", 196, 212], ["diseases", "OBSERVATION", 5, 13], ["infections", "OBSERVATION", 202, 212]]], ["Previous studies conducted in Norway and Sweden have evaluated the association between herd-level characteristics and BCV and BRSV infections in dairy herds.", [["BRSV infections", "DISEASE", 126, 141], ["BCV", "ORGANISM", 118, 121], ["BRSV", "ORGANISM", 126, 130], ["BRSV", "SPECIES", 126, 130], ["BCV", "SPECIES", 118, 121], ["BRSV", "SPECIES", 126, 130], ["Previous studies", "TEST", 0, 16], ["BCV", "PROBLEM", 118, 121], ["BRSV infections", "PROBLEM", 126, 141], ["BCV", "ANATOMY", 118, 121], ["BRSV infections", "OBSERVATION", 126, 141]]], ["The identified risk factors were similar for both viruses: large herd size was found to be a risk factor compared with small herd size (Tr\u00e5v\u00e9n et al., 1999; Norstr\u00f6m et al., 2000) , as was artificial insemination (AI) by farm personnel compared with AI by external technicians, conventional compared with organic management (Bidokhti et al., 2009) , and not providing boots for visitors (Ohlson et al., 2010) .", [["The identified risk factors", "PROBLEM", 0, 27], ["large herd size", "PROBLEM", 59, 74], ["a risk factor", "PROBLEM", 91, 104], ["small herd size", "PROBLEM", 119, 134], ["organic management", "TREATMENT", 305, 323], ["viruses", "OBSERVATION", 50, 57], ["large", "OBSERVATION_MODIFIER", 59, 64], ["size", "OBSERVATION_MODIFIER", 70, 74], ["size", "OBSERVATION_MODIFIER", 130, 134]]], ["However, in the present study, animal trade seems to be more important for BCV than BRSV.", [["BCV", "ORGANISM", 75, 78], ["BRSV", "ORGANISM", 84, 88], ["BRSV", "SPECIES", 84, 88], ["BCV", "SPECIES", 75, 78], ["BRSV", "SPECIES", 84, 88], ["the present study", "TEST", 12, 29]]], ["This is an interesting finding that may be explained by the slightly different epidemiology of these two viral diseases.", [["viral diseases", "DISEASE", 105, 119], ["these two viral diseases", "PROBLEM", 95, 119], ["may be explained", "UNCERTAINTY", 36, 52], ["slightly", "OBSERVATION_MODIFIER", 60, 68], ["different", "OBSERVATION_MODIFIER", 69, 78], ["two", "OBSERVATION_MODIFIER", 101, 104], ["viral diseases", "OBSERVATION", 105, 119]]], ["Signs of diarrhoea (the main symptom of BCV) might not be recorded by the farmer as easily as coughing (the main symptom of BRSV), so the risk of selling animals with ongoing BRSV infection might therefore be lower.", [["diarrhoea", "DISEASE", 9, 18], ["BRSV", "DISEASE", 124, 128], ["BRSV infection", "DISEASE", 175, 189], ["BRSV", "ORGANISM", 124, 128], ["BRSV", "ORGANISM", 175, 179], ["BRSV", "SPECIES", 175, 179], ["BRSV", "SPECIES", 124, 128], ["BRSV", "SPECIES", 175, 179], ["diarrhoea", "PROBLEM", 9, 18], ["coughing", "PROBLEM", 94, 102], ["BRSV", "PROBLEM", 124, 128], ["ongoing BRSV infection", "PROBLEM", 167, 189], ["diarrhoea", "OBSERVATION", 9, 18], ["BRSV infection", "OBSERVATION", 175, 189]]], ["The fact that BCV is shed via faeces (Clark, 1993) could also contribute, as it is difficult to clean out and more voluminous than nasal discharge, which is the primary means of transmission for BRSV (Van der Poel et al., 1994) .VariableThe investigated covariates in this study were on herd level and the outcomes were based on just one single animal.", [["nasal", "ANATOMY", 131, 136], ["BRSV", "DISEASE", 195, 199], ["BCV", "ORGANISM", 14, 17], ["faeces", "ORGANISM_SUBSTANCE", 30, 36], ["nasal", "ORGAN", 131, 136], ["BRSV", "ORGANISM", 195, 199], ["BRSV", "SPECIES", 195, 199], ["BCV", "SPECIES", 14, 17], ["BRSV", "SPECIES", 195, 199], ["this study", "TEST", 268, 278], ["herd level", "TEST", 287, 297], ["BCV", "ANATOMY", 14, 17]]], ["Although both BRSV and BCV are highly infectious with high within-herd seroprevalence (Verhoeff et al., 1984; Alenius et al., 1991; H\u00e4gglund et al., 2006; Bidokhti et al., 2009; Ohlson et al., 2009) , herd sensitivity can thus be expected to be less than 100% and to vary to some extent.", [["BRSV", "ORGANISM", 14, 18], ["BCV", "ORGANISM", 23, 26], ["BRSV", "SPECIES", 14, 18], ["BRSV", "SPECIES", 14, 18], ["BCV", "SPECIES", 23, 26], ["highly infectious", "PROBLEM", 31, 48], ["BRSV", "OBSERVATION", 14, 18], ["BCV", "ANATOMY", 23, 26], ["highly", "OBSERVATION_MODIFIER", 31, 37], ["infectious", "OBSERVATION", 38, 48], ["high", "OBSERVATION_MODIFIER", 54, 58]]], ["This means that on herd level some of our observations probably were false negatives.", [["false negatives", "PROBLEM", 69, 84]]], ["Because all serological results used here came from analysis of samples from young stock, presence of antibodies can be assumed to reflect a relatively recent infection.", [["samples", "ANATOMY", 64, 71], ["infection", "DISEASE", 159, 168], ["antibodies", "PROTEIN", 102, 112], ["all serological", "TEST", 8, 23], ["antibodies", "PROBLEM", 102, 112], ["a relatively recent infection", "PROBLEM", 139, 168], ["relatively", "OBSERVATION_MODIFIER", 141, 151], ["infection", "OBSERVATION", 159, 168]]], ["A truly positive animal could nevertheless be a false positive on herd level, i.e. if the animal was born elsewhere and had gone through infection before introduction to its current herd.", [["infection", "DISEASE", 137, 146], ["a false positive on herd level", "PROBLEM", 46, 76], ["infection", "PROBLEM", 137, 146], ["positive", "OBSERVATION", 8, 16], ["false", "OBSERVATION_MODIFIER", 48, 53], ["positive", "OBSERVATION", 54, 62], ["infection", "OBSERVATION", 137, 146]]], ["On-farm biosecurity measures and frequency of categories of visitors are examples of higher level covariates that could also be of interest.VariableAlthough the number of detected positives was highest when the sampling was based on the 100 herds with the highest 'in-degree' in this study, this does not disqualify selection based on 'ingoing infection chain'.", [["infection", "DISEASE", 344, 353], ["farm biosecurity measures", "TREATMENT", 3, 28], ["higher level covariates", "PROBLEM", 85, 108], ["the sampling", "TEST", 207, 219], ["this study", "TEST", 279, 289], ["infection", "OBSERVATION", 344, 353]]], ["The usefulness of these measures in the design of future surveillance activities will depend on the epidemiology of the disease studied.", [["the disease studied", "PROBLEM", 116, 135], ["disease", "OBSERVATION", 120, 127]]], ["For example, 'ingoing infection chain' is expected to be more useful when included in risk-based surveillance of diseases such as bovine paratuberculosis, where infected animals often show few or no clinical symptoms.", [["infection", "DISEASE", 22, 31], ["bovine paratuberculosis", "DISEASE", 130, 153], ["bovine paratuberculosis", "ORGANISM", 130, 153], ["animals", "ORGANISM", 170, 177], ["bovine", "SPECIES", 130, 136], ["paratuberculosis", "SPECIES", 137, 153], ["bovine paratuberculosis", "SPECIES", 130, 153], ["'ingoing infection chain'", "PROBLEM", 13, 38], ["diseases", "PROBLEM", 113, 121], ["bovine paratuberculosis", "PROBLEM", 130, 153], ["infected animals", "PROBLEM", 161, 177], ["clinical symptoms", "PROBLEM", 199, 216], ["infection", "OBSERVATION", 22, 31], ["diseases", "OBSERVATION", 113, 121], ["bovine paratuberculosis", "OBSERVATION", 130, 153]]], ["Many of the Swedish cattle herds have few direct contacts and 'indegree' and thus 'ingoing infection chain' do not always correspond (N\u00f6remark et al., 2011) , e.g. a holding with low 'in-degree' can have a high 'ingoing infection chain'.", [["infection", "DISEASE", 91, 100], ["infection", "DISEASE", 220, 229], ["cattle", "ORGANISM", 20, 26], ["cattle", "SPECIES", 20, 26], ["cattle", "SPECIES", 20, 26], ["a high 'ingoing infection chain'", "PROBLEM", 204, 236], ["infection", "OBSERVATION", 220, 229]]], ["With a focus on 'in-degree' only, such herds may be excluded from sampling.VariableOne possible alternative would be to combine the two measures, and another improvement could be adding different weights to the contacts in the 'ingoing infection chain' depending on the number of animals for each contact and on how many steps away the source herds are from the recipient herd.", [["infection", "DISEASE", 236, 245], ["may be excluded", "UNCERTAINTY", 45, 60]]], ["Also, the time periods for which the network measures are calculated need to be adjusted depending on the disease studied and on the age category of the tested animals.", [["the disease studied", "PROBLEM", 102, 121]]], ["For some diseases, the more recent contacts will be the most interesting whereas for others, with long incubation periods, e.g. such as scrapie or paratuberculosis, trade events several years back may be still be of great importance.", [["scrapie or paratuberculosis", "DISEASE", 136, 163], ["scrapie", "SPECIES", 136, 143], ["paratuberculosis", "SPECIES", 147, 163], ["some diseases", "PROBLEM", 4, 17], ["scrapie", "PROBLEM", 136, 143], ["paratuberculosis", "PROBLEM", 147, 163], ["diseases", "OBSERVATION", 9, 17], ["paratuberculosis", "OBSERVATION", 147, 163]]], ["Moreover, the measures out-degree and outgoing infection chain (Dub\u00e9 et al., 2008) can be used to identify outgoing contacts when the target of the surveillance is herds with a high risk of spreading disease.ConclusionFor diseases where live animal trade constitute a main risk for disease introduction, and where reliable animal movement data is available, including network analysis parameters in the selection of herds can increase the surveillance sensitivity compared to total random sampling.Conflict of interestThere are no conflicts of interest.", [["infection", "DISEASE", 47, 56], ["outgoing infection chain", "PROBLEM", 38, 62], ["spreading disease", "PROBLEM", 190, 207], ["diseases", "PROBLEM", 222, 230], ["disease", "PROBLEM", 282, 289], ["reliable animal movement data", "TEST", 314, 343], ["network analysis parameters", "TEST", 368, 395], ["the surveillance sensitivity", "TEST", 435, 463], ["total random sampling", "TEST", 476, 497], ["infection", "OBSERVATION", 47, 56], ["spreading", "OBSERVATION_MODIFIER", 190, 199], ["disease", "OBSERVATION", 200, 207], ["no", "UNCERTAINTY", 528, 530], ["conflicts", "OBSERVATION", 531, 540]]]], "0fd8671929873835863077a1f33fa9e2e833c417": [["IntroductionCoronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["infectious disease", "DISEASE", 54, 72], ["acute respiratory syndrome coronavirus", "DISEASE", 90, 128], ["SARS-CoV-2", "ORGANISM", 132, 142], ["IntroductionCoronavirus disease-2019 (COVID-19", "SPECIES", 0, 46], ["severe acute respiratory syndrome coronavirus", "SPECIES", 83, 128], ["SARS-CoV-2", "SPECIES", 132, 142], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["an infectious disease", "PROBLEM", 51, 72], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 83, 128], ["SARS", "TEST", 132, 136], ["CoV", "TEST", 137, 140], ["infectious", "OBSERVATION", 54, 64], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory syndrome", "OBSERVATION", 96, 116]]], ["The outbreak of COVID-19 appeared in China in December 2019 and, since then, has spread worldwide at a rapid pace and has been declared a global pandemic by the World Health Organization as of 11 March 2020.", [["COVID-19", "CHEMICAL", 16, 24], ["COVID", "TEST", 16, 21]]], ["1 Several cardiovascular complications of COVID-19 have been described in the adult population, and acute myocarditis appears to be relatively frequent.", [["cardiovascular", "ANATOMY", 10, 24], ["cardiovascular complications", "DISEASE", 10, 38], ["COVID-19", "CHEMICAL", 42, 50], ["myocarditis", "DISEASE", 106, 117], ["COVID-19", "CHEMICAL", 42, 50], ["COVID-19", "GENE_OR_GENE_PRODUCT", 42, 50], ["Several cardiovascular complications", "PROBLEM", 2, 38], ["COVID", "TEST", 42, 47], ["acute myocarditis", "PROBLEM", 100, 117], ["cardiovascular", "ANATOMY", 10, 24], ["complications", "OBSERVATION", 25, 38], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["myocarditis", "OBSERVATION", 106, 117], ["appears to be", "UNCERTAINTY", 118, 131]]], ["2 Younger patients with COVID-19 infection can present with few or no symptoms or with atypical symptoms.", [["COVID-19 infection", "DISEASE", 24, 42], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["COVID-19", "SPECIES", 24, 32], ["COVID-19 infection", "PROBLEM", 24, 42], ["symptoms", "PROBLEM", 70, 78], ["atypical symptoms", "PROBLEM", 87, 104], ["infection", "OBSERVATION", 33, 42]]], ["3 On 27 April 2020, the Paediatric Intensive Care Society launched an alert concerning an increased number of reported cases of multisystem inflammatory disease with myocardial injury in children tested positive for COVID-19.", [["myocardial", "ANATOMY", 166, 176], ["inflammatory disease", "DISEASE", 140, 160], ["myocardial injury", "DISEASE", 166, 183], ["myocardial", "MULTI-TISSUE_STRUCTURE", 166, 176], ["children", "ORGANISM", 187, 195], ["children", "SPECIES", 187, 195], ["multisystem inflammatory disease", "PROBLEM", 128, 160], ["myocardial injury", "PROBLEM", 166, 183], ["COVID", "TEST", 216, 221], ["multisystem", "OBSERVATION_MODIFIER", 128, 139], ["inflammatory disease", "OBSERVATION", 140, 160], ["myocardial", "ANATOMY", 166, 176], ["injury", "OBSERVATION", 177, 183]]], ["4 We report here the initial presentation, medical care, and clinical course of a paediatric patient presenting with an isolated myocarditis due to COVID-19 infection.Learning points\u2022 Cases of multisystem inflammatory disease with myocardial injury are increasing in children tested positive for COVID-19.Learning points\u2022 Acute myocarditis without pulmonary lesion can be observed in COVID-19 children.Learning points\u2022 In the context of the acute COVID-19 outbreak, screening for COVID-19 infection should be performed in patients presenting with myocardial injury in an inflammatory context.Case presentationA 15-year-old boy without cardiovascular risk factors or previous history of cardiovascular disease presented to the emergency department in our institution for persistent chest pain with mild fever (<38 C) for the last 3 days.", [["myocardial", "ANATOMY", 231, 241], ["pulmonary lesion", "ANATOMY", 348, 364], ["myocardial", "ANATOMY", 547, 557], ["cardiovascular", "ANATOMY", 635, 649], ["cardiovascular", "ANATOMY", 686, 700], ["chest", "ANATOMY", 781, 786], ["myocarditis", "DISEASE", 129, 140], ["COVID-19", "CHEMICAL", 148, 156], ["infection", "DISEASE", 157, 166], ["multisystem inflammatory disease", "DISEASE", 193, 225], ["myocardial injury", "DISEASE", 231, 248], ["myocarditis", "DISEASE", 328, 339], ["pulmonary lesion", "DISEASE", 348, 364], ["COVID-19", "CHEMICAL", 480, 488], ["infection", "DISEASE", 489, 498], ["myocardial injury", "DISEASE", 547, 564], ["cardiovascular disease", "DISEASE", 686, 708], ["chest pain", "DISEASE", 781, 791], ["fever", "DISEASE", 802, 807], ["patient", "ORGANISM", 93, 100], ["myocardial", "MULTI-TISSUE_STRUCTURE", 231, 241], ["children", "ORGANISM", 267, 275], ["pulmonary", "ORGAN", 348, 357], ["children", "ORGANISM", 393, 401], ["COVID-19", "ORGANISM", 480, 488], ["patients", "ORGANISM", 522, 530], ["myocardial", "MULTI-TISSUE_STRUCTURE", 547, 557], ["boy", "ORGANISM", 623, 626], ["cardiovascular", "ANATOMICAL_SYSTEM", 686, 700], ["chest", "ORGANISM_SUBDIVISION", 781, 786], ["patient", "SPECIES", 93, 100], ["children", "SPECIES", 267, 275], ["children", "SPECIES", 393, 401], ["patients", "SPECIES", 522, 530], ["boy", "SPECIES", 623, 626], ["COVID-19", "SPECIES", 480, 488], ["an isolated myocarditis", "PROBLEM", 117, 140], ["COVID-19 infection", "PROBLEM", 148, 166], ["multisystem inflammatory disease", "PROBLEM", 193, 225], ["myocardial injury", "PROBLEM", 231, 248], ["COVID", "TEST", 296, 301], ["Acute myocarditis", "PROBLEM", 322, 339], ["pulmonary lesion", "PROBLEM", 348, 364], ["the acute COVID", "PROBLEM", 437, 452], ["screening", "TEST", 466, 475], ["COVID", "TEST", 480, 485], ["infection", "PROBLEM", 489, 498], ["myocardial injury", "PROBLEM", 547, 564], ["cardiovascular risk factors", "PROBLEM", 635, 662], ["cardiovascular disease", "PROBLEM", 686, 708], ["persistent chest pain", "PROBLEM", 770, 791], ["mild fever", "PROBLEM", 797, 807], ["myocarditis", "OBSERVATION", 129, 140], ["infection", "OBSERVATION", 157, 166], ["multisystem", "OBSERVATION_MODIFIER", 193, 204], ["inflammatory", "OBSERVATION_MODIFIER", 205, 217], ["myocardial", "ANATOMY", 231, 241], ["injury", "OBSERVATION", 242, 248], ["increasing", "OBSERVATION_MODIFIER", 253, 263], ["myocarditis", "OBSERVATION", 328, 339], ["without", "UNCERTAINTY", 340, 347], ["pulmonary", "ANATOMY", 348, 357], ["lesion", "OBSERVATION", 358, 364], ["acute", "OBSERVATION_MODIFIER", 441, 446], ["myocardial", "ANATOMY", 547, 557], ["injury", "OBSERVATION", 558, 564], ["inflammatory", "OBSERVATION", 571, 583], ["cardiovascular", "ANATOMY", 686, 700], ["disease", "OBSERVATION", 701, 708], ["chest", "ANATOMY", 781, 786], ["mild", "OBSERVATION_MODIFIER", 797, 801], ["fever", "OBSERVATION", 802, 807]]], ["The patient reported no respiratory tract signs.", [["respiratory tract", "ANATOMY", 24, 41], ["respiratory tract signs", "DISEASE", 24, 47], ["patient", "ORGANISM", 4, 11], ["tract", "ORGANISM_SUBDIVISION", 36, 41], ["patient", "SPECIES", 4, 11], ["respiratory tract signs", "PROBLEM", 24, 47], ["no", "UNCERTAINTY", 21, 23], ["respiratory tract", "ANATOMY", 24, 41]]], ["The physical examination revealed blood pressure of 100/60 mmHg, heart rate of 75 b.p.m., oxygen saturation of 98% while breathing ambient air, and body temperature of 36.9 C. The electrocardiogram showed diffuse ST elevation without reciprocal changes ( Figure 1) .Case presentationBlood tests revealed a slight increase in C-reactive protein level (41 mg/L, normal <6 mg/L) with normal leucocytes (6.1 \u00c2 10 9 /L, normal 4-10 \u00c2 10 9 cells/L) and elevated cardiac troponin 6.1 lg/L (99th upper reference limit 0.045 lg/L).", [["blood", "ANATOMY", 34, 39], ["heart", "ANATOMY", 65, 70], ["body", "ANATOMY", 148, 152], ["Blood", "ANATOMY", 283, 288], ["leucocytes", "ANATOMY", 388, 398], ["cells", "ANATOMY", 434, 439], ["cardiac", "ANATOMY", 456, 463], ["oxygen", "CHEMICAL", 90, 96], ["oxygen", "CHEMICAL", 90, 96], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["heart", "ORGAN", 65, 70], ["oxygen", "SIMPLE_CHEMICAL", 90, 96], ["body", "ORGANISM_SUBDIVISION", 148, 152], ["Blood", "ORGANISM_SUBSTANCE", 283, 288], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 325, 343], ["leucocytes", "CELL", 388, 398], ["cardiac", "ORGAN", 456, 463], ["troponin", "GENE_OR_GENE_PRODUCT", 464, 472], ["C-reactive protein", "PROTEIN", 325, 343], ["normal leucocytes", "CELL_TYPE", 381, 398], ["troponin", "PROTEIN", 464, 472], ["The physical examination", "TEST", 0, 24], ["blood pressure", "TEST", 34, 48], ["heart rate", "TEST", 65, 75], ["oxygen saturation", "TEST", 90, 107], ["breathing ambient air", "TEST", 121, 142], ["body temperature", "TEST", 148, 164], ["The electrocardiogram", "TEST", 176, 197], ["diffuse ST elevation", "PROBLEM", 205, 225], ["reciprocal changes", "PROBLEM", 234, 252], ["Blood tests", "TEST", 283, 294], ["a slight increase in C-reactive protein level", "PROBLEM", 304, 349], ["cells", "TEST", 434, 439], ["elevated cardiac troponin", "PROBLEM", 447, 472], ["heart", "ANATOMY", 65, 70], ["diffuse", "OBSERVATION_MODIFIER", 205, 212], ["elevation", "OBSERVATION", 216, 225], ["without", "UNCERTAINTY", 226, 233], ["slight", "OBSERVATION_MODIFIER", 306, 312], ["increase", "OBSERVATION_MODIFIER", 313, 321], ["leucocytes", "ANATOMY", 388, 398], ["cardiac", "ANATOMY", 456, 463]]], ["N-terminal probrain natriuretic peptide (NT-proBNP 65 ng/L, normal <300 ng/L) and D-dimer (259 ng/mL, normal <500 ng/mL) remained normal.Case presentationBecause of systematic suspicion of COVID-19 in patients with unexplained fever, a PCR was performed on a nasopharyngeal swab and resulted positive for SARS-CoV-2.", [["nasopharyngeal swab", "ANATOMY", 259, 278], ["fever", "DISEASE", 227, 232], ["N", "CHEMICAL", 0, 1], ["N-terminal probrain natriuretic peptide", "GENE_OR_GENE_PRODUCT", 0, 39], ["NT-proBNP", "GENE_OR_GENE_PRODUCT", 41, 50], ["D-dimer", "GENE_OR_GENE_PRODUCT", 82, 89], ["patients", "ORGANISM", 201, 209], ["nasopharyngeal swab", "CANCER", 259, 278], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 305, 315], ["patients", "SPECIES", 201, 209], ["SARS-CoV", "SPECIES", 305, 313], ["terminal probrain natriuretic peptide", "PROBLEM", 2, 39], ["NT", "TEST", 41, 43], ["proBNP", "TEST", 44, 50], ["D-dimer", "TEST", 82, 89], ["ng/mL", "TEST", 95, 100], ["COVID", "TEST", 189, 194], ["unexplained fever", "PROBLEM", 215, 232], ["a PCR", "TEST", 234, 239], ["a nasopharyngeal swab", "TEST", 257, 278], ["SARS", "PROBLEM", 305, 309], ["CoV", "TEST", 310, 313], ["normal", "OBSERVATION", 130, 136]]], ["A multiplex real-time PCR was also performed and resulted negative, allowing the exclusion of viral co-infections.", [["viral co-infections", "DISEASE", 94, 113], ["A multiplex real-time PCR", "TEST", 0, 25], ["viral co-infections", "PROBLEM", 94, 113], ["viral co-infections", "OBSERVATION", 94, 113]]], ["Chest CT scan showed no lung anomalies (Supplementary material online).", [["lung", "ANATOMY", 24, 28], ["lung anomalies", "DISEASE", 24, 38], ["lung", "ORGAN", 24, 28], ["Chest CT scan", "TEST", 0, 13], ["lung anomalies", "PROBLEM", 24, 38], ["no", "UNCERTAINTY", 21, 23], ["lung", "ANATOMY", 24, 28], ["anomalies", "OBSERVATION", 29, 38]]], ["There were no other family members tested positive for SARS-coV-2.Case presentationTransthoracic echocardiography showed a mild diffuse hypokinesia with left ventricular ejection fraction (LVEF) at 50%, preserved cardiac output, normal right ventricular function, no significant valvular disease, and normal pulmonary pressure without lower vena cava dilatation.", [["left ventricular", "ANATOMY", 153, 169], ["cardiac", "ANATOMY", 213, 220], ["right ventricular", "ANATOMY", 236, 253], ["valvular", "ANATOMY", 279, 287], ["pulmonary", "ANATOMY", 308, 317], ["lower vena cava", "ANATOMY", 335, 350], ["SARS", "DISEASE", 55, 59], ["hypokinesia", "DISEASE", 136, 147], ["valvular disease", "DISEASE", 279, 295], ["lower vena cava dilatation", "DISEASE", 335, 361], ["SARS-coV-2", "GENE_OR_GENE_PRODUCT", 55, 65], ["ventricular", "MULTI-TISSUE_STRUCTURE", 158, 169], ["cardiac", "ORGAN", 213, 220], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 236, 253], ["valvular", "MULTI-TISSUE_STRUCTURE", 279, 287], ["pulmonary", "ORGAN", 308, 317], ["vena cava", "MULTI-TISSUE_STRUCTURE", 341, 350], ["SARS-coV-2", "DNA", 55, 65], ["SARS", "PROBLEM", 55, 59], ["Transthoracic echocardiography", "TEST", 83, 113], ["a mild diffuse hypokinesia", "PROBLEM", 121, 147], ["left ventricular ejection fraction", "TEST", 153, 187], ["LVEF", "TEST", 189, 193], ["significant valvular disease", "PROBLEM", 267, 295], ["lower vena cava dilatation", "PROBLEM", 335, 361], ["no", "UNCERTAINTY", 11, 13], ["mild", "OBSERVATION_MODIFIER", 123, 127], ["diffuse", "OBSERVATION_MODIFIER", 128, 135], ["hypokinesia", "OBSERVATION", 136, 147], ["left ventricular", "ANATOMY", 153, 169], ["ejection fraction", "OBSERVATION", 170, 187], ["cardiac output", "OBSERVATION", 213, 227], ["normal", "OBSERVATION", 229, 235], ["right ventricular", "ANATOMY", 236, 253], ["no", "UNCERTAINTY", 264, 266], ["significant", "OBSERVATION_MODIFIER", 267, 278], ["valvular", "ANATOMY", 279, 287], ["disease", "OBSERVATION", 288, 295], ["normal", "OBSERVATION", 301, 307], ["pulmonary pressure", "OBSERVATION", 308, 326], ["lower vena cava", "ANATOMY", 335, 350], ["dilatation", "OBSERVATION", 351, 361]]], ["There was a mild pericardial effusion around the lateral wall of the left ventricle (maximum, 5 mm) without signs of tamponade (Supplementary material online).Case presentationThe patient was admitted to the cardiology intensive care unit with a diagnosis of suspected myocarditis.", [["pericardial", "ANATOMY", 17, 28], ["lateral wall", "ANATOMY", 49, 61], ["left ventricle", "ANATOMY", 69, 83], ["pericardial effusion", "DISEASE", 17, 37], ["tamponade", "DISEASE", 117, 126], ["myocarditis", "DISEASE", 269, 280], ["pericardial effusion", "PATHOLOGICAL_FORMATION", 17, 37], ["lateral wall", "MULTI-TISSUE_STRUCTURE", 49, 61], ["left ventricle", "MULTI-TISSUE_STRUCTURE", 69, 83], ["patient", "ORGANISM", 180, 187], ["patient", "SPECIES", 180, 187], ["a mild pericardial effusion", "PROBLEM", 10, 37], ["tamponade", "PROBLEM", 117, 126], ["suspected myocarditis", "PROBLEM", 259, 280], ["mild", "OBSERVATION_MODIFIER", 12, 16], ["pericardial", "ANATOMY", 17, 28], ["effusion", "OBSERVATION", 29, 37], ["lateral", "ANATOMY_MODIFIER", 49, 56], ["wall", "ANATOMY_MODIFIER", 57, 61], ["left ventricle", "ANATOMY", 69, 83], ["maximum", "OBSERVATION_MODIFIER", 85, 92], ["5 mm", "OBSERVATION_MODIFIER", 94, 98], ["without signs of", "UNCERTAINTY", 100, 116], ["tamponade", "OBSERVATION", 117, 126], ["myocarditis", "OBSERVATION", 269, 280]]], ["Given the echocardiography changes and elevated markers of myocardial injury in a low cardiovascular risk patient, emergent cardiac magnetic resonance (CMR) imaging was performed on the day of admission.Case presentationCMR showed moderate left ventricular dysfunction with LVEF of 48% and normal right ventricular function.", [["myocardial", "ANATOMY", 59, 69], ["cardiovascular", "ANATOMY", 86, 100], ["cardiac", "ANATOMY", 124, 131], ["left ventricular", "ANATOMY", 240, 256], ["right ventricular", "ANATOMY", 297, 314], ["myocardial injury", "DISEASE", 59, 76], ["left ventricular dysfunction", "DISEASE", 240, 268], ["myocardial", "MULTI-TISSUE_STRUCTURE", 59, 69], ["patient", "ORGANISM", 106, 113], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 240, 256], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 297, 314], ["patient", "SPECIES", 106, 113], ["the echocardiography changes", "TEST", 6, 34], ["elevated markers", "PROBLEM", 39, 55], ["myocardial injury", "PROBLEM", 59, 76], ["a low cardiovascular risk", "PROBLEM", 80, 105], ["emergent cardiac magnetic resonance", "TEST", 115, 150], ["CMR) imaging", "TEST", 152, 164], ["Case presentationCMR", "TEST", 203, 223], ["moderate left ventricular dysfunction", "PROBLEM", 231, 268], ["LVEF", "TEST", 274, 278], ["elevated", "OBSERVATION_MODIFIER", 39, 47], ["myocardial", "ANATOMY", 59, 69], ["injury", "OBSERVATION", 70, 76], ["moderate", "OBSERVATION_MODIFIER", 231, 239], ["left ventricular", "ANATOMY", 240, 256], ["dysfunction", "OBSERVATION", 257, 268], ["LVEF", "OBSERVATION", 274, 278], ["normal", "OBSERVATION", 290, 296], ["right ventricular", "ANATOMY", 297, 314], ["function", "OBSERVATION", 315, 323]]], ["Tissue characterization based on T2-weighted and late gadolinium enhancement sequences revealed interstitial oedema and myocardial damage involving the subepicardial layer in the posterolaterobasal wall of the left ventricle.", [["Tissue", "ANATOMY", 0, 6], ["interstitial", "ANATOMY", 96, 108], ["myocardial", "ANATOMY", 120, 130], ["subepicardial layer", "ANATOMY", 152, 171], ["posterolaterobasal wall", "ANATOMY", 179, 202], ["left ventricle", "ANATOMY", 210, 224], ["gadolinium", "CHEMICAL", 54, 64], ["interstitial oedema", "DISEASE", 96, 115], ["myocardial damage", "DISEASE", 120, 137], ["gadolinium", "CHEMICAL", 54, 64], ["Tissue", "TISSUE", 0, 6], ["interstitial oedema", "PATHOLOGICAL_FORMATION", 96, 115], ["myocardial", "MULTI-TISSUE_STRUCTURE", 120, 130], ["subepicardial layer", "TISSUE", 152, 171], ["posterolaterobasal wall", "MULTI-TISSUE_STRUCTURE", 179, 202], ["left ventricle", "MULTI-TISSUE_STRUCTURE", 210, 224], ["T2", "DNA", 33, 35], ["Tissue characterization", "TEST", 0, 23], ["T2-weighted and late gadolinium enhancement sequences", "TEST", 33, 86], ["interstitial oedema", "PROBLEM", 96, 115], ["myocardial damage", "PROBLEM", 120, 137], ["interstitial", "ANATOMY_MODIFIER", 96, 108], ["oedema", "OBSERVATION", 109, 115], ["myocardial", "ANATOMY", 120, 130], ["damage", "OBSERVATION", 131, 137], ["subepicardial", "ANATOMY_MODIFIER", 152, 165], ["layer", "ANATOMY_MODIFIER", 166, 171], ["posterolaterobasal", "ANATOMY_MODIFIER", 179, 197], ["wall", "ANATOMY_MODIFIER", 198, 202], ["left ventricle", "ANATOMY", 210, 224]]], ["First-pass perfusion was normal.", [["normal", "OBSERVATION", 25, 31]]], ["There was a mild pericardial effusion with an enhancement of the pericardium adjacent to the posterolaterobasal segment.", [["pericardial", "ANATOMY", 17, 28], ["pericardium", "ANATOMY", 65, 76], ["posterolaterobasal segment", "ANATOMY", 93, 119], ["pericardial effusion", "DISEASE", 17, 37], ["pericardial effusion", "PATHOLOGICAL_FORMATION", 17, 37], ["pericardium", "ORGAN", 65, 76], ["posterolaterobasal segment", "MULTI-TISSUE_STRUCTURE", 93, 119], ["a mild pericardial effusion", "PROBLEM", 10, 37], ["an enhancement of the pericardium", "PROBLEM", 43, 76], ["mild", "OBSERVATION_MODIFIER", 12, 16], ["pericardial", "ANATOMY", 17, 28], ["effusion", "OBSERVATION", 29, 37], ["enhancement", "OBSERVATION", 46, 57], ["pericardium", "ANATOMY", 65, 76], ["posterolaterobasal", "ANATOMY_MODIFIER", 93, 111], ["segment", "ANATOMY_MODIFIER", 112, 119]]], ["Diagnosis of acute myocarditis was thus confirmed based on the classic Lake Louise criteria 5 (Figure 2 ;Case presentationAccording to the reliable CMR findings, typical of acute myocarditis, no subsequent coronary angiography and no endomyocardial biopsy were done.Case presentationThe haemodynamics of the patient remained stable without indication for inotropic support.", [["coronary", "ANATOMY", 206, 214], ["endomyocardial", "ANATOMY", 234, 248], ["myocarditis", "DISEASE", 19, 30], ["myocarditis", "DISEASE", 179, 190], ["coronary", "MULTI-TISSUE_STRUCTURE", 206, 214], ["endomyocardial biopsy", "MULTI-TISSUE_STRUCTURE", 234, 255], ["patient", "ORGANISM", 308, 315], ["patient", "SPECIES", 308, 315], ["acute myocarditis", "PROBLEM", 13, 30], ["acute myocarditis", "PROBLEM", 173, 190], ["subsequent coronary angiography", "TEST", 195, 226], ["endomyocardial biopsy", "TEST", 234, 255], ["inotropic support", "TREATMENT", 355, 372], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["myocarditis", "OBSERVATION", 19, 30], ["acute", "OBSERVATION_MODIFIER", 173, 178], ["myocarditis", "OBSERVATION", 179, 190], ["coronary", "ANATOMY", 206, 214], ["no", "UNCERTAINTY", 231, 233], ["endomyocardial", "ANATOMY", 234, 248], ["biopsy", "OBSERVATION", 249, 255]]], ["He remained afebrile and the biological inflammatory syndrome gradually decreased.", [["afebrile", "PROBLEM", 12, 20], ["the biological inflammatory syndrome", "PROBLEM", 25, 61], ["afebrile", "OBSERVATION", 12, 20], ["inflammatory syndrome", "OBSERVATION", 40, 61], ["gradually", "OBSERVATION_MODIFIER", 62, 71], ["decreased", "OBSERVATION_MODIFIER", 72, 81]]], ["No ventricular arrythmia was observed during his hospitalization.", [["ventricular", "ANATOMY", 3, 14], ["ventricular arrythmia", "DISEASE", 3, 24], ["ventricular", "MULTI-TISSUE_STRUCTURE", 3, 14], ["ventricular arrythmia", "PROBLEM", 3, 24], ["ventricular", "ANATOMY", 3, 14], ["arrythmia", "OBSERVATION", 15, 24]]], ["High-sensitivity troponin I peaked at 13.1 lg/L (99th upper reference limit 0.045 lg/L) on day 3.", [["troponin I", "GENE_OR_GENE_PRODUCT", 17, 27], ["troponin I", "PROTEIN", 17, 27], ["High-sensitivity troponin I", "PROBLEM", 0, 27]]], ["The patient was treated with beta-blockers (bisoprolol 2.5 mg daily) and angiotensin-converting enzyme inhibitors (ramipril 2.5 mg daily).", [["bisoprolol", "CHEMICAL", 44, 54], ["angiotensin", "CHEMICAL", 73, 84], ["ramipril", "CHEMICAL", 115, 123], ["bisoprolol", "CHEMICAL", 44, 54], ["ramipril", "CHEMICAL", 115, 123], ["patient", "ORGANISM", 4, 11], ["beta-blockers", "SIMPLE_CHEMICAL", 29, 42], ["bisoprolol", "SIMPLE_CHEMICAL", 44, 54], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 73, 102], ["ramipril", "SIMPLE_CHEMICAL", 115, 123], ["patient", "SPECIES", 4, 11], ["beta-blockers", "TREATMENT", 29, 42], ["bisoprolol", "TREATMENT", 44, 54], ["angiotensin-converting enzyme inhibitors", "TREATMENT", 73, 113], ["ramipril", "TREATMENT", 115, 123]]], ["Due to this favourable clinical course, no specific treatment of COVID-19 was introduced.Case presentationThe patient was discharged from hospital on day 5 with a CMR scheduled control at 6 months.", [["COVID-19", "CHEMICAL", 65, 73], ["COVID-19", "CHEMICAL", 65, 73], ["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 110, 117], ["COVID", "TREATMENT", 65, 70], ["a CMR scheduled control", "TREATMENT", 161, 184]]], ["The echocardiography performed atAprilFirst symptoms: persistent chest pain with mild fever (38 C) 10 April 10:00 hAprilThe patient presented to the emergency department.", [["chest", "ANATOMY", 65, 70], ["chest pain", "DISEASE", 65, 75], ["fever", "DISEASE", 86, 91], ["chest", "ORGANISM_SUBDIVISION", 65, 70], ["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131], ["The echocardiography", "TEST", 0, 20], ["atAprilFirst symptoms", "PROBLEM", 31, 52], ["persistent chest pain", "PROBLEM", 54, 75], ["mild fever", "PROBLEM", 81, 91], ["persistent", "OBSERVATION_MODIFIER", 54, 64], ["chest", "ANATOMY", 65, 70]]], ["Despite apyrexia and the absence of respiratory signs, a nasopharyngeal swab was performed.April10 April 14:00 h Nasopharyngeal swab returned positive for SARS-CoV-2.AprilChest CT scan showed no lung anomalies.AprilBlood tests revealed a slight increase in C-reactive protein level (41 mg/L, normal <6 mg/L) with normal leucocytes (6.1 \u00c2 10 9 / L), and elevated cardiac troponin 6.1 lg/L (99th upper reference limit 0.045 lg/L).", [["respiratory", "ANATOMY", 36, 47], ["nasopharyngeal swab", "ANATOMY", 57, 76], ["Nasopharyngeal swab", "ANATOMY", 113, 132], ["lung", "ANATOMY", 195, 199], ["leucocytes", "ANATOMY", 320, 330], ["cardiac", "ANATOMY", 362, 369], ["apyrexia", "DISEASE", 8, 16], ["respiratory signs", "DISEASE", 36, 53], ["lung anomalies", "DISEASE", 195, 209], ["nasopharyngeal swab", "CANCER", 57, 76], ["Nasopharyngeal swab", "CANCER", 113, 132], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 155, 165], ["lung", "ORGAN", 195, 199], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 257, 275], ["leucocytes", "CELL", 320, 330], ["troponin", "GENE_OR_GENE_PRODUCT", 370, 378], ["C-reactive protein", "PROTEIN", 257, 275], ["normal leucocytes", "CELL_TYPE", 313, 330], ["SARS-CoV", "SPECIES", 155, 163], ["apyrexia", "TREATMENT", 8, 16], ["respiratory signs", "PROBLEM", 36, 53], ["a nasopharyngeal swab", "TEST", 55, 76], ["Nasopharyngeal swab", "TEST", 113, 132], ["SARS", "PROBLEM", 155, 159], ["CoV", "TEST", 160, 163], ["AprilChest CT scan", "TEST", 166, 184], ["lung anomalies", "PROBLEM", 195, 209], ["AprilBlood tests", "TEST", 210, 226], ["a slight increase in C-reactive protein level", "PROBLEM", 236, 281], ["elevated cardiac troponin", "PROBLEM", 353, 378], ["respiratory signs", "OBSERVATION", 36, 53], ["nasopharyngeal", "ANATOMY", 57, 71], ["no", "UNCERTAINTY", 192, 194], ["lung", "ANATOMY", 195, 199], ["anomalies", "OBSERVATION", 200, 209], ["slight", "OBSERVATION_MODIFIER", 238, 244], ["increase", "OBSERVATION_MODIFIER", 245, 253], ["reactive", "OBSERVATION_MODIFIER", 259, 267], ["leucocytes", "ANATOMY", 320, 330], ["cardiac", "ANATOMY", 362, 369]]], ["Transthoracic echocardiography showed a mild diffuse hypokinesia with left ventricular ejection fraction at 50%, mild pericardial effusion around the lateral wall of the left ventricle (maximum, 5 mm) without signs of tamponade.April10 April 14:30AprilThe patient was admitted to the cardiologic intensive care unit with a diagnosis of suspected myocarditis.DiscussionHerein, we describe a 15-year-old boy without a history of cardiovascular disease admitted to the hospital with COVID-19 and an acute myocarditis.", [["left ventricular", "ANATOMY", 70, 86], ["pericardial", "ANATOMY", 118, 129], ["lateral wall", "ANATOMY", 150, 162], ["left ventricle", "ANATOMY", 170, 184], ["cardiovascular", "ANATOMY", 427, 441], ["hypokinesia", "DISEASE", 53, 64], ["pericardial effusion", "DISEASE", 118, 138], ["tamponade", "DISEASE", 218, 227], ["myocarditis", "DISEASE", 346, 357], ["cardiovascular disease", "DISEASE", 427, 449], ["myocarditis", "DISEASE", 502, 513], ["ventricular", "MULTI-TISSUE_STRUCTURE", 75, 86], ["pericardial effusion", "PATHOLOGICAL_FORMATION", 118, 138], ["lateral wall", "MULTI-TISSUE_STRUCTURE", 150, 162], ["left ventricle", "MULTI-TISSUE_STRUCTURE", 170, 184], ["patient", "ORGANISM", 256, 263], ["boy", "ORGANISM", 402, 405], ["cardiovascular", "ANATOMICAL_SYSTEM", 427, 441], ["patient", "SPECIES", 256, 263], ["boy", "SPECIES", 402, 405], ["Transthoracic echocardiography", "TEST", 0, 30], ["a mild diffuse hypokinesia", "PROBLEM", 38, 64], ["left ventricular ejection fraction", "TEST", 70, 104], ["mild pericardial effusion", "PROBLEM", 113, 138], ["tamponade", "PROBLEM", 218, 227], ["suspected myocarditis", "PROBLEM", 336, 357], ["cardiovascular disease", "PROBLEM", 427, 449], ["COVID", "TEST", 480, 485], ["an acute myocarditis", "PROBLEM", 493, 513], ["mild", "OBSERVATION_MODIFIER", 40, 44], ["diffuse", "OBSERVATION_MODIFIER", 45, 52], ["hypokinesia", "OBSERVATION", 53, 64], ["left ventricular", "ANATOMY", 70, 86], ["ejection fraction", "OBSERVATION", 87, 104], ["50%", "OBSERVATION", 108, 111], ["mild", "OBSERVATION_MODIFIER", 113, 117], ["pericardial", "ANATOMY", 118, 129], ["effusion", "OBSERVATION", 130, 138], ["lateral", "ANATOMY_MODIFIER", 150, 157], ["wall", "ANATOMY_MODIFIER", 158, 162], ["left ventricle", "ANATOMY", 170, 184], ["maximum", "OBSERVATION_MODIFIER", 186, 193], ["5 mm", "OBSERVATION", 195, 199], ["without signs of", "UNCERTAINTY", 201, 217], ["tamponade", "OBSERVATION", 218, 227], ["myocarditis", "OBSERVATION", 346, 357], ["cardiovascular", "ANATOMY", 427, 441], ["disease", "OBSERVATION", 442, 449], ["acute", "OBSERVATION_MODIFIER", 496, 501], ["myocarditis", "OBSERVATION", 502, 513]]], ["While the spectrum of clinical manifestation is highly related to the inflammation process of the respiratory tract, this case provides evidence of isolated cardiac involvement in a teenager at low cardiovascular risk without respiratory symptoms and a normal chest CT scan.", [["respiratory tract", "ANATOMY", 98, 115], ["cardiac", "ANATOMY", 157, 164], ["cardiovascular", "ANATOMY", 198, 212], ["respiratory", "ANATOMY", 226, 237], ["inflammation", "DISEASE", 70, 82], ["cardiac involvement", "DISEASE", 157, 176], ["respiratory tract", "ORGANISM_SUBDIVISION", 98, 115], ["cardiac", "ORGAN", 157, 164], ["chest", "ORGANISM_SUBDIVISION", 260, 265], ["clinical manifestation", "PROBLEM", 22, 44], ["the inflammation process of the respiratory tract", "PROBLEM", 66, 115], ["isolated cardiac involvement", "PROBLEM", 148, 176], ["respiratory symptoms", "PROBLEM", 226, 246], ["a normal chest CT scan", "TEST", 251, 273], ["inflammation", "OBSERVATION", 70, 82], ["respiratory tract", "ANATOMY", 98, 115], ["cardiac", "ANATOMY", 157, 164], ["involvement", "OBSERVATION", 165, 176], ["chest", "ANATOMY", 260, 265]]], ["First, although children are less likely than older adults to become severely ill, there are subpopulations of at-risk children including those with an underlying pulmonary pathology or immunocompromising conditions.", [["pulmonary", "ANATOMY", 163, 172], ["children", "ORGANISM", 16, 24], ["children", "ORGANISM", 119, 127], ["pulmonary", "ORGAN", 163, 172], ["children", "SPECIES", 16, 24], ["children", "SPECIES", 119, 127], ["severely ill", "PROBLEM", 69, 81], ["an underlying pulmonary pathology", "PROBLEM", 149, 182], ["immunocompromising conditions", "PROBLEM", 186, 215], ["pulmonary", "ANATOMY", 163, 172], ["pathology", "OBSERVATION", 173, 182]]], ["Nevertheless, no risk factor was found in our patient, including the absence of family history of cardiomyopathies.", [["cardiomyopathies", "DISEASE", 98, 114], ["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53], ["risk factor", "PROBLEM", 17, 28], ["cardiomyopathies", "PROBLEM", 98, 114], ["no", "UNCERTAINTY", 14, 16], ["cardiomyopathies", "OBSERVATION", 98, 114]]], ["Recently, an alert was launched concerning an increased number of reported cases of multisystem inflammatory disease with myocardial injury in children tested positive for COVID-19.", [["myocardial", "ANATOMY", 122, 132], ["inflammatory disease", "DISEASE", 96, 116], ["myocardial injury", "DISEASE", 122, 139], ["myocardial", "MULTI-TISSUE_STRUCTURE", 122, 132], ["children", "ORGANISM", 143, 151], ["children", "SPECIES", 143, 151], ["multisystem inflammatory disease", "PROBLEM", 84, 116], ["myocardial injury", "PROBLEM", 122, 139], ["COVID", "TEST", 172, 177], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["multisystem", "OBSERVATION_MODIFIER", 84, 95], ["inflammatory disease", "OBSERVATION", 96, 116], ["myocardial", "ANATOMY", 122, 132], ["injury", "OBSERVATION", 133, 139]]], ["4 Secondly, infection with viral pathogens, such as influenza and parvovirus B-19, has been widely described as the most common infectious cause of acute myocarditis.", [["infection", "DISEASE", 12, 21], ["viral pathogens", "DISEASE", 27, 42], ["influenza", "DISEASE", 52, 61], ["parvovirus B-19", "CHEMICAL", 66, 81], ["myocarditis", "DISEASE", 154, 165], ["parvovirus B-19", "ORGANISM", 66, 81], ["parvovirus B-19", "SPECIES", 66, 81], ["parvovirus B-19", "SPECIES", 66, 81], ["infection", "PROBLEM", 12, 21], ["viral pathogens", "PROBLEM", 27, 42], ["influenza", "PROBLEM", 52, 61], ["parvovirus B", "PROBLEM", 66, 78], ["acute myocarditis", "PROBLEM", 148, 165], ["infection", "OBSERVATION", 12, 21], ["viral pathogens", "OBSERVATION", 27, 42], ["most common", "OBSERVATION_MODIFIER", 116, 127], ["infectious", "OBSERVATION", 128, 138], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["myocarditis", "OBSERVATION", 154, 165]]], ["6 However, less is known about the cardiac involvement as a complication of SARS-CoV-2 infection.", [["cardiac", "ANATOMY", 35, 42], ["SARS-CoV-2 infection", "DISEASE", 76, 96], ["cardiac", "ORGAN", 35, 42], ["SARS-CoV-2", "ORGANISM", 76, 86], ["the cardiac involvement", "PROBLEM", 31, 54], ["SARS", "PROBLEM", 76, 80], ["CoV", "PROBLEM", 81, 84], ["2 infection", "PROBLEM", 85, 96], ["cardiac", "ANATOMY", 35, 42], ["involvement", "OBSERVATION", 43, 54], ["infection", "OBSERVATION", 87, 96]]], ["The attributable risk for severe disease from COVID-19 in children is challenging to discern.", [["COVID-19", "CHEMICAL", 46, 54], ["children", "ORGANISM", 58, 66], ["children", "SPECIES", 58, 66], ["severe disease", "PROBLEM", 26, 40], ["COVID", "TEST", 46, 51], ["attributable risk for", "UNCERTAINTY", 4, 25], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["disease", "OBSERVATION", 33, 40]]], ["Previous studies have revealed that children in whom coronaviruses are detected from the respiratory tract can have viral co-infections in up to two-thirds of cases.", [["respiratory tract", "ANATOMY", 89, 106], ["viral co-infections", "DISEASE", 116, 135], ["children", "ORGANISM", 36, 44], ["coronaviruses", "ORGANISM", 53, 66], ["respiratory tract", "ORGANISM_SUBDIVISION", 89, 106], ["children", "SPECIES", 36, 44], ["Previous studies", "TEST", 0, 16], ["coronaviruses", "PROBLEM", 53, 66], ["viral co-infections", "PROBLEM", 116, 135], ["respiratory tract", "ANATOMY", 89, 106]]], ["7 In order to exclude viral co-infections, a multiplex real-time PCR was performed and resulted negative.DiscussionThirdly, determination of the presence of myocardial injury in the COVID-19 population should be performed in all symptomatic patient.", [["myocardial", "ANATOMY", 157, 167], ["viral co-infections", "DISEASE", 22, 41], ["myocardial injury", "DISEASE", 157, 174], ["myocardial", "MULTI-TISSUE_STRUCTURE", 157, 167], ["patient", "ORGANISM", 241, 248], ["patient", "SPECIES", 241, 248], ["viral co-infections", "PROBLEM", 22, 41], ["a multiplex real-time PCR", "TEST", 43, 68], ["myocardial injury", "PROBLEM", 157, 174], ["the COVID", "TEST", 178, 187], ["viral", "OBSERVATION_MODIFIER", 22, 27], ["co-infections", "OBSERVATION", 28, 41], ["myocardial", "ANATOMY", 157, 167], ["injury", "OBSERVATION", 168, 174]]], ["Shi et al. 8 reported the importance of myocardial injury in COVID-19 mortality in 416 patients hospitalized with COVID-19, of whom 57 died.", [["myocardial", "ANATOMY", 40, 50], ["myocardial injury", "DISEASE", 40, 57], ["myocardial", "MULTI-TISSUE_STRUCTURE", 40, 50], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["myocardial injury", "PROBLEM", 40, 57], ["myocardial", "ANATOMY", 40, 50], ["injury", "OBSERVATION", 51, 57]]], ["Approximately 20% of patients had cardiac injury defined as high-sensitivity troponin I greater than the 99% percentile upper reference limit.", [["cardiac", "ANATOMY", 34, 41], ["cardiac injury", "DISEASE", 34, 48], ["patients", "ORGANISM", 21, 29], ["cardiac", "ORGAN", 34, 41], ["troponin I", "GENE_OR_GENE_PRODUCT", 77, 87], ["troponin I", "PROTEIN", 77, 87], ["patients", "SPECIES", 21, 29], ["cardiac injury", "PROBLEM", 34, 48], ["troponin I", "TEST", 77, 87], ["cardiac", "ANATOMY", 34, 41], ["injury", "OBSERVATION", 42, 48]]], ["Unlike our patient, patients with elevated cardiac troponin in that study were older, had more comorbidities, and had higher levels of leucocytes, NT-proBNP, C-reactive protein, and procalcitonin, but lower lymphocyte counts.", [["cardiac", "ANATOMY", 43, 50], ["leucocytes", "ANATOMY", 135, 145], ["lymphocyte", "ANATOMY", 207, 217], ["patient", "ORGANISM", 11, 18], ["patients", "ORGANISM", 20, 28], ["cardiac", "ORGAN", 43, 50], ["troponin", "GENE_OR_GENE_PRODUCT", 51, 59], ["leucocytes", "CELL", 135, 145], ["NT-proBNP", "GENE_OR_GENE_PRODUCT", 147, 156], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 158, 176], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 182, 195], ["lymphocyte", "CELL", 207, 217], ["cardiac troponin", "PROTEIN", 43, 59], ["leucocytes", "CELL_TYPE", 135, 145], ["proBNP", "PROTEIN", 150, 156], ["C-reactive protein", "PROTEIN", 158, 176], ["procalcitonin", "PROTEIN", 182, 195], ["patient", "SPECIES", 11, 18], ["patients", "SPECIES", 20, 28], ["elevated cardiac troponin", "PROBLEM", 34, 59], ["higher levels of leucocytes", "PROBLEM", 118, 145], ["NT", "TEST", 147, 149], ["proBNP", "TEST", 150, 156], ["C", "TEST", 158, 159], ["reactive protein", "TEST", 160, 176], ["procalcitonin", "TEST", 182, 195], ["lower lymphocyte counts", "PROBLEM", 201, 224], ["cardiac", "ANATOMY", 43, 50], ["leucocytes", "ANATOMY", 135, 145], ["reactive protein", "OBSERVATION", 160, 176], ["lower lymphocyte counts", "OBSERVATION", 201, 224]]], ["Patients with cardiac injury had a higher incidence of acute respiratory distress syndrome (ARDS) (58.5% vs. 14.7%; P < 0.001) and a higher mortality rate (51.2% vs. 4.5%; P < 0.001) than those without cardiac injury.", [["cardiac", "ANATOMY", 14, 21], ["respiratory", "ANATOMY", 61, 72], ["cardiac", "ANATOMY", 202, 209], ["cardiac injury", "DISEASE", 14, 28], ["acute respiratory distress syndrome", "DISEASE", 55, 90], ["ARDS", "DISEASE", 92, 96], ["cardiac injury", "DISEASE", 202, 216], ["Patients", "ORGANISM", 0, 8], ["cardiac", "ORGAN", 14, 21], ["cardiac", "ORGAN", 202, 209], ["Patients", "SPECIES", 0, 8], ["cardiac injury", "PROBLEM", 14, 28], ["acute respiratory distress syndrome", "PROBLEM", 55, 90], ["ARDS", "PROBLEM", 92, 96], ["P", "TEST", 116, 117], ["a higher mortality rate", "PROBLEM", 131, 154], ["P", "TEST", 172, 173], ["cardiac injury", "PROBLEM", 202, 216], ["cardiac", "ANATOMY", 14, 21], ["injury", "OBSERVATION", 22, 28], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["respiratory distress", "OBSERVATION", 61, 81], ["without", "UNCERTAINTY", 194, 201], ["cardiac", "ANATOMY", 202, 209], ["injury", "OBSERVATION", 210, 216]]], ["In multivariable adjusted models, cardiac injury and ARDS were significantly and independently associated with mortality, with hazard ratios of 4.26 and 7.89, respectively.DiscussionFourthly, patients presenting with myocardial injury may be susceptible to proarrhythmic effects of COVID-19-related issues such as fever, stress, electrolyte disturbances, and use of antiviral drugs.", [["cardiac", "ANATOMY", 34, 41], ["myocardial", "ANATOMY", 217, 227], ["cardiac injury", "DISEASE", 34, 48], ["ARDS", "DISEASE", 53, 57], ["myocardial injury", "DISEASE", 217, 234], ["COVID-19", "CHEMICAL", 282, 290], ["fever", "DISEASE", 314, 319], ["electrolyte disturbances", "DISEASE", 329, 353], ["COVID-19", "CHEMICAL", 282, 290], ["cardiac", "ORGAN", 34, 41], ["patients", "ORGANISM", 192, 200], ["myocardial", "MULTI-TISSUE_STRUCTURE", 217, 227], ["patients", "SPECIES", 192, 200], ["cardiac injury", "PROBLEM", 34, 48], ["ARDS", "PROBLEM", 53, 57], ["hazard ratios", "TEST", 127, 140], ["myocardial injury", "PROBLEM", 217, 234], ["COVID", "TEST", 282, 287], ["fever", "PROBLEM", 314, 319], ["stress", "PROBLEM", 321, 327], ["electrolyte disturbances", "PROBLEM", 329, 353], ["antiviral drugs", "TREATMENT", 366, 381], ["cardiac", "ANATOMY", 34, 41], ["injury", "OBSERVATION", 42, 48], ["ARDS", "OBSERVATION", 53, 57], ["myocardial", "ANATOMY", 217, 227], ["injury", "OBSERVATION", 228, 234]]], ["Our patient did not present with any ventricular arrhythmia during his hospitalization.", [["ventricular", "ANATOMY", 37, 48], ["ventricular arrhythmia", "DISEASE", 37, 59], ["patient", "ORGANISM", 4, 11], ["ventricular", "ORGAN", 37, 48], ["patient", "SPECIES", 4, 11], ["any ventricular arrhythmia", "PROBLEM", 33, 59], ["ventricular", "ANATOMY", 37, 48], ["arrhythmia", "OBSERVATION", 49, 59]]], ["Moreover, immune injury observed in COVID-19 patients may be the main cause of myocardial injury.", [["myocardial", "ANATOMY", 79, 89], ["immune injury", "DISEASE", 10, 23], ["myocardial injury", "DISEASE", 79, 96], ["patients", "ORGANISM", 45, 53], ["myocardial", "MULTI-TISSUE_STRUCTURE", 79, 89], ["patients", "SPECIES", 45, 53], ["immune injury", "PROBLEM", 10, 23], ["myocardial injury", "PROBLEM", 79, 96], ["myocardial", "ANATOMY", 79, 89], ["injury", "OBSERVATION", 90, 96]]], ["A study showed that after SARS-CoV infection, interferon-related cytokine storms may be involved in the immunopathology of SARS patients.", [["SARS-CoV infection", "DISEASE", 26, 44], ["SARS", "DISEASE", 123, 127], ["SARS-CoV", "ORGANISM", 26, 34], ["interferon-related cytokine", "GENE_OR_GENE_PRODUCT", 46, 73], ["patients", "ORGANISM", 128, 136], ["interferon", "PROTEIN", 46, 56], ["cytokine", "PROTEIN", 65, 73], ["patients", "SPECIES", 128, 136], ["SARS-CoV", "SPECIES", 26, 34], ["A study", "TEST", 0, 7], ["SARS", "PROBLEM", 26, 30], ["CoV infection", "PROBLEM", 31, 44], ["interferon", "TREATMENT", 46, 56], ["cytokine storms", "PROBLEM", 65, 80], ["infection", "OBSERVATION", 35, 44]]], ["9 Cytokine storms may lead to increased vascular wall permeability and myocardial oedema.", [["vascular wall", "ANATOMY", 40, 53], ["myocardial", "ANATOMY", 71, 81], ["myocardial oedema", "DISEASE", 71, 88], ["vascular wall", "TISSUE", 40, 53], ["myocardial oedema", "PATHOLOGICAL_FORMATION", 71, 88], ["Cytokine storms", "PROBLEM", 2, 17], ["increased vascular wall permeability", "PROBLEM", 30, 66], ["myocardial oedema", "PROBLEM", 71, 88], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["vascular wall", "ANATOMY", 40, 53], ["permeability", "OBSERVATION_MODIFIER", 54, 66], ["myocardial", "ANATOMY", 71, 81], ["oedema", "OBSERVATION", 82, 88]]], ["10 However, in view of the patient's rapid recovery, low increase of C-reactive protein, Isolated COVID-19 myocarditis in a paediatric patient . . . . . . . and the early presentation of the acute myocarditis, myocardial injury was considered to be transient damage from viral infection rather than from the cytokine storm.", [["myocardial", "ANATOMY", 210, 220], ["myocarditis", "DISEASE", 107, 118], ["myocarditis", "DISEASE", 197, 208], ["myocardial injury", "DISEASE", 210, 227], ["viral infection", "DISEASE", 271, 286], ["patient", "ORGANISM", 27, 34], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 69, 87], ["patient", "ORGANISM", 135, 142], ["myocardial", "MULTI-TISSUE_STRUCTURE", 210, 220], ["C-reactive protein", "PROTEIN", 69, 87], ["cytokine", "PROTEIN", 308, 316], ["patient", "SPECIES", 27, 34], ["patient", "SPECIES", 135, 142], ["low increase of C-reactive protein", "PROBLEM", 53, 87], ["Isolated COVID", "PROBLEM", 89, 103], ["myocarditis", "PROBLEM", 107, 118], ["the acute myocarditis", "PROBLEM", 187, 208], ["myocardial injury", "PROBLEM", 210, 227], ["transient damage", "PROBLEM", 249, 265], ["viral infection", "PROBLEM", 271, 286], ["the cytokine storm", "PROBLEM", 304, 322], ["reactive protein", "OBSERVATION", 71, 87], ["myocarditis", "OBSERVATION", 107, 118], ["acute", "OBSERVATION_MODIFIER", 191, 196], ["myocarditis", "OBSERVATION", 197, 208], ["myocardial", "ANATOMY", 210, 220], ["injury", "OBSERVATION", 221, 227], ["transient", "OBSERVATION_MODIFIER", 249, 258], ["damage", "OBSERVATION", 259, 265], ["viral", "OBSERVATION_MODIFIER", 271, 276], ["infection", "OBSERVATION", 277, 286], ["cytokine storm", "OBSERVATION", 308, 322]]], ["In addition, the clinical outcome of the patient was favourable, without use of corticosteroids, antiviral drugs, or chloroquine.ConclusionWe report here the case of a paediatric patient presenting with an isolated acute myocarditis as the sole manifestation of COVID-19 infection and without pulmonary lesion.ConclusionIn the context of an acute COVID-19 outbreak, screening for COVID-19 infection should be performed in children presenting with myocardial injury in an inflammatory context.Lead author biographyDr Quenitn Fischer is a 31-year-old interventional cardiologist working in Bichat Hospital, Paris, France. in short-axis view showed diffuse myocardial signal hyperintensity involving the posterolaterobasal wall of the left ventricle, suggesting interstitial oedema.", [["pulmonary lesion", "ANATOMY", 293, 309], ["myocardial", "ANATOMY", 447, 457], ["myocardial", "ANATOMY", 654, 664], ["posterolaterobasal wall", "ANATOMY", 701, 724], ["left ventricle", "ANATOMY", 732, 746], ["interstitial", "ANATOMY", 759, 771], ["chloroquine", "CHEMICAL", 117, 128], ["myocarditis", "DISEASE", 221, 232], ["COVID-19", "CHEMICAL", 262, 270], ["infection", "DISEASE", 271, 280], ["pulmonary lesion", "DISEASE", 293, 309], ["COVID-19", "CHEMICAL", 380, 388], ["infection", "DISEASE", 389, 398], ["myocardial injury", "DISEASE", 447, 464], ["interstitial oedema", "DISEASE", 759, 778], ["chloroquine", "CHEMICAL", 117, 128], ["patient", "ORGANISM", 41, 48], ["chloroquine", "SIMPLE_CHEMICAL", 117, 128], ["patient", "ORGANISM", 179, 186], ["pulmonary lesion", "PATHOLOGICAL_FORMATION", 293, 309], ["COVID-19", "ORGANISM", 380, 388], ["children", "ORGANISM", 422, 430], ["myocardial", "MULTI-TISSUE_STRUCTURE", 447, 457], ["myocardial signal", "PATHOLOGICAL_FORMATION", 654, 671], ["posterolaterobasal wall", "MULTI-TISSUE_STRUCTURE", 701, 724], ["ventricle", "MULTI-TISSUE_STRUCTURE", 737, 746], ["interstitial oedema", "PATHOLOGICAL_FORMATION", 759, 778], ["patient", "SPECIES", 41, 48], ["patient", "SPECIES", 179, 186], ["children", "SPECIES", 422, 430], ["COVID-19", "SPECIES", 380, 388], ["corticosteroids", "TREATMENT", 80, 95], ["antiviral drugs", "TREATMENT", 97, 112], ["chloroquine", "TREATMENT", 117, 128], ["an isolated acute myocarditis", "PROBLEM", 203, 232], ["COVID-19 infection", "PROBLEM", 262, 280], ["pulmonary lesion", "PROBLEM", 293, 309], ["an acute COVID", "PROBLEM", 338, 352], ["screening", "TEST", 366, 375], ["COVID", "TEST", 380, 385], ["infection", "PROBLEM", 389, 398], ["myocardial injury", "PROBLEM", 447, 464], ["short-axis view", "TEST", 623, 638], ["diffuse myocardial signal hyperintensity", "PROBLEM", 646, 686], ["interstitial oedema", "PROBLEM", 759, 778], ["acute", "OBSERVATION_MODIFIER", 215, 220], ["myocarditis", "OBSERVATION", 221, 232], ["infection", "OBSERVATION", 271, 280], ["without", "UNCERTAINTY", 285, 292], ["pulmonary", "ANATOMY", 293, 302], ["lesion", "OBSERVATION", 303, 309], ["acute", "OBSERVATION_MODIFIER", 341, 346], ["infection", "OBSERVATION", 389, 398], ["myocardial", "ANATOMY", 447, 457], ["injury", "OBSERVATION", 458, 464], ["inflammatory", "OBSERVATION", 471, 483], ["diffuse", "OBSERVATION_MODIFIER", 646, 653], ["myocardial", "ANATOMY", 654, 664], ["signal hyperintensity", "OBSERVATION", 665, 686], ["posterolaterobasal", "ANATOMY_MODIFIER", 701, 719], ["wall", "ANATOMY_MODIFIER", 720, 724], ["left ventricle", "ANATOMY", 732, 746], ["suggesting", "UNCERTAINTY", 748, 758], ["interstitial", "ANATOMY_MODIFIER", 759, 771], ["oedema", "OBSERVATION", 772, 778]]], ["Myocardial damage was confirmed on the late gadolinium enhancement involving the subepicardial layer of the myocardium (C and D).", [["Myocardial", "ANATOMY", 0, 10], ["subepicardial layer", "ANATOMY", 81, 100], ["myocardium", "ANATOMY", 108, 118], ["Myocardial damage", "DISEASE", 0, 17], ["gadolinium", "CHEMICAL", 44, 54], ["gadolinium", "CHEMICAL", 44, 54], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 0, 10], ["subepicardial layer", "TISSUE", 81, 100], ["myocardium", "MULTI-TISSUE_STRUCTURE", 108, 118], ["Myocardial damage", "PROBLEM", 0, 17], ["the late gadolinium enhancement", "PROBLEM", 35, 66], ["damage", "OBSERVATION", 11, 17], ["subepicardial", "ANATOMY_MODIFIER", 81, 94], ["layer", "ANATOMY_MODIFIER", 95, 100], ["myocardium", "ANATOMY", 108, 118]]], ["Pericardial enhancement (D) and pericardial effusion were seen around the laterobasal wall of the left ventricle (Supplementary material online, Video S1), suggesting pericardial oedema.", [["Pericardial", "ANATOMY", 0, 11], ["pericardial effusion", "ANATOMY", 32, 52], ["laterobasal wall", "ANATOMY", 74, 90], ["left ventricle", "ANATOMY", 98, 112], ["pericardial", "ANATOMY", 167, 178], ["pericardial effusion", "DISEASE", 32, 52], ["pericardial oedema", "DISEASE", 167, 185], ["Pericardial", "MULTI-TISSUE_STRUCTURE", 0, 11], ["laterobasal wall", "MULTI-TISSUE_STRUCTURE", 74, 90], ["ventricle", "MULTI-TISSUE_STRUCTURE", 103, 112], ["pericardial oedema", "PATHOLOGICAL_FORMATION", 167, 185], ["Pericardial enhancement (D) and pericardial effusion", "PROBLEM", 0, 52], ["pericardial oedema", "PROBLEM", 167, 185], ["enhancement", "OBSERVATION", 12, 23], ["pericardial", "ANATOMY", 32, 43], ["effusion", "OBSERVATION", 44, 52], ["laterobasal", "ANATOMY_MODIFIER", 74, 85], ["wall", "ANATOMY_MODIFIER", 86, 90], ["left ventricle", "ANATOMY", 98, 112], ["suggesting", "UNCERTAINTY", 156, 166], ["pericardial", "ANATOMY", 167, 178], ["oedema", "OBSERVATION", 179, 185]]]], "e173715510d484cfd2cf56abd035900bdccb0a30": [["4 Ulrich Beck had already stressed the fact that the often invisible nature of the global risks, the unforeseeability of their effects and the only potential character of the damage which they provoke mean that they are removed from our perception and require the intervention of a re fl exive attitude interpreting the new scenarios through a knowledge that is equal to the new challenges.", [["the damage", "PROBLEM", 171, 181], ["a re fl exive attitude", "TREATMENT", 280, 302], ["damage", "OBSERVATION", 175, 181], ["new", "OBSERVATION_MODIFIER", 375, 378]]], ["But in reality the problem is more complex still, since rather than an absence, we are faced with processes that distort the perception and assessment of the risk, which affect both the emotional and the cognitive spheres, and above all how they interact together.", [["assessment", "TEST", 140, 150], ["more complex", "OBSERVATION_MODIFIER", 30, 42]]]], "65084f5b311cb50b0eca19c8f1a97ca89a69f5fb": [["IntroductionSARS (severe acute respiratory syndrome) exploded on the face of the global village and on health care like a dormant volcano erupting in the dead of night.", [["IntroductionSARS", "DISEASE", 0, 16], ["acute respiratory syndrome", "DISEASE", 25, 51], ["IntroductionSARS (severe acute respiratory syndrome", "PROBLEM", 0, 51], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["respiratory syndrome", "OBSERVATION", 31, 51]]], ["Patients, doctors and nurses in hospital intensive care units (ICUs) arguably bore the brunt of the SARS epidemic more acutely and painfully than most other groups, especially in geographic 'hotspots' such as Toronto [1] .IntroductionThere are many ethical issues raised by the SARS epidemic, including global cooperation and information sharing [2] , isolation of patients and their families, quarantining of patients and health care workers [3] , lack of patient access to medical care [4] , loss of privacy, stigmatization of individuals or populations [5] , and appropriate priority setting and use of limited resources.IntroductionMuch has already been published describing the epidemiology of the illness, its clinical symptoms and its treatment.", [["SARS", "DISEASE", 100, 104], ["SARS", "DISEASE", 278, 282], ["illness", "DISEASE", 703, 710], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 365, 373], ["patients", "ORGANISM", 410, 418], ["patient", "ORGANISM", 457, 464], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 365, 373], ["patients", "SPECIES", 410, 418], ["patient", "SPECIES", 457, 464], ["the SARS epidemic", "PROBLEM", 96, 113], ["many ethical issues", "PROBLEM", 244, 263], ["the illness", "PROBLEM", 699, 710], ["its clinical symptoms", "PROBLEM", 712, 733], ["its treatment", "TREATMENT", 738, 751]]], ["There has also been some discussion of the nonmedical effects of SARS and potentially future similar outbreaks on the relationships between health care providers and patients and families, their notions of professional integrity, and issues of resource allocation [6] .", [["SARS", "DISEASE", 65, 69], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["SARS", "PROBLEM", 65, 69]]], ["Such ethical and psychologic issues -the 'collateral damage' of the outbreak -cannot be ignored because they challenge some deeply held convictions and ethical conceptions in ways that they have never been questioned previously and, as a result, may be altered for ever.Trust, truth-telling and relationships with colleaguesDuring the SARS outbreak, frontline health care providers found themselves in the midst of conflicting and confusing reports of the nature, seriousness, infectiousness and precautions needed.", [["SARS", "DISEASE", 335, 339], ["Such ethical and psychologic issues", "PROBLEM", 0, 35], ["infectiousness", "PROBLEM", 477, 491], ["precautions", "TREATMENT", 496, 507]]], ["Although droplet transmission was repeatedly said to be the main mode of transmission, providers were ordered to take not only droplet but also fomite and airborne precautions as well, all the while being told that this was not an airborne virus.", [["droplet", "TREATMENT", 127, 134], ["airborne precautions", "TREATMENT", 155, 175], ["an airborne virus", "PROBLEM", 228, 245], ["airborne virus", "OBSERVATION", 231, 245]]], ["On the one hand, measures to increase personal safety were welcomed; on the other, the reassurances that did not always match infection control directives raised concerns about whose information, among infection control and public health colleagues, was most reliable.", [["infection", "DISEASE", 126, 135], ["infection", "DISEASE", 202, 211], ["infection", "OBSERVATION", 126, 135]]], ["Media reports further contributed to confusion and lack of trust by sensationalizing world events, with daily headlines reporting the number of suspected and probable cases, the number of dead and the number of health care providers succumbing to the illness.Trust, truth-telling and relationships with colleaguesAnother challenge to our previously unconditional trust of our colleagues occurred when staff members found themselves watching others to ensure that infection control measures were strictly adhered to and confronting them when they were not.", [["confusion", "DISEASE", 37, 46], ["illness", "DISEASE", 251, 258], ["infection", "DISEASE", 463, 472], ["confusion", "PROBLEM", 37, 46], ["infection control measures", "TREATMENT", 463, 489], ["infection", "OBSERVATION", 463, 472]]], ["Although such vigilance is crucial to the success of infection control protocols, it engenders a lack of trust and challenges multidisciplinary professional relationships in an unprecedented manner.Public health and infection control in the intensive care unitAlthough infection control measures were welcomed and understood, they severely compromised quality of life and heightened the degree of complexity of work tasks that were previously fairly straightforward.", [["infection", "DISEASE", 53, 62], ["infection", "DISEASE", 216, 225], ["infection", "DISEASE", 269, 278], ["infection control protocols", "TREATMENT", 53, 80], ["infection control", "TREATMENT", 216, 233], ["infection control measures", "TREATMENT", 269, 295], ["infection", "OBSERVATION", 53, 62], ["infection", "OBSERVATION", 216, 225]]], ["The physical discomfort associated with containment precautions, such as wearing tight-fitting masks all day, two sets of gowns, goggles, double gloving and washing hands repeatedly in alcoholbased cleaners, tested workers' endurance and patience.", [["The physical discomfort", "PROBLEM", 0, 23], ["containment precautions", "TREATMENT", 40, 63], ["tight-fitting masks", "TREATMENT", 81, 100], ["goggles", "TREATMENT", 129, 136], ["double gloving and washing hands", "TREATMENT", 138, 170], ["discomfort", "OBSERVATION", 13, 23]]], ["Such restrictions and monitoring were unprecedented.", [["monitoring", "TEST", 22, 32]]], ["On the positive side, new close relationships were forged between infection control and ICU teams, and it was a unique opportunity for us to work together, learn from each other and gain a deep respect for each other's knowledge and expertise.Public health and infection control in the intensive care unitEthical justification for measures forced upon society by public health policy has been thoughtfully articulated [7] .", [["infection", "DISEASE", 66, 75], ["infection", "DISEASE", 261, 270], ["infection control", "TREATMENT", 66, 83], ["infection control", "TREATMENT", 261, 278], ["positive side", "OBSERVATION_MODIFIER", 7, 20], ["infection", "OBSERVATION", 261, 270]]], ["Could the staff be given some hope of a light at the end of the tunnel?", [["tunnel", "OBSERVATION", 64, 70]]], ["Our infection control colleagues, both physicians and nonphysicians, cannot be praised highly enough for their herculean efforts and patience.", [["infection", "DISEASE", 4, 13], ["infection", "OBSERVATION", 4, 13]]], ["They bore the brunt of the frustrations and complaints.", [["complaints", "PROBLEM", 44, 54]]], ["While new relationships were forged between infection control and ICU teams, the pressure on them was immense as their knowledge and directives were repeatedly challenged.", [["infection", "DISEASE", 44, 53], ["infection control", "TREATMENT", 44, 61]]], ["People are much quicker to criticize than to praise.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["The SARS outbreak challenged us to learn how to convey respect in the midst of frustrations over the lack of knowledge and challenging working conditions, and to thank our colleagues for their incredible efforts to keep us safe.Professional integrity and relationships with patients and familiesSARS has forced us to confront our notions of professional integrity.", [["SARS", "DISEASE", 4, 8], ["SARS", "DISEASE", 295, 299], ["patients", "ORGANISM", 274, 282], ["patients", "SPECIES", 274, 282]]], ["Patients with SARS were cared for in negative pressure isolation rooms and staff were told to minimize entry as much as possible.", [["SARS", "DISEASE", 14, 18], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["SARS", "PROBLEM", 14, 18]]], ["In many units video cameras were used to monitor patients.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["video cameras", "TREATMENT", 14, 27]]], ["In recent years ICU teams have focused on bringing the humanity back into our highly technological environment, and so having to decrease human contact and deploy more technology struck many of us as sadly ironic.", [["human", "ORGANISM", 138, 143], ["human", "SPECIES", 138, 143], ["human", "SPECIES", 138, 143]]], ["Furthermore, the ICU team, trained to rush in to save someone's life and to respond quickly to any deterioration, found themselves being asked to put aside this ingrained sense of professional responsibility and to ensure that they took infection control precautions and were properly attired before rushing in.", [["infection", "DISEASE", 237, 246], ["any deterioration", "PROBLEM", 95, 112], ["infection control precautions", "TREATMENT", 237, 266]]], ["The resulting delays when every minute counts led many to question their professional integrity -how do you balance your own safety and your patient's needs?Professional integrity and relationships with patients and familiesImagine the devastating psychological distress when you must deny patients access to the hospital for relatively urgent tests and/or treatments and deny families access to hospitalized patients; in other words, imagine the distress of health care workers who are functionally paralyzed from doing their job for patients [8] .", [["patient", "ORGANISM", 141, 148], ["patients", "ORGANISM", 203, 211], ["patients", "ORGANISM", 290, 298], ["patients", "ORGANISM", 409, 417], ["patients", "ORGANISM", 535, 543], ["patient", "SPECIES", 141, 148], ["patients", "SPECIES", 203, 211], ["patients", "SPECIES", 290, 298], ["patients", "SPECIES", 409, 417], ["patients", "SPECIES", 535, 543], ["every minute counts", "TEST", 26, 45], ["the devastating psychological distress", "PROBLEM", 232, 270], ["urgent tests", "TEST", 337, 349], ["treatments", "TREATMENT", 357, 367]]], ["For professionals who pride themselves on caring, to deny access and to fail to be able to support patients and families during this time was devastating psychologically.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107]]], ["It quickly became apparent that many patients who would have to be denied access might well die or be irreversibly compromised by delays in their care.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45]]], ["Receiving referral calls about patients who required your centre's particular expertise, and either being unable to accept them because of a lack of beds or knowing the delay in transfer and/or treatment required to observe the necessary infection controls might result in worse outcomes was demoralizing.Resource allocationThe contemporary framework to evaluate fairness of resource allocation, which is gaining acceptance and traction in the real world, is the so-called accountability for reasonableness framework [9] .", [["infection", "DISEASE", 238, 247], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["treatment", "TREATMENT", 194, 203], ["the necessary infection controls", "PROBLEM", 224, 256]]], ["These four components could well be applied to the ethical issues surrounding SARS, with specific emphasis on the first two.", [["SARS", "DISEASE", 78, 82], ["SARS", "PROBLEM", 78, 82], ["SARS", "OBSERVATION", 78, 82]]], ["Publicity means transparency; all stakeholders must be informed of policies and procedures in an open and timely manner.", [["procedures", "TREATMENT", 80, 90], ["transparency", "OBSERVATION_MODIFIER", 16, 28]]], ["This includes patients, their families and health care workers.ConclusionThe psychological distress to both consumers and deliverers of health care that result from a tragic outbreak such as SARS cannot be underestimated.", [["SARS", "DISEASE", 191, 195], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["The psychological distress", "PROBLEM", 73, 99], ["a tragic outbreak", "PROBLEM", 165, 182], ["SARS", "PROBLEM", 191, 195]]], ["Public health officials, hospital administrations and governments must do everything in their power to ameliorate the suffering of patients and health care workers.", [["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139]]], ["Perhaps the best defence for such a disaster is to have a contingency plan in place, to have well conceived and developed plans well known in advance and rehearsed, in order to limit the damage a natural disaster like SARS can unleash.ConclusionIn order to protect patients, families, doctors, nurses and other health care professionals, public health systems and their component hospitals must have access to up-to-date scientific information [13] , as well as conceptual, ethical and practical frameworks in place to minimize the damage and support all parties when an unforeseen and unexpected enemy such as SARS arises.", [["SARS", "DISEASE", 218, 222], ["SARS", "DISEASE", 611, 615], ["patients", "ORGANISM", 265, 273], ["patients", "SPECIES", 265, 273], ["ethical and practical frameworks", "TREATMENT", 474, 506], ["the damage", "PROBLEM", 528, 538]]], ["These modern day plagues are unlikely to go away, and in fact SARS perhaps was a light dress rehearsal for the next anticipated massive outbreak of influenza, for which there is ongoing planning and intense surveillance [14] .", [["SARS", "DISEASE", 62, 66], ["influenza", "DISEASE", 148, 157], ["a light dress rehearsal", "TREATMENT", 79, 102], ["influenza", "PROBLEM", 148, 157], ["intense surveillance", "TEST", 199, 219], ["influenza", "OBSERVATION", 148, 157]]]], "bf84778dbacb1cd4e0ba818de24f09d84299bf50": [["IntroductionNeurological complications of coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are emerging.", [["coronavirus disease", "DISEASE", 42, 61], ["acute respiratory syndrome coronavirus", "DISEASE", 86, 124], ["coronavirus", "ORGANISM", 42, 53], ["SARS-CoV-2", "ORGANISM", 128, 138], ["severe acute respiratory syndrome coronavirus", "SPECIES", 79, 124], ["SARS-CoV-2", "SPECIES", 128, 138], ["coronavirus disease", "PROBLEM", 42, 61], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 79, 124], ["coronavirus disease", "OBSERVATION", 42, 61], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["respiratory syndrome", "OBSERVATION", 92, 112]]], ["Meanwhile, there are opportunities to learn from previous experiences with other human coronaviruses (HCoVs), among them SARS-CoV-1, triggering an epidemic in 2002, 1 and Middle East respiratory syndrome coronavirus (MERS-CoV), responsible for an epidemic in 2012.", [["SARS", "DISEASE", 121, 125], ["respiratory syndrome coronavirus", "DISEASE", 183, 215], ["human", "ORGANISM", 81, 86], ["coronaviruses", "ORGANISM", 87, 100], ["HCoVs", "CANCER", 102, 107], ["SARS-CoV-1", "ORGANISM", 121, 131], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 171, 215], ["MERS-CoV", "ORGANISM", 217, 225], ["human", "SPECIES", 81, 86], ["human coronaviruses", "SPECIES", 81, 100], ["SARS-CoV-1", "SPECIES", 121, 131], ["Middle East respiratory syndrome coronavirus", "SPECIES", 171, 215], ["MERS-CoV", "SPECIES", 217, 225], ["other human coronaviruses (HCoVs)", "PROBLEM", 75, 108], ["CoV", "TEST", 126, 129], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 171, 215], ["Middle", "ANATOMY_MODIFIER", 171, 177], ["respiratory syndrome", "ANATOMY", 183, 203]]], ["2 Moreover four acute or prior coronavirus infection, that is, neurological symptoms/complications in coronavirus-infected persons (we included studies reporting on any symptom associated with, but not necessarily specific for neurological diseases, e.g., headache, fatigue), neuropathology findings of coronavirus infections as well as neuroimaging findings associated with coronavirus infections.", [["neurological", "ANATOMY", 63, 75], ["neurological", "ANATOMY", 227, 239], ["coronavirus infection", "DISEASE", 31, 52], ["neurological symptoms", "DISEASE", 63, 84], ["coronavirus-infected", "DISEASE", 102, 122], ["neurological diseases", "DISEASE", 227, 248], ["headache", "DISEASE", 256, 264], ["fatigue", "DISEASE", 266, 273], ["coronavirus infections", "DISEASE", 303, 325], ["coronavirus infections", "DISEASE", 375, 397], ["coronavirus", "ORGANISM", 102, 113], ["persons", "ORGANISM", 123, 130], ["coronavirus", "ORGANISM", 303, 314], ["coronavirus", "ORGANISM", 375, 386], ["coronavirus", "SPECIES", 102, 113], ["persons", "SPECIES", 123, 130], ["prior coronavirus infection", "PROBLEM", 25, 52], ["neurological symptoms", "PROBLEM", 63, 84], ["complications", "PROBLEM", 85, 98], ["coronavirus", "PROBLEM", 102, 113], ["studies", "TEST", 144, 151], ["any symptom", "PROBLEM", 165, 176], ["neurological diseases", "PROBLEM", 227, 248], ["headache", "PROBLEM", 256, 264], ["fatigue", "PROBLEM", 266, 273], ["neuropathology", "PROBLEM", 276, 290], ["coronavirus infections", "PROBLEM", 303, 325], ["neuroimaging findings", "TEST", 337, 358], ["coronavirus infections", "PROBLEM", 375, 397], ["four", "OBSERVATION_MODIFIER", 11, 15], ["acute", "OBSERVATION_MODIFIER", 16, 21], ["coronavirus", "OBSERVATION_MODIFIER", 31, 42], ["infection", "OBSERVATION", 43, 52], ["coronavirus infections", "OBSERVATION", 303, 325], ["coronavirus infections", "OBSERVATION", 375, 397]]], ["We excluded animal studies, records with non-English abstracts and reviews.Study selection and data extractionTitles and abstracts of studies were independently screened for their relevance in the web-based application Rayyan (https://rayyan.qcri.org/) by two reviewers (J.A. and B.V.I.) followed by full-text screening.", [["animal studies", "TEST", 12, 26], ["Study selection", "TEST", 75, 90], ["data extraction", "TEST", 95, 110], ["studies", "TEST", 134, 141], ["text screening", "TEST", 305, 319]]], ["14 The same reviewers independently extracted title, authors, publication year, study design, country, number of subjects per group, neurological symptoms/complications, neuropathological findings, and/or neuroimaging findings associated to acute or prior coronavirus infection.", [["neurological", "ANATOMY", 133, 145], ["coronavirus infection", "DISEASE", 256, 277], ["coronavirus", "ORGANISM", 256, 267], ["neurological symptoms", "PROBLEM", 133, 154], ["complications", "PROBLEM", 155, 168], ["neuropathological findings", "PROBLEM", 170, 196], ["neuroimaging findings", "TEST", 205, 226], ["prior coronavirus infection", "PROBLEM", 250, 277], ["acute", "OBSERVATION_MODIFIER", 241, 246], ["coronavirus", "OBSERVATION_MODIFIER", 256, 267], ["infection", "OBSERVATION", 268, 277]]], ["Discrepancies in findings were resolved by discussion among assessors, a third reviewer (T.G.) was consulted as needed.Quality assessmentThe quality of each study with more than 10 included subjects was assessed against pre-defined criteria by the same two reviewers using the Newcastle-Ottawa scale for evaluating risk of bias in non-randomized studies and are further described in Table S2 .", [["Discrepancies in findings", "PROBLEM", 0, 25], ["Quality assessment", "TEST", 119, 137], ["each study", "TEST", 152, 162], ["bias in non-randomized studies", "TEST", 323, 353]]], ["15Data synthesis and analysisStudies and results were qualitatively compared and summarized.", [["analysisStudies", "TEST", 21, 36]]], ["After abstract and title screening, 611 studies were eligible for full-text search of which 371 (8.3% of deduplicated references) and an additional 7 abstract for which the English full-text was not available were included in the qualitative synthesis (Fig. 1 ).", [["title screening", "TEST", 19, 34]]], ["All references are listed in the Data S1.Risk of bias assessmentWe evaluated the risk of bias for all studies with more than 10 subjects.", [["bias assessment", "TEST", 49, 64], ["all studies", "TEST", 98, 109], ["bias", "OBSERVATION", 49, 53]]], ["Most of the studies showed a low risk of bias for the selection domain, as well as for subunits 2 and 3 from the exposure domain, that is, if patients and controls were treated equally and if studies showed low exclusion rates, respectively (see Table S3 ).", [["patients", "ORGANISM", 142, 150], ["subunits 2 and 3", "PROTEIN", 87, 103], ["patients", "SPECIES", 142, 150], ["the studies", "TEST", 8, 19], ["the selection domain", "TEST", 50, 70], ["subunits", "TREATMENT", 87, 95], ["studies", "TEST", 192, 199], ["low exclusion rates", "PROBLEM", 207, 226]]], ["Many studies did not report on adjusting their statistical analyses for subject age, sex or other potential confounders (comparability domain), thus potentially introducing biases.", [["Many studies", "TEST", 0, 12]]], ["Of note, a considerable proportion of studies was published as letters or editorials thus hampering a thorough risk of bias assessment.General study characteristicsOf the eligible 378 publications, 30 publications investigated clinically more benign strains of HCoV, including a total of 961 subjects.", [["HCoV", "ANATOMY", 261, 265], ["HCoV", "CANCER", 261, 265], ["HCoV", "SPECIES", 261, 265], ["bias assessment", "TEST", 119, 134], ["General study", "TEST", 135, 148], ["more benign strains of HCoV", "PROBLEM", 238, 265]]], ["The majority of these publications assessed HCoV OC43 (26 publications), followed by 229E (22) , NL63 (7), and NKU1 (5) .", [["HCoV", "SPECIES", 44, 48], ["these publications", "TEST", 16, 34], ["HCoV OC43", "TEST", 44, 53], ["NL63", "TEST", 97, 101], ["NKU1", "TEST", 111, 115]]], ["Six publications assessed MERS-CoV, comprising a total of 341 patients, while 15 publications assessed SARS-CoV-1, including a total of 1829 cases.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 26, 34], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["MERS-CoV", "SPECIES", 26, 34], ["SARS-CoV-1", "SPECIES", 103, 113], ["SARS", "TEST", 103, 107], ["CoV", "TEST", 108, 111]]], ["About 327 publications assessed SARS-CoV-2, with the majority being case reports (179).", [["SARS-CoV", "SPECIES", 32, 40]]], ["These studies included a total of 14418 SARS-CoV-2 patients (including 45 children) from 35 different countries.", [["SARS", "DISEASE", 40, 44], ["SARS-CoV", "ORGANISM", 40, 48], ["patients", "ORGANISM", 51, 59], ["children", "ORGANISM", 74, 82], ["patients", "SPECIES", 51, 59], ["children", "SPECIES", 74, 82], ["SARS-CoV", "SPECIES", 40, 48], ["These studies", "TEST", 0, 13], ["CoV", "TEST", 45, 48]]], ["Study characteristics and main findings for every HCoV strain are summarized in Tables S4-S7 .Association of coronavirus infections with neurological symptoms and complicationsClinically milder infections with HCoVs: 229E, HKU1, NL63, and OC43Acute infectionsFindings from studies regarding the more clinically benign HCoVs are summarized in Table S4 .", [["neurological", "ANATOMY", 137, 149], ["coronavirus infections", "DISEASE", 109, 131], ["neurological symptoms", "DISEASE", 137, 158], ["infections", "DISEASE", 194, 204], ["OC43Acute infections", "DISEASE", 239, 259], ["coronavirus", "ORGANISM", 109, 120], ["HKU1", "GENE_OR_GENE_PRODUCT", 223, 227], ["HCoVs", "CANCER", 318, 323], ["coronavirus", "SPECIES", 109, 120], ["HCoV", "SPECIES", 50, 54], ["Study characteristics", "TEST", 0, 21], ["every HCoV strain", "PROBLEM", 44, 61], ["coronavirus infections", "PROBLEM", 109, 131], ["neurological symptoms", "PROBLEM", 137, 158], ["complications", "PROBLEM", 163, 176], ["Clinically milder infections", "PROBLEM", 176, 204], ["HCoVs", "TEST", 210, 215], ["HKU1", "TEST", 223, 227], ["NL63", "TEST", 229, 233], ["OC43Acute infections", "PROBLEM", 239, 259], ["coronavirus", "OBSERVATION_MODIFIER", 109, 120], ["infections", "OBSERVATION", 121, 131], ["milder", "OBSERVATION_MODIFIER", 187, 193], ["infections", "OBSERVATION", 194, 204], ["infections", "OBSERVATION", 249, 259]]], ["Most studies assessed neurological manifestations of coronavirus infections in children.", [["neurological", "ANATOMY", 22, 34], ["coronavirus infections", "DISEASE", 53, 75], ["coronavirus", "ORGANISM", 53, 64], ["children", "ORGANISM", 79, 87], ["children", "SPECIES", 79, 87], ["Most studies", "TEST", 0, 12], ["coronavirus infections", "PROBLEM", 53, 75], ["coronavirus infections", "OBSERVATION", 53, 75]]], ["A retrospective cohort study from the USA investigated 1683 respiratory specimens from children and found that 84 of them (5%) were positive for coronavirus (229E, HKU1, NL63, and/or OC43); of these, 5 children (8%) had meningoencephalitis and/or febrile seizures.", [["respiratory specimens", "ANATOMY", 60, 81], ["coronavirus", "DISEASE", 145, 156], ["meningoencephalitis", "DISEASE", 220, 239], ["febrile seizures", "DISEASE", 247, 263], ["children", "ORGANISM", 87, 95], ["coronavirus", "ORGANISM", 145, 156], ["HKU1", "GENE_OR_GENE_PRODUCT", 164, 168], ["children", "ORGANISM", 202, 210], ["children", "SPECIES", 87, 95], ["children", "SPECIES", 202, 210], ["A retrospective cohort study", "TEST", 0, 28], ["the USA", "TEST", 34, 41], ["respiratory specimens", "TEST", 60, 81], ["coronavirus", "PROBLEM", 145, 156], ["HKU1", "TEST", 164, 168], ["NL63", "TEST", 170, 174], ["meningoencephalitis", "PROBLEM", 220, 239], ["febrile seizures", "PROBLEM", 247, 263], ["meningoencephalitis", "OBSERVATION", 220, 239]]], ["16 A prospective multicenter study from China confirmed the association of coronavirus, particularly 17 Five of the 13 children (38%) positive for HKU1 had febrile seizures and one adult patient with OC43 had an aseptic meningitis.", [["coronavirus", "DISEASE", 75, 86], ["febrile seizures", "DISEASE", 156, 172], ["meningitis", "DISEASE", 220, 230], ["coronavirus", "ORGANISM", 75, 86], ["children", "ORGANISM", 119, 127], ["HKU1", "GENE_OR_GENE_PRODUCT", 147, 151], ["patient", "ORGANISM", 187, 194], ["OC43", "CANCER", 200, 204], ["children", "SPECIES", 119, 127], ["patient", "SPECIES", 187, 194], ["A prospective multicenter study", "TEST", 3, 34], ["coronavirus", "PROBLEM", 75, 86], ["HKU1", "PROBLEM", 147, 151], ["febrile seizures", "PROBLEM", 156, 172], ["OC43", "PROBLEM", 200, 204], ["an aseptic meningitis", "PROBLEM", 209, 230], ["coronavirus", "OBSERVATION", 75, 86], ["aseptic", "OBSERVATION_MODIFIER", 212, 219], ["meningitis", "OBSERVATION", 220, 230]]], ["Two prospective studies from Slovenia investigating the same patient cohort found that 19 of the 278 children (7%) with febrile seizures were tested positive for coronavirus (mostly OC43: 12/19 patients, 63%).", [["febrile seizures", "DISEASE", 120, 136], ["coronavirus", "DISEASE", 162, 173], ["patient", "ORGANISM", 61, 68], ["children", "ORGANISM", 101, 109], ["coronavirus", "ORGANISM", 162, 173], ["patients", "ORGANISM", 194, 202], ["patient", "SPECIES", 61, 68], ["children", "SPECIES", 101, 109], ["patients", "SPECIES", 194, 202], ["Two prospective studies", "TEST", 0, 23], ["febrile seizures", "PROBLEM", 120, 136], ["coronavirus", "PROBLEM", 162, 173], ["OC43", "TEST", 182, 186]]], ["18, 19 Another prospective multicenter study from Turkey included 192 children with febrile seizures and found that HCoV OC43 is the single most common, yet still rare, cause for febrile seizures in children under 12 months (6% of children under 12 months with febrile seizures were positive for OC43).", [["febrile seizures", "DISEASE", 84, 100], ["seizures", "DISEASE", 187, 195], ["febrile seizures", "DISEASE", 261, 277], ["children", "ORGANISM", 70, 78], ["HCoV OC43", "GENE_OR_GENE_PRODUCT", 116, 125], ["children", "ORGANISM", 199, 207], ["children", "ORGANISM", 231, 239], ["children", "SPECIES", 70, 78], ["children", "SPECIES", 199, 207], ["children", "SPECIES", 231, 239], ["HCoV", "SPECIES", 116, 120], ["Another prospective multicenter study", "TEST", 7, 44], ["febrile seizures", "PROBLEM", 84, 100], ["HCoV OC43", "PROBLEM", 116, 125], ["febrile seizures", "PROBLEM", 179, 195], ["febrile seizures", "PROBLEM", 261, 277], ["OC43", "PROBLEM", 296, 300]]], ["20 Finally, five case reports in children described the following neurological complications associated with the detection of coronavirus: acute flaccid paralysis, acute disseminated encephalomyelitis (ADEM), Guillain-Barr e syndrome (GBS) and two cases of fatal encephalitis (both in children with underlying immune deficiency), described in Table S4 .Acute infectionsOne retrospective cohort study from Finland assessed neurological complications associated with HCoV infections in adults.", [["neurological", "ANATOMY", 66, 78], ["neurological", "ANATOMY", 422, 434], ["coronavirus", "DISEASE", 126, 137], ["flaccid paralysis", "DISEASE", 145, 162], ["acute disseminated encephalomyelitis", "DISEASE", 164, 200], ["ADEM", "DISEASE", 202, 206], ["Guillain-Barr e syndrome", "DISEASE", 209, 233], ["GBS", "DISEASE", 235, 238], ["encephalitis", "DISEASE", 263, 275], ["immune deficiency", "DISEASE", 310, 327], ["infections", "DISEASE", 359, 369], ["neurological complications", "DISEASE", 422, 448], ["HCoV infections", "DISEASE", 465, 480], ["children", "ORGANISM", 33, 41], ["coronavirus", "ORGANISM", 126, 137], ["children", "ORGANISM", 285, 293], ["children", "SPECIES", 33, 41], ["children", "SPECIES", 285, 293], ["Guillain-Barr e syndrome (GBS)", "SPECIES", 209, 239], ["HCoV", "SPECIES", 465, 469], ["neurological complications", "PROBLEM", 66, 92], ["coronavirus", "PROBLEM", 126, 137], ["acute flaccid paralysis", "PROBLEM", 139, 162], ["acute disseminated encephalomyelitis", "PROBLEM", 164, 200], ["ADEM", "PROBLEM", 202, 206], ["Guillain", "PROBLEM", 209, 217], ["Barr e syndrome", "PROBLEM", 218, 233], ["GBS", "PROBLEM", 235, 238], ["fatal encephalitis", "PROBLEM", 257, 275], ["underlying immune deficiency", "PROBLEM", 299, 327], ["Acute infections", "PROBLEM", 353, 369], ["One retrospective cohort study", "TEST", 369, 399], ["neurological complications", "PROBLEM", 422, 448], ["HCoV infections", "PROBLEM", 465, 480], ["acute", "OBSERVATION_MODIFIER", 139, 144], ["flaccid", "OBSERVATION_MODIFIER", 145, 152], ["paralysis", "OBSERVATION", 153, 162], ["acute", "OBSERVATION_MODIFIER", 164, 169], ["disseminated", "OBSERVATION_MODIFIER", 170, 182], ["encephalomyelitis", "OBSERVATION", 183, 200], ["Barr e syndrome", "OBSERVATION", 218, 233], ["fatal", "OBSERVATION_MODIFIER", 257, 262], ["encephalitis", "OBSERVATION", 263, 275], ["immune deficiency", "OBSERVATION", 310, 327], ["infections", "OBSERVATION", 359, 369], ["infections", "OBSERVATION", 470, 480]]], ["OC43 was detected in 28 out of 14000 sera from patients with infectious diseases.", [["sera", "ANATOMY", 37, 41], ["infectious diseases", "DISEASE", 61, 80], ["OC43", "GENE_OR_GENE_PRODUCT", 0, 4], ["sera", "ORGANISM_SUBSTANCE", 37, 41], ["patients", "ORGANISM", 47, 55], ["OC43", "PROTEIN", 0, 4], ["patients", "SPECIES", 47, 55], ["OC43", "PROBLEM", 0, 4], ["infectious diseases", "PROBLEM", 61, 80], ["infectious", "OBSERVATION", 61, 71]]], ["21 Four of these patients suffered either meningitis, convulsions, headache, or vertigo.Association of prior infections to neurological/psychiatric diseasesFindings are summarized in Table S8 .", [["neurological", "ANATOMY", 123, 135], ["meningitis", "DISEASE", 42, 52], ["convulsions", "DISEASE", 54, 65], ["headache", "DISEASE", 67, 75], ["vertigo", "DISEASE", 80, 87], ["infections", "DISEASE", 109, 119], ["neurological/psychiatric diseases", "DISEASE", 123, 156], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["meningitis", "PROBLEM", 42, 52], ["convulsions", "PROBLEM", 54, 65], ["headache", "PROBLEM", 67, 75], ["vertigo", "PROBLEM", 80, 87], ["prior infections to neurological/psychiatric diseases", "PROBLEM", 103, 156], ["meningitis", "OBSERVATION", 42, 52], ["vertigo", "OBSERVATION", 80, 87], ["infections", "OBSERVATION", 109, 119], ["psychiatric diseases", "OBSERVATION", 136, 156]]], ["An early case-control study from 1980 isolated infectious coronavirus particles from autopsy brain material from two MS patients (of the 13 MS patients and 12 controls).", [["brain", "ANATOMY", 93, 98], ["coronavirus", "ORGANISM", 58, 69], ["brain material", "MULTI-TISSUE_STRUCTURE", 93, 107], ["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 143, 151], ["control study", "TEST", 14, 27], ["isolated infectious coronavirus particles", "PROBLEM", 38, 79], ["autopsy brain material", "PROBLEM", 85, 107], ["infectious coronavirus particles", "OBSERVATION", 47, 79], ["brain", "ANATOMY", 93, 98]]], ["22 Injection of 10% homogenate of the HCoV positive brain material (in saline solution) led to encephalitis in mice within 3-5 days.", [["brain", "ANATOMY", 52, 57], ["encephalitis", "DISEASE", 95, 107], ["brain material", "MULTI-TISSUE_STRUCTURE", 52, 66], ["saline", "SIMPLE_CHEMICAL", 71, 77], ["mice", "ORGANISM", 111, 115], ["mice", "SPECIES", 111, 115], ["HCoV", "SPECIES", 38, 42], ["mice", "SPECIES", 111, 115], ["the HCoV positive brain material (in saline solution", "TREATMENT", 34, 86], ["encephalitis", "PROBLEM", 95, 107], ["brain", "ANATOMY", 52, 57], ["encephalitis", "OBSERVATION", 95, 107]]], ["Several subsequent studies confirmed the presence of OC43 and/or 229E in different tissues including brain, serum and cerebrospinal fluid (CSF).", [["tissues", "ANATOMY", 83, 90], ["brain", "ANATOMY", 101, 106], ["serum", "ANATOMY", 108, 113], ["cerebrospinal fluid", "ANATOMY", 118, 137], ["OC43", "GENE_OR_GENE_PRODUCT", 53, 57], ["229E", "GENE_OR_GENE_PRODUCT", 65, 69], ["tissues", "TISSUE", 83, 90], ["brain", "ORGAN", 101, 106], ["serum", "ORGANISM_SUBSTANCE", 108, 113], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 118, 137], ["CSF", "ORGANISM_SUBSTANCE", 139, 142], ["OC43", "PROTEIN", 53, 57], ["Several subsequent studies", "TEST", 0, 26], ["OC43", "PROBLEM", 53, 57], ["brain, serum and cerebrospinal fluid", "TEST", 101, 137], ["OC43", "OBSERVATION", 53, 57], ["brain", "ANATOMY", 101, 106], ["cerebrospinal", "ANATOMY", 118, 131], ["fluid", "OBSERVATION", 132, 137]]], ["[23] [24] [25] Yet, while some studies observed a higher prevalence of coronavirus antibodies in MS patients versus controls, most studies could not confirm this finding (Table S8) .Association of prior infections to neurological/psychiatric diseasesTwo studies have assessed the association of prior coronavirus infections with psychiatric symptoms.", [["neurological", "ANATOMY", 217, 229], ["MS", "DISEASE", 97, 99], ["infections", "DISEASE", 203, 213], ["neurological/psychiatric diseases", "DISEASE", 217, 250], ["coronavirus infections", "DISEASE", 301, 323], ["psychiatric", "DISEASE", 329, 340], ["[23] [24] [25", "SIMPLE_CHEMICAL", 0, 13], ["coronavirus", "ORGANISM", 71, 82], ["patients", "ORGANISM", 100, 108], ["coronavirus", "ORGANISM", 301, 312], ["coronavirus antibodies", "PROTEIN", 71, 93], ["patients", "SPECIES", 100, 108], ["some studies", "TEST", 26, 38], ["coronavirus antibodies", "PROBLEM", 71, 93], ["most studies", "TEST", 126, 138], ["prior infections to neurological/psychiatric diseases", "PROBLEM", 197, 250], ["Two studies", "TEST", 250, 261], ["prior coronavirus infections", "PROBLEM", 295, 323], ["psychiatric symptoms", "PROBLEM", 329, 349], ["infections", "OBSERVATION", 203, 213], ["psychiatric diseases", "OBSERVATION", 230, 250], ["coronavirus", "OBSERVATION_MODIFIER", 301, 312], ["infections", "OBSERVATION", 313, 323]]], ["A case-control study that included 257 subjects with major depression or suicide attempt, found that seropositivity for coronavirus strain NL63 (as well as Influenza A and B) was associated with the history of mood disorders.", [["major depression", "DISEASE", 53, 69], ["Influenza A and B", "DISEASE", 156, 173], ["mood disorders", "DISEASE", 210, 224], ["coronavirus strain NL63", "ORGANISM", 120, 143], ["B", "CANCER", 172, 173], ["A case-control study", "TEST", 0, 20], ["major depression", "PROBLEM", 53, 69], ["suicide attempt", "PROBLEM", 73, 88], ["coronavirus strain NL63", "PROBLEM", 120, 143], ["Influenza", "PROBLEM", 156, 165], ["mood disorders", "PROBLEM", 210, 224]]], ["26 Another case-control study observed higher immunoglobulin G (IgG) titers toward different coronavirus species in patients with recent onset of psychotic symptoms as compared to controls.", [["psychotic symptoms", "DISEASE", 146, 164], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 46, 62], ["IgG", "GENE_OR_GENE_PRODUCT", 64, 67], ["coronavirus", "ORGANISM", 93, 104], ["patients", "ORGANISM", 116, 124], ["immunoglobulin G", "PROTEIN", 46, 62], ["IgG", "PROTEIN", 64, 67], ["patients", "SPECIES", 116, 124], ["control study", "TEST", 16, 29], ["higher immunoglobulin G (IgG) titers", "PROBLEM", 39, 75], ["different coronavirus species", "PROBLEM", 83, 112], ["psychotic symptoms", "PROBLEM", 146, 164], ["coronavirus species", "OBSERVATION", 93, 112]]], ["Two larger retrospective case series from Saudi Arabia assessed symptomatology among MERS-CoV patients.", [["MERS-CoV", "DISEASE", 85, 93], ["MERS-CoV", "ORGANISM", 85, 93], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["MERS-CoV", "SPECIES", 85, 93], ["larger", "OBSERVATION_MODIFIER", 4, 10]]], ["One multicenter study found that 71% of patients (185/227) reported some form of neurological symptoms.", [["neurological", "ANATOMY", 81, 93], ["neurological symptoms", "DISEASE", 81, 102], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["One multicenter study", "TEST", 0, 21], ["neurological symptoms", "PROBLEM", 81, 102]]], ["28 The most common neurological symptoms were fatigue (108/185, 58%), headache (59, 31%), altered consciousness (53, 29%), and/or focal neurological deficits (10, 5%).", [["neurological", "ANATOMY", 19, 31], ["neurological", "ANATOMY", 136, 148], ["fatigue", "DISEASE", 46, 53], ["headache", "DISEASE", 70, 78], ["altered consciousness", "DISEASE", 90, 111], ["neurological deficits", "DISEASE", 136, 157], ["The most common neurological symptoms", "PROBLEM", 3, 40], ["fatigue", "PROBLEM", 46, 53], ["headache", "PROBLEM", 70, 78], ["altered consciousness", "PROBLEM", 90, 111], ["focal neurological deficits", "PROBLEM", 130, 157], ["focal", "OBSERVATION_MODIFIER", 130, 135]]], ["Additionally, altered level of consciousness at time of diagnosis was a significant risk factor for death.", [["death", "DISEASE", 100, 105], ["altered level of consciousness", "PROBLEM", 14, 44], ["death", "PROBLEM", 100, 105]]], ["The other study included 70 patients with confirmed MERS, of which the large majority had clinical symptoms (67/70, 96%).", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["The other study", "TEST", 0, 15], ["clinical symptoms", "PROBLEM", 90, 107], ["large", "OBSERVATION_MODIFIER", 71, 76]]], ["29 The neurological symptomatology was similar; fatigue (29/67, 43%), confusion (18, 27%), headache (9, 13%), and/or seizures (6, 9%).", [["neurological", "ANATOMY", 7, 19], ["neurological symptomatology", "DISEASE", 7, 34], ["fatigue", "DISEASE", 48, 55], ["confusion", "DISEASE", 70, 79], ["headache", "DISEASE", 91, 99], ["seizures", "DISEASE", 117, 125], ["fatigue", "PROBLEM", 48, 55], ["confusion", "PROBLEM", 70, 79], ["headache", "PROBLEM", 91, 99], ["seizures", "PROBLEM", 117, 125]]], ["Four smaller case series/case reports including a total of 10 patients described neurological complications in MERS-HCoV patients, among them toxic/infectious neuropathy, Bickerstaff brainstem-encephalitis with intracranial hemorrhage, ischemic stroke, critical illness neuropathy, brain stem dysfunction, and ADEM.", [["neurological", "ANATOMY", 81, 93], ["intracranial", "ANATOMY", 211, 223], ["brain stem", "ANATOMY", 282, 292], ["neurological complications", "DISEASE", 81, 107], ["MERS-HCoV", "DISEASE", 111, 120], ["toxic/infectious neuropathy", "DISEASE", 142, 169], ["Bickerstaff brainstem-encephalitis", "DISEASE", 171, 205], ["intracranial hemorrhage", "DISEASE", 211, 234], ["ischemic stroke", "DISEASE", 236, 251], ["critical illness neuropathy", "DISEASE", 253, 280], ["brain stem dysfunction", "DISEASE", 282, 304], ["ADEM", "DISEASE", 310, 314], ["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 121, 129], ["brain stem", "MULTI-TISSUE_STRUCTURE", 282, 292], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 121, 129], ["neurological complications", "PROBLEM", 81, 107], ["them toxic/infectious neuropathy", "PROBLEM", 137, 169], ["Bickerstaff brainstem", "PROBLEM", 171, 192], ["encephalitis", "PROBLEM", 193, 205], ["intracranial hemorrhage", "PROBLEM", 211, 234], ["ischemic stroke", "PROBLEM", 236, 251], ["critical illness neuropathy", "PROBLEM", 253, 280], ["brain stem dysfunction", "PROBLEM", 282, 304], ["ADEM", "PROBLEM", 310, 314], ["smaller", "OBSERVATION_MODIFIER", 5, 12], ["complications", "OBSERVATION", 94, 107], ["toxic", "OBSERVATION_MODIFIER", 142, 147], ["infectious", "OBSERVATION", 148, 158], ["brainstem", "ANATOMY", 183, 192], ["encephalitis", "OBSERVATION", 193, 205], ["intracranial", "ANATOMY", 211, 223], ["hemorrhage", "OBSERVATION", 224, 234], ["ischemic", "OBSERVATION_MODIFIER", 236, 244], ["stroke", "OBSERVATION", 245, 251], ["brain", "ANATOMY", 282, 287], ["stem dysfunction", "OBSERVATION", 288, 304], ["ADEM", "OBSERVATION", 310, 314]]], ["Of note, eight of these patients had pre-existing medical conditions, including diabetes type 2 and/or cardiovascular disease (Table S5) .SARS-CoV-1Findings are summarized in Table S6 .", [["cardiovascular", "ANATOMY", 103, 117], ["diabetes type 2", "DISEASE", 80, 95], ["cardiovascular disease", "DISEASE", 103, 125], ["SARS", "DISEASE", 138, 142], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["pre-existing medical conditions", "PROBLEM", 37, 68], ["diabetes type 2", "PROBLEM", 80, 95], ["cardiovascular disease", "PROBLEM", 103, 125], ["cardiovascular", "ANATOMY", 103, 117], ["disease", "OBSERVATION", 118, 125]]], ["Two cohort studies assessed neurological manifestations of adult SARS-CoV-1 patients.", [["neurological", "ANATOMY", 28, 40], ["SARS", "DISEASE", 65, 69], ["SARS-CoV-1", "ORGANISM", 65, 75], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["Two cohort studies", "TEST", 0, 18]]], ["One study comprised 206 SARS-CoV-1 cases, constituting all SARS-CoV-1 patients from Singapore.", [["SARS", "DISEASE", 24, 28], ["SARS", "DISEASE", 59, 63], ["SARS-CoV-1", "ORGANISM", 59, 69], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["SARS-CoV-1", "SPECIES", 24, 34], ["SARS-CoV-1", "SPECIES", 59, 69], ["One study", "TEST", 0, 9], ["SARS", "TEST", 24, 28], ["CoV", "TEST", 29, 32]]], ["30 Five of these patients (2.4%) suffered large artery cerebral strokes.", [["artery cerebral", "ANATOMY", 48, 63], ["artery cerebral strokes", "DISEASE", 48, 71], ["patients", "ORGANISM", 17, 25], ["artery cerebral", "MULTI-TISSUE_STRUCTURE", 48, 63], ["patients", "SPECIES", 17, 25], ["large artery cerebral strokes", "PROBLEM", 42, 71], ["large", "OBSERVATION_MODIFIER", 42, 47], ["artery cerebral", "ANATOMY", 48, 63], ["strokes", "OBSERVATION", 64, 71]]], ["It is noteworthy that only one of these patients had pre-existing risk factors for cerebrovascular disease.", [["cerebrovascular", "ANATOMY", 83, 98], ["cerebrovascular disease", "DISEASE", 83, 106], ["patients", "ORGANISM", 40, 48], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 83, 98], ["patients", "SPECIES", 40, 48], ["cerebrovascular disease", "PROBLEM", 83, 106], ["cerebrovascular disease", "OBSERVATION", 83, 106]]], ["The other cohort study included 1291 Chinese SARS-CoV-1 patients and investigated how cerebrocardiovascular disease affected SARS-CoV-1 disease outcomes (only abstract available in English).", [["cerebrocardiovascular", "ANATOMY", 86, 107], ["SARS", "DISEASE", 45, 49], ["cerebrocardiovascular disease", "DISEASE", 86, 115], ["SARS", "DISEASE", 125, 129], ["SARS-CoV-1", "ORGANISM", 45, 55], ["patients", "ORGANISM", 56, 64], ["cerebrocardiovascular", "MULTI-TISSUE_STRUCTURE", 86, 107], ["CoV-1", "SPECIES", 50, 55], ["patients", "SPECIES", 56, 64], ["Chinese SARS-CoV-1", "SPECIES", 37, 55], ["The other cohort study", "TEST", 0, 22], ["cerebrocardiovascular disease affected SARS", "PROBLEM", 86, 129], ["1 disease outcomes", "PROBLEM", 134, 152]]], ["31 Critical conditions and multi-organ dysfunction occurred more frequently among SARS-CoV-1 patients with pre-existing cerebrocardiovascular diseases (58% and 27%, respectively) compared to patients without underlying diseases (28% and 10%, respectively).", [["multi-organ", "ANATOMY", 27, 38], ["cerebrocardiovascular", "ANATOMY", 120, 141], ["multi-organ dysfunction", "DISEASE", 27, 50], ["SARS", "DISEASE", 82, 86], ["cerebrocardiovascular diseases", "DISEASE", 120, 150], ["multi-organ", "ORGAN", 27, 38], ["SARS-CoV-1", "ORGANISM", 82, 92], ["patients", "ORGANISM", 93, 101], ["cerebrocardiovascular", "MULTI-TISSUE_STRUCTURE", 120, 141], ["patients", "ORGANISM", 191, 199], ["CoV-1", "SPECIES", 87, 92], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 191, 199], ["SARS-CoV-1", "SPECIES", 82, 92], ["Critical conditions", "PROBLEM", 3, 22], ["multi-organ dysfunction", "PROBLEM", 27, 50], ["pre-existing cerebrocardiovascular diseases", "PROBLEM", 107, 150], ["underlying diseases", "PROBLEM", 208, 227], ["multi-organ", "ANATOMY", 27, 38], ["dysfunction", "OBSERVATION", 39, 50], ["cerebrocardiovascular", "ANATOMY", 120, 141], ["diseases", "OBSERVATION", 142, 150], ["without", "UNCERTAINTY", 200, 207], ["diseases", "OBSERVATION", 219, 227]]], ["One cross-sectional study aimed at assessing neuropsychiatric symptoms during acute and convalescence phases of SARS-CoV-1 via a questionnaire sent out to 308 patients.", [["neuropsychiatric symptoms", "DISEASE", 45, 70], ["SARS", "DISEASE", 112, 116], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["SARS-CoV-1", "SPECIES", 112, 122], ["One cross-sectional study", "TEST", 0, 25], ["neuropsychiatric symptoms", "PROBLEM", 45, 70], ["SARS", "TEST", 112, 116], ["CoV", "TEST", 117, 120], ["a questionnaire", "TEST", 127, 142]]], ["32 The response rate was 33% (102 patients); 65% of these patients had suffered neuropsychiatric symptoms during the convalescence phase of SARS-CoV-1.", [["SARS", "DISEASE", 140, 144], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 58, 66], ["The response rate", "TEST", 3, 20], ["neuropsychiatric symptoms", "PROBLEM", 80, 105]]], ["Steroid treatment during hospitalization was predictive for anxiety, depression, psychosis, and behavioral symptoms during both the acute and convalescence phases.", [["anxiety", "DISEASE", 60, 67], ["depression", "DISEASE", 69, 79], ["psychosis", "DISEASE", 81, 90], ["behavioral symptoms", "DISEASE", 96, 115], ["Steroid", "CHEMICAL", 0, 7], ["Steroid", "SIMPLE_CHEMICAL", 0, 7], ["Steroid treatment", "TREATMENT", 0, 17], ["anxiety", "PROBLEM", 60, 67], ["depression", "PROBLEM", 69, 79], ["psychosis", "PROBLEM", 81, 90], ["behavioral symptoms", "PROBLEM", 96, 115]]], ["Another Chinese study (only abstract available in English) including 173 SARS-CoV-1 patients confirmed high rates of neurological/neuropsychiatric symptoms in SARS-CoV-1 patients (53%).", [["neurological", "ANATOMY", 117, 129], ["SARS", "DISEASE", 73, 77], ["neurological/neuropsychiatric symptoms", "DISEASE", 117, 155], ["SARS", "DISEASE", 159, 163], ["SARS-CoV-1", "ORGANISM", 73, 83], ["patients", "ORGANISM", 84, 92], ["SARS-CoV", "ORGANISM", 159, 167], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 170, 178], ["SARS-CoV-1", "SPECIES", 159, 169], ["Another Chinese study", "TEST", 0, 21], ["CoV", "TEST", 78, 81], ["neurological/neuropsychiatric symptoms", "PROBLEM", 117, 155], ["CoV", "TEST", 164, 167]]], ["33 The symptomatology comprised headache (67%), affective disorder (31%), dizziness (29%), anxiety (20%), reduced consciousness (10%), phobia (8%), depression (6%), unspecified mental disorder (5%), suicidal ideation (1%), seizures (1%), and focal neurological signs (0.6%).", [["neurological", "ANATOMY", 248, 260], ["headache", "DISEASE", 32, 40], ["affective disorder", "DISEASE", 48, 66], ["dizziness", "DISEASE", 74, 83], ["anxiety", "DISEASE", 91, 98], ["reduced consciousness", "DISEASE", 106, 127], ["phobia", "DISEASE", 135, 141], ["depression", "DISEASE", 148, 158], ["unspecified mental disorder", "DISEASE", 165, 192], ["suicidal ideation", "DISEASE", 199, 216], ["seizures", "DISEASE", 223, 231], ["neurological signs", "DISEASE", 248, 266], ["headache", "PROBLEM", 32, 40], ["affective disorder", "PROBLEM", 48, 66], ["dizziness", "PROBLEM", 74, 83], ["anxiety", "PROBLEM", 91, 98], ["reduced consciousness", "PROBLEM", 106, 127], ["phobia", "PROBLEM", 135, 141], ["depression", "PROBLEM", 148, 158], ["unspecified mental disorder", "PROBLEM", 165, 192], ["suicidal ideation", "PROBLEM", 199, 216], ["seizures", "PROBLEM", 223, 231], ["focal neurological signs", "PROBLEM", 242, 266], ["headache", "OBSERVATION", 32, 40], ["mental disorder", "OBSERVATION", 177, 192], ["focal", "OBSERVATION_MODIFIER", 242, 247]]], ["Several case reports, comprising a total of 11 patients, described neurological complications in SARS-CoV-1, among them critical illness neuro-/myopathy, seizures, persistent sleeping difficulties, persistent anosmia, delirium, and generalized pain (Table S6 ).ChildrenOne cohort study assessed neurological manifestation of SARS-CoV-1 in children.", [["neurological", "ANATOMY", 67, 79], ["neurological", "ANATOMY", 295, 307], ["SARS", "DISEASE", 97, 101], ["neuro-/myopathy", "DISEASE", 137, 152], ["seizures", "DISEASE", 154, 162], ["sleeping difficulties", "DISEASE", 175, 196], ["anosmia", "DISEASE", 209, 216], ["delirium", "DISEASE", 218, 226], ["pain", "DISEASE", 244, 248], ["SARS", "DISEASE", 325, 329], ["patients", "ORGANISM", 47, 55], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 325, 335], ["children", "ORGANISM", 339, 347], ["patients", "SPECIES", 47, 55], ["children", "SPECIES", 339, 347], ["SARS-CoV-1", "SPECIES", 97, 107], ["SARS-CoV-1", "SPECIES", 325, 335], ["neurological complications", "PROBLEM", 67, 93], ["SARS", "PROBLEM", 97, 101], ["myopathy", "PROBLEM", 144, 152], ["seizures", "PROBLEM", 154, 162], ["persistent sleeping difficulties", "PROBLEM", 164, 196], ["persistent anosmia", "PROBLEM", 198, 216], ["delirium", "PROBLEM", 218, 226], ["generalized pain", "PROBLEM", 232, 248], ["cohort study", "TEST", 273, 285], ["myopathy", "OBSERVATION", 144, 152], ["persistent", "OBSERVATION_MODIFIER", 198, 208], ["anosmia", "OBSERVATION", 209, 216], ["delirium", "OBSERVATION", 218, 226]]], ["34 The study comprised 183 children with encephalitis out of which 22 (12%) were positive for SARS-CoV-1.", [["encephalitis", "DISEASE", 41, 53], ["SARS", "DISEASE", 94, 98], ["children", "ORGANISM", 27, 35], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 94, 104], ["children", "SPECIES", 27, 35], ["SARS-CoV-1", "SPECIES", 94, 104], ["The study", "TEST", 3, 12], ["encephalitis", "PROBLEM", 41, 53], ["SARS", "TEST", 94, 98], ["CoV", "TEST", 99, 102]]], ["Headache, seizures, and neck stiffness were common symptoms among SARS-CoV-1 positive children with encephalitis (10/22 [46%], 5/22Children[23%] and 7/22 [32%], respectively).", [["neck", "ANATOMY", 24, 28], ["Headache", "DISEASE", 0, 8], ["seizures", "DISEASE", 10, 18], ["neck stiffness", "DISEASE", 24, 38], ["SARS-CoV-1 positive", "DISEASE", 66, 85], ["encephalitis", "DISEASE", 100, 112], ["neck", "ORGANISM_SUBDIVISION", 24, 28], ["SARS-CoV-1", "ORGANISM", 66, 76], ["children", "ORGANISM", 86, 94], ["children", "SPECIES", 86, 94], ["Children", "SPECIES", 131, 139], ["SARS-CoV-1", "SPECIES", 66, 76], ["Headache", "PROBLEM", 0, 8], ["seizures", "PROBLEM", 10, 18], ["neck stiffness", "PROBLEM", 24, 38], ["common symptoms", "PROBLEM", 44, 59], ["encephalitis", "PROBLEM", 100, 112], ["seizures", "OBSERVATION", 10, 18], ["neck", "ANATOMY", 24, 28], ["stiffness", "OBSERVATION", 29, 38], ["encephalitis", "OBSERVATION", 100, 112]]], ["A total 16 of these children underwent neuroimaging of which 8 (50%) showed abnormal findings, among them abnormalities in the temporal lobe, in the periventricular region, and in the basal ganglia/thalamus.", [["temporal lobe", "ANATOMY", 127, 140], ["periventricular region", "ANATOMY", 149, 171], ["basal ganglia", "ANATOMY", 184, 197], ["thalamus", "ANATOMY", 198, 206], ["children", "ORGANISM", 20, 28], ["temporal lobe", "MULTI-TISSUE_STRUCTURE", 127, 140], ["periventricular region", "TISSUE", 149, 171], ["basal ganglia", "MULTI-TISSUE_STRUCTURE", 184, 197], ["thalamus", "ORGAN", 198, 206], ["children", "SPECIES", 20, 28], ["neuroimaging", "TEST", 39, 51], ["abnormal findings", "PROBLEM", 76, 93], ["them abnormalities in the temporal lobe", "PROBLEM", 101, 140], ["abnormalities", "OBSERVATION", 106, 119], ["temporal lobe", "ANATOMY", 127, 140], ["periventricular", "ANATOMY_MODIFIER", 149, 164], ["region", "ANATOMY_MODIFIER", 165, 171], ["basal", "ANATOMY_MODIFIER", 184, 189], ["ganglia", "ANATOMY", 190, 197], ["thalamus", "ANATOMY", 198, 206]]], ["This study also measured different inflammatory proteins in serum and CSF; in matched serum-CSF samples, interleukin (IL)-6, IL-8, and chemokine (C-C motif) ligand 2 were increased in CSF compared to serum.NeuropathologySeveral studies addressed neuropathological changes of SARS-CoV-1.", [["serum", "ANATOMY", 60, 65], ["serum", "ANATOMY", 86, 91], ["samples", "ANATOMY", 96, 103], ["serum", "ANATOMY", 200, 205], ["SARS", "DISEASE", 275, 279], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["CSF", "ORGANISM_SUBSTANCE", 70, 73], ["serum", "ORGANISM_SUBSTANCE", 86, 91], ["CSF samples", "ORGANISM_SUBSTANCE", 92, 103], ["interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 105, 123], ["IL-8", "GENE_OR_GENE_PRODUCT", 125, 129], ["C-C motif) ligand 2", "GENE_OR_GENE_PRODUCT", 146, 165], ["CSF", "ORGANISM_SUBSTANCE", 184, 187], ["serum", "ORGANISM_SUBSTANCE", 200, 205], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 275, 285], ["inflammatory proteins", "PROTEIN", 35, 56], ["interleukin (IL)-6", "PROTEIN", 105, 123], ["IL-8", "PROTEIN", 125, 129], ["chemokine (C-C motif) ligand 2", "PROTEIN", 135, 165], ["SARS-CoV-1", "SPECIES", 275, 285], ["This study", "TEST", 0, 10], ["different inflammatory proteins", "PROBLEM", 25, 56], ["serum and CSF", "TEST", 60, 73], ["matched serum", "TEST", 78, 91], ["CSF samples", "TEST", 92, 103], ["interleukin (IL)", "TEST", 105, 121], ["IL", "TEST", 125, 127], ["chemokine (C-C motif) ligand", "TEST", 135, 163], ["CSF", "TEST", 184, 187], ["serum", "TEST", 200, 205], ["NeuropathologySeveral studies", "TEST", 206, 235], ["neuropathological changes of SARS", "PROBLEM", 246, 279], ["CoV", "TEST", 280, 283], ["inflammatory", "OBSERVATION_MODIFIER", 35, 47]]], ["One relatively large study including findings from 18 autopsies (of which eight were confirmed SARS-CoV-1 infections pre-mortem) detected SARS-CoV-1 infected neurons in the hypothalamus and cortex using in situ hybridization and electron microscopy.", [["neurons", "ANATOMY", 158, 165], ["hypothalamus", "ANATOMY", 173, 185], ["cortex", "ANATOMY", 190, 196], ["SARS", "DISEASE", 95, 99], ["infections", "DISEASE", 106, 116], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 138, 148], ["neurons", "CELL", 158, 165], ["hypothalamus", "MULTI-TISSUE_STRUCTURE", 173, 185], ["cortex", "MULTI-TISSUE_STRUCTURE", 190, 196], ["CoV-1", "SPECIES", 143, 148], ["SARS-CoV-1", "SPECIES", 95, 105], ["SARS-CoV-1", "SPECIES", 138, 148], ["18 autopsies", "TEST", 51, 63], ["SARS", "PROBLEM", 95, 99], ["CoV", "TEST", 100, 103], ["1 infections pre-mortem", "PROBLEM", 104, 127], ["SARS", "PROBLEM", 138, 142], ["1 infected neurons in the hypothalamus and cortex", "PROBLEM", 147, 196], ["electron microscopy", "TEST", 229, 248], ["large", "OBSERVATION_MODIFIER", 15, 20], ["infected neurons", "OBSERVATION", 149, 165], ["hypothalamus", "ANATOMY", 173, 185], ["cortex", "ANATOMY_MODIFIER", 190, 196]]], ["35 Six of eight patients (75%) showed diffuse hypoxic neuronal injury.", [["neuronal", "ANATOMY", 54, 62], ["neuronal injury", "DISEASE", 54, 69], ["patients", "ORGANISM", 16, 24], ["neuronal", "CELL", 54, 62], ["patients", "SPECIES", 16, 24], ["diffuse hypoxic neuronal injury", "PROBLEM", 38, 69], ["diffuse", "OBSERVATION_MODIFIER", 38, 45], ["hypoxic neuronal injury", "OBSERVATION", 46, 69]]], ["Interestingly, SARS-CoV-1 viral sequences and pathologic changes were unique to brains of SARS-CoV-1-confirmed cases.", [["brains", "ANATOMY", 80, 86], ["SARS", "DISEASE", 90, 94], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 15, 25], ["SARS-CoV-1", "ORGANISM", 90, 100], ["SARS-CoV-1 viral sequences", "DNA", 15, 41], ["SARS-CoV-1", "SPECIES", 15, 25], ["SARS-CoV", "SPECIES", 90, 98], ["SARS", "TEST", 15, 19], ["CoV", "TEST", 20, 23], ["viral sequences", "TEST", 26, 41], ["pathologic changes", "PROBLEM", 46, 64], ["SARS", "TEST", 90, 94], ["CoV", "TEST", 95, 98]]], ["A smaller case series including three patients who died from SARS-CoV-1 showed signs of systemic vasculitis engaging smaller brain vessels.", [["brain vessels", "ANATOMY", 125, 138], ["SARS", "DISEASE", 61, 65], ["vasculitis", "DISEASE", 97, 107], ["patients", "ORGANISM", 38, 46], ["brain vessels", "MULTI-TISSUE_STRUCTURE", 125, 138], ["patients", "SPECIES", 38, 46], ["SARS", "PROBLEM", 61, 65], ["CoV", "TEST", 66, 69], ["systemic vasculitis", "PROBLEM", 88, 107], ["smaller", "OBSERVATION_MODIFIER", 2, 9], ["systemic", "OBSERVATION_MODIFIER", 88, 96], ["vasculitis", "OBSERVATION", 97, 107], ["brain vessels", "ANATOMY", 125, 138]]], ["36 In one case with CT findings suggestive of ischemia, the histopathological exam showed signs of neuronal necrosis and glial cell hyperplasia.", [["neuronal", "ANATOMY", 99, 107], ["glial cell", "ANATOMY", 121, 131], ["ischemia", "DISEASE", 46, 54], ["neuronal necrosis", "DISEASE", 99, 116], ["neuronal", "CELL", 99, 107], ["glial cell", "CELL", 121, 131], ["CT findings", "TEST", 20, 31], ["ischemia", "PROBLEM", 46, 54], ["the histopathological exam", "TEST", 56, 82], ["neuronal necrosis", "PROBLEM", 99, 116], ["glial cell hyperplasia", "PROBLEM", 121, 143], ["suggestive of", "UNCERTAINTY", 32, 45], ["ischemia", "OBSERVATION", 46, 54], ["neuronal", "ANATOMY", 99, 107], ["necrosis", "OBSERVATION", 108, 116], ["glial cell hyperplasia", "OBSERVATION", 121, 143]]], ["37 One study including 5 SARS-CoV-1 patients found changes in cell numbers/staining intensities compared to controls in various endocrine cell pools of the adenohypophysis.", [["cell", "ANATOMY", 62, 66], ["endocrine cell", "ANATOMY", 128, 142], ["adenohypophysis", "ANATOMY", 156, 171], ["SARS", "DISEASE", 25, 29], ["5", "ORGANISM", 23, 24], ["SARS-CoV-1", "ORGANISM", 25, 35], ["patients", "ORGANISM", 36, 44], ["cell", "CELL", 62, 66], ["endocrine cell", "CELL", 128, 142], ["adenohypophysis", "ORGAN", 156, 171], ["patients", "SPECIES", 36, 44], ["One study", "TEST", 3, 12], ["5 SARS", "TEST", 23, 29], ["CoV", "TEST", 30, 33], ["changes in cell numbers", "PROBLEM", 51, 74], ["staining intensities", "PROBLEM", 75, 95], ["cell numbers", "OBSERVATION", 62, 74], ["endocrine cell pools", "OBSERVATION", 128, 148], ["adenohypophysis", "ANATOMY", 156, 171]]], ["38 Finally, one study found myopathic changes in four of eight SARS-CoV-1 cases (50%) undergoing autopsy (in situ hybridization for SARS-CoV-1 in the skeletal muscle was negative though).", [["skeletal muscle", "ANATOMY", 150, 165], ["SARS", "DISEASE", 63, 67], ["SARS", "DISEASE", 132, 136], ["SARS-CoV-1", "ORGANISM", 63, 73], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 132, 142], ["skeletal muscle", "ORGAN", 150, 165], ["SARS-CoV-1", "SPECIES", 63, 73], ["SARS-CoV-1", "SPECIES", 132, 142], ["one study", "TEST", 12, 21], ["myopathic changes", "PROBLEM", 28, 45], ["eight SARS", "TEST", 57, 67], ["autopsy", "TEST", 97, 104], ["SARS", "PROBLEM", 132, 136], ["CoV", "TEST", 137, 140], ["myopathic", "OBSERVATION", 28, 37], ["skeletal muscle", "ANATOMY", 150, 165]]], ["39Neurological symptomatologyFindings are summarized in Table S7 .", [["Neurological", "ANATOMY", 2, 14], ["Neurological symptomatology", "DISEASE", 2, 29], ["Neurological symptomatology", "PROBLEM", 2, 29]]], ["Two large retrospective studies from Spain and China including 841 patients and 214 patients reported that 57% and 38% of patients had neurological manifestations, respectively.", [["neurological", "ANATOMY", 135, 147], ["patients", "ORGANISM", 67, 75], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 122, 130], ["neurological manifestations", "PROBLEM", 135, 162], ["large", "OBSERVATION_MODIFIER", 4, 9]]], ["40, 41 Both studies also found that neurological symptoms were more common in patients with more severe disease courses.Neurological symptomatologySeveral common neurological symptoms among SARS-CoV-2 patients have been described in these studies, such as fatigue (44-64% of patients), 42 41 and confusion (0.9-9% of patients).", [["neurological", "ANATOMY", 36, 48], ["Neurological", "ANATOMY", 120, 132], ["neurological", "ANATOMY", 162, 174], ["neurological symptoms", "DISEASE", 36, 57], ["Neurological symptomatology", "DISEASE", 120, 147], ["SARS", "DISEASE", 190, 194], ["fatigue", "DISEASE", 256, 263], ["confusion", "DISEASE", 296, 305], ["patients", "ORGANISM", 78, 86], ["SARS-CoV-2", "ORGANISM", 190, 200], ["patients", "ORGANISM", 201, 209], ["patients", "ORGANISM", 275, 283], ["patients", "ORGANISM", 317, 325], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 201, 209], ["patients", "SPECIES", 275, 283], ["patients", "SPECIES", 317, 325], ["SARS-CoV", "SPECIES", 190, 198], ["Both studies", "TEST", 7, 19], ["neurological symptoms", "PROBLEM", 36, 57], ["more severe disease courses", "PROBLEM", 92, 119], ["Neurological symptomatology", "PROBLEM", 120, 147], ["Several common neurological symptoms", "PROBLEM", 147, 183], ["SARS", "PROBLEM", 190, 194], ["these studies", "TEST", 233, 246], ["fatigue", "PROBLEM", 256, 263], ["confusion", "PROBLEM", 296, 305], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["disease", "OBSERVATION", 104, 111]]], ["44, 46 Smell and/or taste disorders are other symptoms reported by several studies, 45, 48, 49 having a prevalence of 39-88% in SARS-CoV-2 patients, 47, 50 Two studies also observed that smell/taste disorders are the initial manifestation of SARS-CoV-2 infection in 36%/60% of patients.", [["taste disorders", "DISEASE", 20, 35], ["SARS", "DISEASE", 128, 132], ["smell/taste disorders", "DISEASE", 187, 208], ["SARS-CoV-2 infection", "DISEASE", 242, 262], ["SARS-CoV", "ORGANISM", 128, 136], ["patients", "ORGANISM", 139, 147], ["SARS-CoV-2", "ORGANISM", 242, 252], ["patients", "ORGANISM", 277, 285], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 277, 285], ["SARS-CoV", "SPECIES", 128, 136], ["SARS-CoV-2", "SPECIES", 242, 252], ["taste disorders", "PROBLEM", 20, 35], ["other symptoms", "PROBLEM", 40, 54], ["smell/taste disorders", "PROBLEM", 187, 208], ["SARS", "PROBLEM", 242, 246], ["CoV", "TEST", 247, 250], ["2 infection", "PROBLEM", 251, 262]]], ["41, 50 A Spanish survey-based study showed that smell disorders can persist for several weeks in about 1/3 of patients.", [["smell disorders", "DISEASE", 48, 63], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["A Spanish survey", "TEST", 7, 23], ["based study", "TEST", 24, 35], ["smell disorders", "PROBLEM", 48, 63]]], ["51 Also other symptoms may persist; an Italian study followed 143 patients for an average of 60 days after onset of SARS-CoV-2 symptoms, finding that 76 patients (53%) suffered persisting fatigue.", [["SARS", "DISEASE", 116, 120], ["fatigue", "DISEASE", 188, 195], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 153, 161], ["other symptoms", "PROBLEM", 8, 22], ["an Italian study", "TEST", 36, 52], ["SARS", "PROBLEM", 116, 120], ["CoV-2 symptoms", "PROBLEM", 121, 135], ["persisting fatigue", "PROBLEM", 177, 195], ["persisting", "OBSERVATION_MODIFIER", 177, 187], ["fatigue", "OBSERVATION", 188, 195]]], ["52Neurological complicationsSeveral studies reported on neurological complications of SARS-CoV-2, mostly in severe or critically ill patients.", [["Neurological", "ANATOMY", 2, 14], ["neurological", "ANATOMY", 56, 68], ["Neurological complications", "DISEASE", 2, 28], ["SARS", "DISEASE", 86, 90], ["critically ill", "DISEASE", 118, 132], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["SARS-CoV", "SPECIES", 86, 94], ["Neurological complications", "PROBLEM", 2, 28], ["Several studies", "TEST", 28, 43], ["neurological complications", "PROBLEM", 56, 82], ["SARS", "PROBLEM", 86, 90], ["severe", "OBSERVATION_MODIFIER", 108, 114]]], ["A case series from the UK included 43 SARS-CoV-2 patients who had been admitted to a specialized COVID neurology unit.", [["SARS", "DISEASE", 38, 42], ["SARS-CoV", "ORGANISM", 38, 46], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["A case series", "TEST", 0, 13]]], ["53 Based on symptomatology, patients could be classified into four major subgroups: (1) ischemic stroke (8 patients), (2) inflammatory CNS syndromes (para-/ postinfectious, 12 patients), (3) peripheral nervous system (PNS) syndromes such as GBS (7 patients), and (4) encephalopathies (10 patients).Neurological complicationsSeveral larger studies have confirmed these classes of neurological complications in SARS-CoV-2.", [["CNS", "ANATOMY", 135, 138], ["peripheral nervous system", "ANATOMY", 191, 216], ["PNS", "ANATOMY", 218, 221], ["Neurological", "ANATOMY", 298, 310], ["neurological", "ANATOMY", 379, 391], ["ischemic stroke", "DISEASE", 88, 103], ["peripheral nervous system (PNS) syndromes", "DISEASE", 191, 232], ["GBS", "DISEASE", 241, 244], ["encephalopathies", "DISEASE", 267, 283], ["Neurological complications", "DISEASE", 298, 324], ["neurological complications", "DISEASE", 379, 405], ["SARS", "DISEASE", 409, 413], ["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 107, 115], ["patients", "ORGANISM", 176, 184], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 191, 216], ["PNS", "ANATOMICAL_SYSTEM", 218, 221], ["patients", "ORGANISM", 248, 256], ["patients", "ORGANISM", 288, 296], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 176, 184], ["patients", "SPECIES", 248, 256], ["patients", "SPECIES", 288, 296], ["SARS-CoV", "SPECIES", 409, 417], ["symptomatology", "PROBLEM", 12, 26], ["ischemic stroke", "PROBLEM", 88, 103], ["inflammatory CNS syndromes", "PROBLEM", 122, 148], ["postinfectious", "PROBLEM", 157, 171], ["peripheral nervous system (PNS) syndromes", "PROBLEM", 191, 232], ["GBS", "TEST", 241, 244], ["encephalopathies", "PROBLEM", 267, 283], ["Neurological complications", "PROBLEM", 298, 324], ["Several larger studies", "TEST", 324, 346], ["neurological complications", "PROBLEM", 379, 405], ["CoV", "TEST", 414, 417], ["ischemic", "OBSERVATION_MODIFIER", 88, 96], ["stroke", "OBSERVATION", 97, 103], ["inflammatory", "OBSERVATION_MODIFIER", 122, 134], ["CNS", "ANATOMY", 135, 138], ["peripheral", "ANATOMY_MODIFIER", 191, 201], ["nervous system", "ANATOMY", 202, 216], ["neurological", "OBSERVATION_MODIFIER", 379, 391], ["complications", "OBSERVATION", 392, 405]]], ["Cerebrovascular diseases were among the most commonly reported complications, including ischemic stroke, and cerebral hemorrhages.", [["Cerebrovascular", "ANATOMY", 0, 15], ["cerebral", "ANATOMY", 109, 117], ["Cerebrovascular diseases", "DISEASE", 0, 24], ["ischemic stroke", "DISEASE", 88, 103], ["cerebral hemorrhages", "DISEASE", 109, 129], ["Cerebrovascular", "MULTI-TISSUE_STRUCTURE", 0, 15], ["cerebral", "ORGAN", 109, 117], ["Cerebrovascular diseases", "PROBLEM", 0, 24], ["ischemic stroke", "PROBLEM", 88, 103], ["cerebral hemorrhages", "PROBLEM", 109, 129], ["diseases", "OBSERVATION", 16, 24], ["complications", "OBSERVATION", 63, 76], ["ischemic", "OBSERVATION_MODIFIER", 88, 96], ["stroke", "OBSERVATION", 97, 103], ["cerebral", "ANATOMY", 109, 117], ["hemorrhages", "OBSERVATION", 118, 129]]], ["41, [54] [55] [56] [57] [58] [59] .", [["[54] [55] [56] [57] [58] [59]", "SIMPLE_CHEMICAL", 4, 33]]], ["Studies from China, Spain and the US report that 1-1.6% of hospitalized patients were affected by cerebrovascular disease.", [["cerebrovascular", "ANATOMY", 98, 113], ["cerebrovascular disease", "DISEASE", 98, 121], ["patients", "ORGANISM", 72, 80], ["cerebrovascular", "ANATOMICAL_SYSTEM", 98, 113], ["patients", "SPECIES", 72, 80], ["the US", "TEST", 30, 36], ["cerebrovascular disease", "PROBLEM", 98, 121], ["cerebrovascular", "ANATOMY", 98, 113], ["disease", "OBSERVATION", 114, 121]]], ["41, 54, 55, 57, 59 Yet, cardiovascular risk factors were pre-existent in many of the \u00aa 2020 The Authors.", [["cardiovascular", "ANATOMY", 24, 38]]], ["Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association stroke patients.", [["stroke", "DISEASE", 129, 135], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144]]], ["60 Ischemic brain lesions seem to be more common in more severe disease courses: In a Chinese study, 20% of deceased SARS-CoV-2 patients had signs of hypoxic encephalopathy compared to only 1% in patients who recovered.", [["brain lesions", "ANATOMY", 12, 25], ["Ischemic brain lesions", "DISEASE", 3, 25], ["SARS", "DISEASE", 117, 121], ["encephalopathy", "DISEASE", 158, 172], ["brain lesions", "CANCER", 12, 25], ["SARS-CoV", "ORGANISM", 117, 125], ["patients", "ORGANISM", 128, 136], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 196, 204], ["SARS-CoV", "SPECIES", 117, 125], ["Ischemic brain lesions", "PROBLEM", 3, 25], ["a Chinese study", "TEST", 84, 99], ["deceased SARS", "TEST", 108, 121], ["CoV", "TEST", 122, 125], ["hypoxic encephalopathy", "PROBLEM", 150, 172], ["Ischemic", "OBSERVATION_MODIFIER", 3, 11], ["brain", "ANATOMY", 12, 17], ["lesions", "OBSERVATION", 18, 25], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["disease", "OBSERVATION", 64, 71], ["hypoxic encephalopathy", "OBSERVATION", 150, 172]]], ["43 Cerebral susceptibility abnormalities (i.e., microbleeds/-thrombosis) were also described as a relatively common neuroimaging feature, particularly in atypical locations such as in the corpus callosum or juxtacortically.", [["Cerebral", "ANATOMY", 3, 11], ["corpus callosum", "ANATOMY", 188, 203], ["juxtacortically", "ANATOMY", 207, 222], ["Cerebral susceptibility abnormalities", "DISEASE", 3, 40], ["microbleeds", "DISEASE", 48, 59], ["thrombosis", "DISEASE", 61, 71], ["corpus callosum", "MULTI-TISSUE_STRUCTURE", 188, 203], ["Cerebral susceptibility abnormalities", "PROBLEM", 3, 40], ["microbleeds", "PROBLEM", 48, 59], ["thrombosis", "PROBLEM", 61, 71], ["Cerebral", "ANATOMY", 3, 11], ["susceptibility", "OBSERVATION", 12, 26], ["thrombosis", "OBSERVATION", 61, 71], ["corpus callosum", "ANATOMY", 188, 203]]], ["[61] [62] [63] [64] Several cases of cerebral venous thromboses have been observed.", [["cerebral venous", "ANATOMY", 37, 52], ["cerebral venous thromboses", "DISEASE", 37, 63], ["[61] [62] [63", "SIMPLE_CHEMICAL", 0, 13], ["cerebral venous thromboses", "PATHOLOGICAL_FORMATION", 37, 63], ["cerebral venous thromboses", "PROBLEM", 37, 63], ["cerebral venous", "ANATOMY", 37, 52], ["thromboses", "OBSERVATION", 53, 63]]], ["56, 61 Inflammatory and/or demyelinating syndromes of both the central and the peripheral nervous system have been reported, among them GBS, 53,56,65 ADEM, 53 Miller-Fisher syndrome, and facial nerve palsy (Table S7 ).Neurological complicationsEncephalopathy and/or encephalitis are also reported by an increasing number of studies.", [["peripheral nervous system", "ANATOMY", 79, 104], ["facial nerve", "ANATOMY", 187, 199], ["demyelinating syndromes of both the central and the peripheral nervous system", "DISEASE", 27, 104], ["GBS", "DISEASE", 136, 139], ["ADEM", "DISEASE", 150, 154], ["Miller-Fisher syndrome", "DISEASE", 159, 181], ["facial nerve palsy", "DISEASE", 187, 205], ["Encephalopathy", "DISEASE", 244, 258], ["encephalitis", "DISEASE", 266, 278], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 79, 104], ["facial nerve", "MULTI-TISSUE_STRUCTURE", 187, 199], ["Inflammatory and/or demyelinating syndromes", "PROBLEM", 7, 50], ["GBS", "TEST", 136, 139], ["ADEM", "PROBLEM", 150, 154], ["Fisher syndrome", "PROBLEM", 166, 181], ["facial nerve palsy", "PROBLEM", 187, 205], ["Neurological complications", "PROBLEM", 218, 244], ["Encephalopathy", "PROBLEM", 244, 258], ["encephalitis", "PROBLEM", 266, 278], ["studies", "TEST", 324, 331], ["Inflammatory", "OBSERVATION", 7, 19], ["demyelinating syndromes", "OBSERVATION", 27, 50], ["both", "ANATOMY_MODIFIER", 54, 58], ["central", "ANATOMY_MODIFIER", 63, 70], ["peripheral", "ANATOMY_MODIFIER", 79, 89], ["nervous system", "ANATOMY", 90, 104], ["facial nerve", "ANATOMY", 187, 199], ["palsy", "OBSERVATION", 200, 205], ["complications", "OBSERVATION", 231, 244], ["encephalitis", "OBSERVATION", 266, 278], ["increasing", "OBSERVATION_MODIFIER", 303, 313]]], ["An observational case series from France reported on neurological complications in intensive care unit patients: 13/58 of patients (22%) presented with encephalopathic features.", [["neurological", "ANATOMY", 53, 65], ["neurological complications", "DISEASE", 53, 79], ["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 122, 130], ["encephalopathic features", "PROBLEM", 152, 176], ["encephalopathic", "OBSERVATION", 152, 167]]], ["66 Brain MRI showed that 8/13 patients displayed leptomeningeal enhancement on post-contrast T 1 -weighted and fluid-attenuated inversion recovery (FLAIR) sequencesa sign of leptomeningeal inflammation.", [["leptomeningeal", "ANATOMY", 49, 63], ["leptomeningeal", "ANATOMY", 174, 188], ["leptomeningeal inflammation", "DISEASE", 174, 201], ["patients", "ORGANISM", 30, 38], ["leptomeningeal inflammation", "PATHOLOGICAL_FORMATION", 174, 201], ["patients", "SPECIES", 30, 38], ["Brain MRI", "TEST", 3, 12], ["leptomeningeal enhancement", "PROBLEM", 49, 75], ["post-contrast T", "TEST", 79, 94], ["fluid-attenuated inversion recovery", "TEST", 111, 146], ["leptomeningeal inflammation", "PROBLEM", 174, 201], ["leptomeningeal enhancement", "OBSERVATION", 49, 75], ["leptomeningeal", "ANATOMY", 174, 188], ["inflammation", "OBSERVATION", 189, 201]]], ["Another French study found that 7/26 patients (27%) showed electroencephalogram (EEG)/MRI changes suggestive of encephalopathy.", [["encephalopathy", "DISEASE", 112, 126], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["Another French study", "TEST", 0, 20], ["electroencephalogram", "TEST", 59, 79], ["EEG", "TEST", 81, 84], ["MRI changes", "TEST", 86, 97], ["encephalopathy", "PROBLEM", 112, 126], ["suggestive of", "UNCERTAINTY", 98, 111], ["encephalopathy", "OBSERVATION", 112, 126]]], ["64 Also, several cases of acute necrotizing encephalopathy (ANE) or posterior reversible encephalopathy syndrome (PRES) have been described.", [["encephalopathy", "DISEASE", 44, 58], ["ANE", "DISEASE", 60, 63], ["posterior reversible encephalopathy syndrome", "DISEASE", 68, 112], ["PRES", "DISEASE", 114, 118], ["acute necrotizing encephalopathy", "PROBLEM", 26, 58], ["posterior reversible encephalopathy syndrome", "PROBLEM", 68, 112], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["necrotizing", "OBSERVATION_MODIFIER", 32, 43], ["encephalopathy", "OBSERVATION", 44, 58], ["posterior", "ANATOMY_MODIFIER", 68, 77], ["reversible", "OBSERVATION_MODIFIER", 78, 88], ["encephalopathy syndrome", "OBSERVATION", 89, 112]]], ["67,68 A Turkish study showed that 12/27 patients (44%) showed abnormalities on brain MRI with signs suggestive of ischemia or menigoencephalitis.", [["brain", "ANATOMY", 79, 84], ["ischemia", "DISEASE", 114, 122], ["menigoencephalitis", "DISEASE", 126, 144], ["patients", "ORGANISM", 40, 48], ["brain", "ORGAN", 79, 84], ["patients", "SPECIES", 40, 48], ["A Turkish study", "TEST", 6, 21], ["abnormalities", "PROBLEM", 62, 75], ["brain MRI", "TEST", 79, 88], ["ischemia", "PROBLEM", 114, 122], ["menigoencephalitis", "PROBLEM", 126, 144], ["brain", "ANATOMY", 79, 84], ["suggestive of", "UNCERTAINTY", 100, 113], ["ischemia", "OBSERVATION", 114, 122], ["menigoencephalitis", "OBSERVATION", 126, 144]]], ["69 Of note, only minimal evidence points to direct infection of neurons/glial cells by SARS-CoV-2 viral particles, as shown by mostly negative RT-PCR analyses from CSF (Table S7) .", [["neurons", "ANATOMY", 64, 71], ["glial cells", "ANATOMY", 72, 83], ["infection", "DISEASE", 51, 60], ["neurons", "CELL", 64, 71], ["glial cells", "CELL", 72, 83], ["SARS-CoV-2", "ORGANISM", 87, 97], ["CSF (Table S7", "GENE_OR_GENE_PRODUCT", 164, 177], ["neurons", "CELL_TYPE", 64, 71], ["glial cells", "CELL_TYPE", 72, 83], ["CSF", "PROTEIN", 164, 167], ["direct infection of neurons/glial cells", "PROBLEM", 44, 83], ["SARS", "TEST", 87, 91], ["CoV", "TEST", 92, 95], ["2 viral particles", "PROBLEM", 96, 113], ["PCR analyses", "TEST", 146, 158], ["CSF", "TEST", 164, 167], ["infection", "OBSERVATION", 51, 60], ["glial cells", "ANATOMY", 72, 83]]], ["53, 64, 66 Nevertheless, CSF from a small subset of patients with encephalitic features did test positive for SARS-CoV-2 RNA.", [["CSF", "GENE_OR_GENE_PRODUCT", 25, 28], ["patients", "ORGANISM", 52, 60], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 110, 120], ["CSF", "PROTEIN", 25, 28], ["SARS-CoV-2 RNA", "RNA", 110, 124], ["patients", "SPECIES", 52, 60], ["SARS-CoV", "SPECIES", 110, 118], ["CSF", "TEST", 25, 28], ["encephalitic features", "PROBLEM", 66, 87], ["SARS", "PROBLEM", 110, 114], ["CoV", "TEST", 115, 118], ["small", "OBSERVATION_MODIFIER", 36, 41]]], ["70, 71 Seizures have been reported in SARS-CoV-2 patients; in a Chinese cohort, 4/78 hospitalized patients (0.5%) suffered at least one seizure.", [["Seizures", "DISEASE", 7, 15], ["SARS", "DISEASE", 38, 42], ["seizure", "DISEASE", 136, 143], ["SARS-CoV-2", "ORGANISM", 38, 48], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 98, 106], ["SARS-CoV", "SPECIES", 38, 46], ["Seizures", "PROBLEM", 7, 15], ["one seizure", "PROBLEM", 132, 143], ["seizure", "OBSERVATION", 136, 143]]], ["40 This was mirrored in a Spanish cohort, where 6/841 hospitalized patients (0.7%) had at least one seizure.", [["seizure", "DISEASE", 100, 107], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["one seizure", "PROBLEM", 96, 107]]], ["41 However, a study focusing on seizure prevalence among SARS-CoV-2 patients did not observe any acute symptomatic seizures at all, despite seizure-triggering metabolic changes such as electrolyte imbalance in 84/311 patients (27%).", [["seizure", "DISEASE", 32, 39], ["SARS", "DISEASE", 57, 61], ["seizures", "DISEASE", 115, 123], ["seizure", "DISEASE", 140, 147], ["SARS-CoV", "ORGANISM", 57, 65], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 217, 225], ["SARS-CoV", "SPECIES", 57, 65], ["a study", "TEST", 12, 19], ["seizure prevalence", "TEST", 32, 50], ["any acute symptomatic seizures", "PROBLEM", 93, 123], ["seizure", "PROBLEM", 140, 147], ["metabolic changes", "PROBLEM", 159, 176], ["electrolyte imbalance", "PROBLEM", 185, 206]]], ["72 Finally, several recent studies observed psychiatric complications in SARS-CoV-2 patients.", [["psychiatric complications", "DISEASE", 44, 69], ["SARS", "DISEASE", 73, 77], ["SARS-CoV-2", "ORGANISM", 73, 83], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["SARS-CoV", "SPECIES", 73, 81], ["psychiatric complications", "PROBLEM", 44, 69]]], ["An Italian surveybased study observed sleep impairment as the most commonly reported neurological symptom (94/103 patients).", [["neurological", "ANATOMY", 85, 97], ["sleep impairment", "DISEASE", 38, 54], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["An Italian surveybased study", "TEST", 0, 28], ["sleep impairment", "PROBLEM", 38, 54], ["neurological symptom", "PROBLEM", 85, 105]]], ["73 A prospective cross-sectional study from the USA showed that impaired sense of smell was associated with anxiety and depressed mood.", [["impaired sense of smell", "DISEASE", 64, 87], ["anxiety", "DISEASE", 108, 115], ["depressed mood", "DISEASE", 120, 134], ["A prospective cross-sectional study", "TEST", 3, 38], ["the USA", "TEST", 44, 51], ["impaired sense of smell", "PROBLEM", 64, 87], ["anxiety", "PROBLEM", 108, 115], ["depressed mood", "PROBLEM", 120, 134], ["impaired", "OBSERVATION", 64, 72]]], ["74 Finally, a UK-wide surveillance study recorded 23 patients with neuropsychiatric disorders, among them new-onset psychosis (10 patients, 43%), neurocognitive syndrome (6 patients, 26%), and affective disorders (4 patients, 17%).", [["neuropsychiatric disorders", "DISEASE", 67, 93], ["psychosis", "DISEASE", 116, 125], ["neurocognitive syndrome", "DISEASE", 146, 169], ["affective disorders", "DISEASE", 193, 212], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 130, 138], ["patients", "ORGANISM", 173, 181], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 173, 181], ["patients", "SPECIES", 216, 224], ["wide surveillance study", "TEST", 17, 40], ["neuropsychiatric disorders", "PROBLEM", 67, 93], ["onset psychosis", "PROBLEM", 110, 125], ["neurocognitive syndrome", "PROBLEM", 146, 169], ["affective disorders", "PROBLEM", 193, 212], ["onset", "OBSERVATION_MODIFIER", 110, 115], ["psychosis", "OBSERVATION", 116, 125]]], ["58 Children In a study from the UK, 4 of the 27 children (15%) suffering multisystem inflammatory syndromes also developed neurological symptoms, including encephalopathy, brainstem/cerebellar signs, and reduced reflexes.", [["neurological", "ANATOMY", 123, 135], ["brainstem", "ANATOMY", 172, 181], ["cerebellar", "ANATOMY", 182, 192], ["neurological symptoms", "DISEASE", 123, 144], ["encephalopathy", "DISEASE", 156, 170], ["Children", "ORGANISM", 3, 11], ["children", "ORGANISM", 48, 56], ["cerebellar", "ORGAN", 182, 192], ["Children", "SPECIES", 3, 11], ["children", "SPECIES", 48, 56], ["a study", "TEST", 15, 22], ["multisystem inflammatory syndromes", "PROBLEM", 73, 107], ["neurological symptoms", "PROBLEM", 123, 144], ["encephalopathy", "PROBLEM", 156, 170], ["brainstem/cerebellar signs", "PROBLEM", 172, 198], ["reduced reflexes", "PROBLEM", 204, 220], ["multisystem", "OBSERVATION_MODIFIER", 73, 84], ["inflammatory syndromes", "OBSERVATION", 85, 107], ["brainstem", "ANATOMY", 172, 181], ["cerebellar", "ANATOMY", 182, 192], ["signs", "OBSERVATION", 193, 198], ["reduced", "OBSERVATION_MODIFIER", 204, 211], ["reflexes", "OBSERVATION", 212, 220]]], ["MRI showed signal changes of the splenium in all patients, interpreted as a sign suggestive of an ongoing (para-)infectious process.", [["splenium", "ANATOMY", 33, 41], ["splenium", "CANCER", 33, 41], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["MRI", "TEST", 0, 3], ["signal changes of the splenium", "PROBLEM", 11, 41], ["an ongoing (para-)infectious process", "PROBLEM", 95, 131], ["signal changes", "OBSERVATION", 11, 25], ["splenium", "ANATOMY", 33, 41], ["suggestive of", "UNCERTAINTY", 81, 94], ["infectious", "OBSERVATION", 113, 123]]], ["75 However, virus was undetectable in CSF from 2/2 sampled children.", [["CSF", "ORGANISM_SUBSTANCE", 38, 41], ["children", "ORGANISM", 59, 67], ["children", "SPECIES", 59, 67], ["virus", "PROBLEM", 12, 17]]], ["All patients showed at least some degree of recovery by the end of the study.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["the study", "TEST", 67, 76], ["at least", "OBSERVATION_MODIFIER", 20, 28], ["some degree", "OBSERVATION_MODIFIER", 29, 40]]], ["One case series from China included eight children with severe SARS-CoV-2 courses: 76 Of them, one child presented with headache and another with fatigue.", [["SARS", "DISEASE", 63, 67], ["headache", "DISEASE", 120, 128], ["fatigue", "DISEASE", 146, 153], ["children", "ORGANISM", 42, 50], ["children", "SPECIES", 42, 50], ["severe SARS", "PROBLEM", 56, 67], ["headache", "PROBLEM", 120, 128], ["fatigue", "PROBLEM", 146, 153], ["headache", "OBSERVATION", 120, 128]]], ["Furthermore, cases of children with GBS, stroke and encephalitis have been described (Table S7) .Fluid biomarkersIn a Chinese study, patients with neurological symptoms had lower lymphocyte levels, platelet counts as well as higher blood urea nitrogen levels compared with those without neurological symptoms.", [["neurological", "ANATOMY", 147, 159], ["lymphocyte", "ANATOMY", 179, 189], ["platelet", "ANATOMY", 198, 206], ["blood", "ANATOMY", 232, 237], ["neurological", "ANATOMY", 287, 299], ["GBS", "DISEASE", 36, 39], ["stroke", "DISEASE", 41, 47], ["encephalitis", "DISEASE", 52, 64], ["neurological symptoms", "DISEASE", 147, 168], ["urea nitrogen", "CHEMICAL", 238, 251], ["neurological symptoms", "DISEASE", 287, 308], ["urea", "CHEMICAL", 238, 242], ["nitrogen", "CHEMICAL", 243, 251], ["children", "ORGANISM", 22, 30], ["patients", "ORGANISM", 133, 141], ["lymphocyte", "CELL", 179, 189], ["platelet", "CELL", 198, 206], ["blood", "ORGANISM_SUBSTANCE", 232, 237], ["urea", "SIMPLE_CHEMICAL", 238, 242], ["children", "SPECIES", 22, 30], ["patients", "SPECIES", 133, 141], ["GBS", "PROBLEM", 36, 39], ["stroke", "PROBLEM", 41, 47], ["encephalitis", "PROBLEM", 52, 64], ["Fluid biomarkers", "TEST", 97, 113], ["a Chinese study", "TEST", 116, 131], ["neurological symptoms", "PROBLEM", 147, 168], ["lower lymphocyte levels", "PROBLEM", 173, 196], ["platelet counts", "TEST", 198, 213], ["higher blood urea nitrogen levels", "PROBLEM", 225, 258], ["neurological symptoms", "PROBLEM", 287, 308], ["stroke", "OBSERVATION", 41, 47], ["encephalitis", "OBSERVATION", 52, 64]]], ["40 Blood neurofilament light chain (NfL) levels have been linked to SARS-CoV-2: SARS-CoV-2 status seems to be an independent predictor of serum NfL levels.", [["serum", "ANATOMY", 138, 143], ["Blood", "ORGANISM_SUBSTANCE", 3, 8], ["neurofilament light chain", "GENE_OR_GENE_PRODUCT", 9, 34], ["NfL", "GENE_OR_GENE_PRODUCT", 36, 39], ["SARS-CoV-2", "ORGANISM", 68, 78], ["SARS-CoV-2", "ORGANISM", 80, 90], ["serum", "ORGANISM_SUBSTANCE", 138, 143], ["NfL", "GENE_OR_GENE_PRODUCT", 144, 147], ["Blood neurofilament light chain", "PROTEIN", 3, 34], ["NfL", "PROTEIN", 36, 39], ["NfL", "PROTEIN", 144, 147], ["SARS-CoV", "SPECIES", 68, 76], ["Blood neurofilament light chain", "TEST", 3, 34], ["NfL) levels", "TEST", 36, 47], ["SARS", "TEST", 68, 72], ["CoV", "TEST", 73, 76], ["SARS", "PROBLEM", 80, 84], ["CoV", "TEST", 85, 88], ["serum NfL levels", "TEST", 138, 154]]], ["Additionally, in severe SARS-CoV-2 patients, an early peak in plasma GFAP was followed by a slower increase in NfL, possibly reflecting a more acute involvement of astrocytes followed by a more prolonged neuro-axonal degeneration.NeuropathologySeveral studies assessed neuropathological changes associated with SARS-CoV-2 infections: One case series including six SARS-CoV-2 patients found lymphocytic panencephalitis and meningitis and, in three patients aged <65 years, widespread petechial hemorrhages.", [["plasma", "ANATOMY", 62, 68], ["astrocytes", "ANATOMY", 164, 174], ["neuro-axonal", "ANATOMY", 204, 216], ["lymphocytic", "ANATOMY", 390, 401], ["petechial", "ANATOMY", 483, 492], ["SARS", "DISEASE", 24, 28], ["SARS-CoV-2 infections", "DISEASE", 311, 332], ["SARS", "DISEASE", 364, 368], ["lymphocytic panencephalitis", "DISEASE", 390, 417], ["meningitis", "DISEASE", 422, 432], ["hemorrhages", "DISEASE", 493, 504], ["SARS-CoV-2", "ORGANISM", 24, 34], ["patients", "ORGANISM", 35, 43], ["plasma", "ORGANISM_SUBSTANCE", 62, 68], ["GFAP", "GENE_OR_GENE_PRODUCT", 69, 73], ["NfL", "GENE_OR_GENE_PRODUCT", 111, 114], ["astrocytes", "CELL", 164, 174], ["CoV-2", "ORGANISM", 316, 321], ["SARS-CoV", "ORGANISM", 364, 372], ["patients", "ORGANISM", 375, 383], ["lymphocytic panencephalitis", "CANCER", 390, 417], ["patients", "ORGANISM", 447, 455], ["petechial hemorrhages", "PATHOLOGICAL_FORMATION", 483, 504], ["plasma GFAP", "PROTEIN", 62, 73], ["NfL", "PROTEIN", 111, 114], ["astrocytes", "CELL_TYPE", 164, 174], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 375, 383], ["patients", "SPECIES", 447, 455], ["SARS-CoV", "SPECIES", 311, 319], ["SARS-CoV", "SPECIES", 364, 372], ["plasma GFAP", "TEST", 62, 73], ["a slower increase in NfL", "PROBLEM", 90, 114], ["a more acute involvement of astrocytes", "PROBLEM", 136, 174], ["a more prolonged neuro-axonal degeneration", "PROBLEM", 187, 229], ["NeuropathologySeveral studies", "TEST", 230, 259], ["neuropathological changes", "PROBLEM", 269, 294], ["SARS", "PROBLEM", 311, 315], ["One case series", "TEST", 334, 349], ["six SARS", "TEST", 360, 368], ["lymphocytic panencephalitis", "PROBLEM", 390, 417], ["meningitis", "PROBLEM", 422, 432], ["widespread petechial hemorrhages", "PROBLEM", 472, 504], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["SARS", "OBSERVATION", 24, 28], ["early", "OBSERVATION_MODIFIER", 48, 53], ["peak", "OBSERVATION_MODIFIER", 54, 58], ["slower", "OBSERVATION_MODIFIER", 92, 98], ["increase", "OBSERVATION_MODIFIER", 99, 107], ["possibly reflecting", "UNCERTAINTY", 116, 135], ["more", "OBSERVATION_MODIFIER", 138, 142], ["acute", "OBSERVATION_MODIFIER", 143, 148], ["involvement", "OBSERVATION", 149, 160], ["astrocytes", "ANATOMY", 164, 174], ["prolonged", "OBSERVATION_MODIFIER", 194, 203], ["neuro-axonal degeneration", "OBSERVATION", 204, 229], ["lymphocytic panencephalitis", "OBSERVATION", 390, 417], ["meningitis", "OBSERVATION", 422, 432], ["widespread", "OBSERVATION_MODIFIER", 472, 482], ["petechial", "OBSERVATION_MODIFIER", 483, 492], ["hemorrhages", "OBSERVATION", 493, 504]]], ["77 Interestingly, all patients also showed signs of brain stem encephalitis.", [["brain stem", "ANATOMY", 52, 62], ["brain stem encephalitis", "DISEASE", 52, 75], ["patients", "ORGANISM", 22, 30], ["brain stem", "CANCER", 52, 62], ["patients", "SPECIES", 22, 30], ["brain stem encephalitis", "PROBLEM", 52, 75], ["brain stem", "ANATOMY", 52, 62], ["encephalitis", "OBSERVATION", 63, 75]]], ["Signs of perivenular inflammation/demyelination suggestive of ADEM have also been described.", [["perivenular", "ANATOMY", 9, 20], ["inflammation", "DISEASE", 21, 33], ["demyelination", "DISEASE", 34, 47], ["ADEM", "DISEASE", 62, 66], ["perivenular inflammation", "PROBLEM", 9, 33], ["demyelination", "PROBLEM", 34, 47], ["ADEM", "PROBLEM", 62, 66], ["perivenular", "ANATOMY_MODIFIER", 9, 20], ["inflammation", "OBSERVATION", 21, 33], ["demyelination", "OBSERVATION", 34, 47], ["ADEM", "OBSERVATION", 62, 66]]], ["53, 78 A neuropathological assessment of 18 SARS-CoV-2 patients showed changes consistent with hypoxic injury.", [["SARS", "DISEASE", 44, 48], ["hypoxic injury", "DISEASE", 95, 109], ["SARS-CoV-2", "ORGANISM", 44, 54], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["A neuropathological assessment", "TEST", 7, 37], ["SARS-CoV", "TEST", 44, 52], ["hypoxic injury", "PROBLEM", 95, 109], ["consistent with", "UNCERTAINTY", 79, 94], ["hypoxic injury", "OBSERVATION", 95, 109]]], ["However, RT-PCR and immunohistochemistry disclosed only minimal evidence of SARS-CoV-2 infection.", [["infection", "DISEASE", 87, 96], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 76, 86], ["SARS-CoV-2", "SPECIES", 76, 86], ["RT-PCR", "TEST", 9, 15], ["immunohistochemistry", "TEST", 20, 40], ["SARS", "PROBLEM", 76, 80], ["CoV", "PROBLEM", 81, 84], ["2 infection", "PROBLEM", 85, 96], ["minimal", "OBSERVATION_MODIFIER", 56, 63], ["evidence of", "UNCERTAINTY", 64, 75], ["SARS", "OBSERVATION", 76, 80], ["CoV", "OBSERVATION_MODIFIER", 81, 84], ["infection", "OBSERVATION", 87, 96]]], ["79 Yet, one SARS-CoV-2 case in a patient with Parkinson's disease showed electron dense particles suggestive of SARS-CoV-2 in both brain endothelial cells and neurons.", [["brain endothelial cells", "ANATOMY", 131, 154], ["neurons", "ANATOMY", 159, 166], ["SARS", "DISEASE", 12, 16], ["Parkinson's disease", "DISEASE", 46, 65], ["SARS", "DISEASE", 112, 116], ["patient", "ORGANISM", 33, 40], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 112, 122], ["brain endothelial cells", "CELL", 131, 154], ["neurons", "CELL", 159, 166], ["brain endothelial cells", "CELL_TYPE", 131, 154], ["neurons", "CELL_TYPE", 159, 166], ["patient", "SPECIES", 33, 40], ["Parkinson's disease", "PROBLEM", 46, 65], ["electron dense particles", "PROBLEM", 73, 97], ["SARS", "PROBLEM", 112, 116], ["CoV", "TEST", 117, 120], ["dense particles", "OBSERVATION", 82, 97], ["suggestive of", "UNCERTAINTY", 98, 111], ["SARS", "OBSERVATION", 112, 116], ["both", "ANATOMY_MODIFIER", 126, 130], ["brain endothelial", "ANATOMY", 131, 148], ["neurons", "ANATOMY", 159, 166]]], ["SARS-CoV-2 RT-PCR was positive in brain tissue but not in the CSF.", [["brain tissue", "ANATOMY", 34, 46], ["CSF", "ANATOMY", 62, 65], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["brain tissue", "TISSUE", 34, 46], ["CSF", "ORGANISM_SUBSTANCE", 62, 65], ["SARS-CoV-2 RT-PCR", "DNA", 0, 17], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["RT-PCR", "TEST", 11, 17], ["positive in brain tissue", "PROBLEM", 22, 46], ["positive", "OBSERVATION", 22, 30], ["brain tissue", "ANATOMY", 34, 46]]], ["80Comparison between SARS-CoV-1 and SARS-CoV-2Direct comparison of neurological manifestations between SARS-CoV-1 and SARS-CoV-2 shows substantial similarities (Table 1 ).", [["neurological", "ANATOMY", 67, 79], ["SARS", "DISEASE", 103, 107], ["SARS-CoV-1", "ORGANISM", 21, 31], ["SARS-CoV", "ORGANISM", 36, 44], ["SARS-CoV-1", "ORGANISM", 103, 113], ["SARS-CoV-2", "ORGANISM", 118, 128], ["SARS-CoV", "SPECIES", 21, 29], ["SARS-CoV", "SPECIES", 36, 44], ["SARS-CoV-1", "SPECIES", 103, 113], ["SARS-CoV", "SPECIES", 118, 126], ["SARS", "TEST", 21, 25], ["CoV", "TEST", 26, 29], ["SARS", "TEST", 36, 40], ["CoV", "TEST", 41, 44], ["neurological manifestations", "PROBLEM", 67, 94], ["SARS", "TEST", 103, 107], ["CoV", "TEST", 108, 111], ["SARS-CoV", "TEST", 118, 126]]], ["In both diseases, a considerable number of patients suffer neurological complications, in particular those with a more severe disease course.", [["neurological", "ANATOMY", 59, 71], ["neurological complications", "DISEASE", 59, 85], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["neurological complications", "PROBLEM", 59, 85], ["a more severe disease course", "PROBLEM", 112, 140], ["both", "OBSERVATION_MODIFIER", 3, 7], ["diseases", "OBSERVATION", 8, 16], ["considerable", "OBSERVATION_MODIFIER", 20, 32], ["number", "OBSERVATION_MODIFIER", 33, 39], ["complications", "OBSERVATION", 72, 85], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["disease", "OBSERVATION", 126, 133]]], ["Fatigue, headache, smell/taste disorders and reduced consciousness are among the most commonly reported symptoms.", [["Fatigue", "DISEASE", 0, 7], ["headache", "DISEASE", 9, 17], ["taste disorders", "DISEASE", 25, 40], ["reduced consciousness", "DISEASE", 45, 66], ["Fatigue", "PROBLEM", 0, 7], ["headache", "PROBLEM", 9, 17], ["smell/taste disorders", "PROBLEM", 19, 40], ["reduced consciousness", "PROBLEM", 45, 66], ["symptoms", "PROBLEM", 104, 112]]], ["For example, the SARS-CoV-2 patient shown in Figure 2 , presented with altered consciousness to the intensive care unit.", [["SARS-CoV", "ORGANISM", 17, 25], ["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["SARS-CoV", "SPECIES", 17, 25], ["the SARS-CoV", "TEST", 13, 25], ["altered consciousness", "PROBLEM", 71, 92]]], ["Ischemic/hypoxic pathology, including stroke as well as seizures, have been described in both diseases.", [["stroke", "DISEASE", 38, 44], ["seizures", "DISEASE", 56, 64], ["Ischemic/hypoxic pathology", "PROBLEM", 0, 26], ["stroke", "PROBLEM", 38, 44], ["seizures", "PROBLEM", 56, 64], ["hypoxic", "OBSERVATION_MODIFIER", 9, 16], ["pathology", "OBSERVATION", 17, 26], ["stroke", "OBSERVATION", 38, 44], ["both", "OBSERVATION_MODIFIER", 89, 93], ["diseases", "OBSERVATION", 94, 102]]], ["Similarly, neuropsychiatric complications such as psychosis and mood disorders have been reported for both viral infections.", [["neuropsychiatric complications", "DISEASE", 11, 41], ["psychosis", "DISEASE", 50, 59], ["mood disorders", "DISEASE", 64, 78], ["viral infections", "DISEASE", 107, 123], ["neuropsychiatric complications", "PROBLEM", 11, 41], ["psychosis", "PROBLEM", 50, 59], ["mood disorders", "PROBLEM", 64, 78], ["both viral infections", "PROBLEM", 102, 123], ["viral", "OBSERVATION_MODIFIER", 107, 112], ["infections", "OBSERVATION", 113, 123]]], ["Finally, immune-mediated complications such as GBS, Miller-Fisher syndrome, or polyneuritis cranialis have been described in both diseases.DiscussionThe findings of this systematic review suggest that all HCoV strains are associated with neurological manifestations.", [["neurological", "ANATOMY", 238, 250], ["GBS", "DISEASE", 47, 50], ["Miller-Fisher syndrome", "DISEASE", 52, 74], ["polyneuritis cranialis", "DISEASE", 79, 101], ["polyneuritis cranialis", "ORGANISM", 79, 101], ["HCoV", "GENE_OR_GENE_PRODUCT", 205, 209], ["polyneuritis cranialis", "SPECIES", 79, 101], ["HCoV", "SPECIES", 205, 209], ["immune-mediated complications", "PROBLEM", 9, 38], ["GBS", "PROBLEM", 47, 50], ["Fisher syndrome", "PROBLEM", 59, 74], ["polyneuritis cranialis", "PROBLEM", 79, 101], ["this systematic review", "TEST", 165, 187], ["all HCoV strains", "PROBLEM", 201, 217], ["neurological manifestations", "PROBLEM", 238, 265], ["complications", "OBSERVATION", 25, 38], ["Fisher syndrome", "OBSERVATION", 59, 74], ["polyneuritis", "OBSERVATION", 79, 91], ["both", "OBSERVATION_MODIFIER", 125, 129], ["diseases", "OBSERVATION", 130, 138]]], ["Specifically, 229E, HKU1, NL63, and OC43Discussioninfections have been mainly studied in children, where they are associated with febrile seizures and meningitis.", [["febrile seizures", "DISEASE", 130, 146], ["meningitis", "DISEASE", 151, 161], ["229E", "GENE_OR_GENE_PRODUCT", 14, 18], ["HKU1", "GENE_OR_GENE_PRODUCT", 20, 24], ["NL63", "GENE_OR_GENE_PRODUCT", 26, 30], ["OC43Discussioninfections", "GENE_OR_GENE_PRODUCT", 36, 60], ["children", "ORGANISM", 89, 97], ["children", "SPECIES", 89, 97], ["HKU1", "TEST", 20, 24], ["febrile seizures", "PROBLEM", 130, 146], ["meningitis", "PROBLEM", 151, 161], ["meningitis", "OBSERVATION", 151, 161]]], ["GBS, ADEM, and encephalitis have also been described in children.", [["GBS", "DISEASE", 0, 3], ["ADEM", "DISEASE", 5, 9], ["encephalitis", "DISEASE", 15, 27], ["children", "ORGANISM", 56, 64], ["children", "SPECIES", 56, 64], ["GBS", "PROBLEM", 0, 3], ["ADEM", "PROBLEM", 5, 9], ["encephalitis", "PROBLEM", 15, 27], ["ADEM", "OBSERVATION", 5, 9], ["encephalitis", "OBSERVATION", 15, 27]]], ["The less abundant evidence for MERS-CoV suggests that fatigue, headache, and altered consciousness are common neurological manifestations.", [["neurological", "ANATOMY", 110, 122], ["fatigue", "DISEASE", 54, 61], ["headache", "DISEASE", 63, 71], ["altered consciousness", "DISEASE", 77, 98], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 31, 39], ["MERS-CoV", "SPECIES", 31, 39], ["MERS", "PROBLEM", 31, 35], ["fatigue", "PROBLEM", 54, 61], ["headache", "PROBLEM", 63, 71], ["altered consciousness", "PROBLEM", 77, 98], ["common neurological manifestations", "PROBLEM", 103, 137], ["less", "OBSERVATION_MODIFIER", 4, 8], ["abundant", "OBSERVATION_MODIFIER", 9, 17], ["fatigue", "OBSERVATION", 54, 61]]], ["Stroke, critical-illness polyneuropathy, and GBS have also been observed.", [["Stroke", "DISEASE", 0, 6], ["critical-illness polyneuropathy", "DISEASE", 8, 39], ["GBS", "DISEASE", 45, 48], ["Stroke", "PROBLEM", 0, 6], ["critical-illness polyneuropathy", "PROBLEM", 8, 39], ["GBS", "PROBLEM", 45, 48], ["GBS", "OBSERVATION", 45, 48]]], ["Finally, SARS-CoV-1 and SARS-CoV-2, which are genetically highly related, 10 show substantial similarities regarding the prevalence and presentation of neurological manifestations; symptoms include fatigue, headache and smell/taste disorders.", [["neurological", "ANATOMY", 152, 164], ["fatigue", "DISEASE", 198, 205], ["headache", "DISEASE", 207, 215], ["taste disorders", "DISEASE", 226, 241], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 9, 19], ["SARS-CoV-2", "ORGANISM", 24, 34], ["SARS-CoV-1", "SPECIES", 9, 19], ["SARS-CoV", "SPECIES", 24, 32], ["SARS", "TEST", 9, 13], ["CoV", "TEST", 14, 17], ["SARS-CoV", "TEST", 24, 32], ["neurological manifestations", "PROBLEM", 152, 179], ["symptoms", "PROBLEM", 181, 189], ["fatigue", "PROBLEM", 198, 205], ["headache", "PROBLEM", 207, 215], ["smell/taste disorders", "PROBLEM", 220, 241]]], ["Complications that were observed among both SARS-CoV-1 and SARS-CoV-1 include cerebrovascular pathology, encephalopathy, autoimmune disorders such as GBS, meningoencephalitis, and seizures.Findings in the context of existing evidenceOverall, HCoV infections show a similar symptom complex across all of the HCoV strains.", [["cerebrovascular", "ANATOMY", 78, 93], ["SARS", "DISEASE", 44, 48], ["SARS", "DISEASE", 59, 63], ["cerebrovascular pathology", "DISEASE", 78, 103], ["encephalopathy", "DISEASE", 105, 119], ["autoimmune disorders", "DISEASE", 121, 141], ["GBS", "DISEASE", 150, 153], ["meningoencephalitis", "DISEASE", 155, 174], ["seizures", "DISEASE", 180, 188], ["infections", "DISEASE", 247, 257], ["SARS-CoV-1", "ORGANISM", 44, 54], ["SARS-CoV-1", "ORGANISM", 59, 69], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 78, 93], ["HCoV", "GENE_OR_GENE_PRODUCT", 307, 311], ["CoV-1", "SPECIES", 64, 69], ["SARS-CoV-1", "SPECIES", 44, 54], ["SARS-CoV-1", "SPECIES", 59, 69], ["HCoV", "SPECIES", 242, 246], ["HCoV", "SPECIES", 307, 311], ["Complications", "PROBLEM", 0, 13], ["CoV", "TEST", 49, 52], ["SARS", "TEST", 59, 63], ["CoV", "TEST", 64, 67], ["cerebrovascular pathology", "PROBLEM", 78, 103], ["encephalopathy", "PROBLEM", 105, 119], ["autoimmune disorders", "PROBLEM", 121, 141], ["GBS", "PROBLEM", 150, 153], ["meningoencephalitis", "PROBLEM", 155, 174], ["seizures", "PROBLEM", 180, 188], ["HCoV infections", "PROBLEM", 242, 257], ["a similar symptom complex", "PROBLEM", 263, 288], ["cerebrovascular", "ANATOMY", 78, 93], ["pathology", "OBSERVATION", 94, 103], ["encephalopathy", "OBSERVATION", 105, 119], ["meningoencephalitis", "OBSERVATION", 155, 174], ["infections", "OBSERVATION", 247, 257]]], ["These symptoms include fatigue and headache.", [["fatigue", "DISEASE", 23, 30], ["headache", "DISEASE", 35, 43], ["These symptoms", "PROBLEM", 0, 14], ["fatigue", "PROBLEM", 23, 30], ["headache", "PROBLEM", 35, 43], ["fatigue", "OBSERVATION", 23, 30]]], ["However, shared symptomatology is not surprising since all respiratory virus infections (including rhinoviruses and influenzaviruses) can cause fatigue and headache.", [["respiratory virus infections", "DISEASE", 59, 87], ["rhinoviruses and influenzaviruses", "DISEASE", 99, 132], ["fatigue", "DISEASE", 144, 151], ["headache", "DISEASE", 156, 164], ["respiratory virus", "ORGANISM", 59, 76], ["rhinoviruses", "ORGANISM", 99, 111], ["all respiratory virus infections", "PROBLEM", 55, 87], ["rhinoviruses", "PROBLEM", 99, 111], ["influenzaviruses", "PROBLEM", 116, 132], ["fatigue", "PROBLEM", 144, 151], ["headache", "PROBLEM", 156, 164], ["respiratory virus", "OBSERVATION", 59, 76]]], ["81 Moreover these are highly unspecific symptoms that are commonly associated with neurological but also non-neurological diseases.", [["neurological", "ANATOMY", 83, 95], ["highly unspecific symptoms", "PROBLEM", 22, 48], ["non-neurological diseases", "PROBLEM", 105, 130]]], ["82 Thus, these symptoms could arise without direct neuronal involvement of HCoV.", [["neuronal", "ANATOMY", 51, 59], ["HCoV", "ANATOMY", 75, 79], ["neuronal", "CELL", 51, 59], ["HCoV", "GENE_OR_GENE_PRODUCT", 75, 79], ["HCoV", "SPECIES", 75, 79], ["these symptoms", "PROBLEM", 9, 23], ["direct neuronal involvement of HCoV", "PROBLEM", 44, 79]]], ["Of note, persistent fatigue has been reported in the recovery/convalescence phase of SARS-CoV-2.", [["fatigue", "DISEASE", 20, 27], ["SARS", "DISEASE", 85, 89], ["SARS-CoV", "SPECIES", 85, 93], ["persistent fatigue", "PROBLEM", 9, 27], ["persistent", "OBSERVATION_MODIFIER", 9, 19], ["fatigue", "OBSERVATION", 20, 27]]], ["52 This is reminiscent of persistent fatigue after Epstein-Barr virus (EBV) infection.", [["fatigue", "DISEASE", 37, 44], ["Epstein-Barr virus (EBV) infection", "DISEASE", 51, 85], ["Epstein-Barr virus", "ORGANISM", 51, 69], ["EBV", "ORGANISM", 71, 74], ["Epstein-Barr virus", "SPECIES", 51, 69], ["EBV", "SPECIES", 71, 74], ["persistent fatigue", "PROBLEM", 26, 44], ["Epstein-Barr virus (EBV) infection", "PROBLEM", 51, 85], ["reminiscent of", "UNCERTAINTY", 11, 25], ["persistent", "OBSERVATION_MODIFIER", 26, 36], ["fatigue", "OBSERVATION", 37, 44], ["Barr virus", "OBSERVATION", 59, 69], ["infection", "OBSERVATION", 76, 85]]], ["83 Here, the most accepted hypothesis suggests a multifactorial pathogenesis including latent EBV infection, immune and/or neuroendocrine dysfunction as well as behavioral factors.", [["neuroendocrine", "ANATOMY", 123, 137], ["EBV infection", "DISEASE", 94, 107], ["immune and/or neuroendocrine dysfunction", "DISEASE", 109, 149], ["EBV", "ORGANISM", 94, 97], ["neuroendocrine", "ORGAN", 123, 137], ["EBV", "SPECIES", 94, 97], ["a multifactorial pathogenesis", "PROBLEM", 47, 76], ["latent EBV infection", "PROBLEM", 87, 107], ["neuroendocrine dysfunction", "PROBLEM", 123, 149], ["behavioral factors", "PROBLEM", 161, 179], ["multifactorial", "OBSERVATION_MODIFIER", 49, 63], ["pathogenesis", "OBSERVATION", 64, 76], ["latent", "OBSERVATION_MODIFIER", 87, 93], ["EBV infection", "OBSERVATION", 94, 107], ["neuroendocrine dysfunction", "OBSERVATION", 123, 149]]], ["It may be speculated if a similar etiopathogenesis could explain such persistent symptoms also with SARS-CoV-2.Findings in the context of existing evidenceIt is evident that SARS-CoV-1 and SARS-CoV-2 not only share neurological symptomatology but also complications.", [["neurological symptomatology", "DISEASE", 215, 242], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 100, 110], ["SARS-CoV-1", "ORGANISM", 174, 184], ["SARS-CoV-2", "ORGANISM", 189, 199], ["SARS-CoV", "SPECIES", 100, 108], ["SARS-CoV-1", "SPECIES", 174, 184], ["SARS-CoV", "SPECIES", 189, 197], ["persistent symptoms", "PROBLEM", 70, 89], ["SARS", "PROBLEM", 100, 104], ["SARS", "TEST", 174, 178], ["CoV", "TEST", 179, 182], ["SARS", "PROBLEM", 189, 193], ["CoV", "TEST", 194, 197], ["neurological symptomatology", "PROBLEM", 215, 242]]], ["This is not surprising since it has been shown recently that both SARS-CoV-1 and SARS-CoV-2 exploit the same membrane bound molecule angiotensin-converting enzyme 2 as a cellular entry target.", [["membrane", "ANATOMY", 109, 117], ["cellular", "ANATOMY", 170, 178], ["angiotensin", "CHEMICAL", 133, 144], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 66, 76], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 81, 91], ["membrane", "CELLULAR_COMPONENT", 109, 117], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 133, 164], ["cellular", "CELL", 170, 178], ["membrane bound molecule", "PROTEIN", 109, 132], ["angiotensin-converting enzyme 2", "PROTEIN", 133, 164], ["SARS", "TEST", 66, 70], ["CoV", "TEST", 71, 74], ["SARS", "PROBLEM", 81, 85], ["CoV", "TEST", 86, 89], ["angiotensin", "TEST", 133, 144]]], ["7 This receptor is, among other tissues, expressed on vessel endothelial cells in the brain, which could serve as a viral entry point to the CNS.", [["tissues", "ANATOMY", 32, 39], ["vessel endothelial cells", "ANATOMY", 54, 78], ["brain", "ANATOMY", 86, 91], ["CNS", "ANATOMY", 141, 144], ["tissues", "TISSUE", 32, 39], ["vessel endothelial cells", "CELL", 54, 78], ["brain", "ORGAN", 86, 91], ["CNS", "ANATOMICAL_SYSTEM", 141, 144], ["vessel endothelial cells", "CELL_TYPE", 54, 78], ["vessel endothelial cells in the brain", "PROBLEM", 54, 91], ["vessel", "ANATOMY", 54, 60], ["endothelial cells", "OBSERVATION", 61, 78], ["brain", "ANATOMY", 86, 91], ["CNS", "ANATOMY", 141, 144]]], ["8 Based on existing literature, five different syndromes can be delineated: (1) cerebrovascular disease, (2) encephalopathy, (3) para-/postinfectious inflammatory CNS/PNS syndromes, (4) (meningo-)encephalitis, and (5) neuropsychiatric complications.Findings in the context of existing evidenceFirst, ischemic stroke has been reported among both SARS-CoV-1 30 and SARS-CoV-2 (and anecdotally also for MERS-CoV).", [["cerebrovascular", "ANATOMY", 80, 95], ["CNS", "ANATOMY", 163, 166], ["PNS", "ANATOMY", 167, 170], ["cerebrovascular disease", "DISEASE", 80, 103], ["encephalopathy", "DISEASE", 109, 123], ["meningo-)encephalitis", "DISEASE", 187, 208], ["neuropsychiatric complications", "DISEASE", 218, 248], ["ischemic stroke", "DISEASE", 300, 315], ["SARS", "DISEASE", 345, 349], ["cerebrovascular", "ORGAN", 80, 95], ["SARS-CoV-1 30", "ORGANISM", 345, 358], ["SARS-CoV-2", "ORGANISM", 363, 373], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 400, 408], ["SARS-CoV-1", "SPECIES", 345, 355], ["SARS-CoV", "SPECIES", 363, 371], ["MERS-CoV", "SPECIES", 400, 408], ["five different syndromes", "PROBLEM", 32, 56], ["cerebrovascular disease", "PROBLEM", 80, 103], ["encephalopathy", "PROBLEM", 109, 123], ["para-/postinfectious inflammatory CNS", "PROBLEM", 129, 166], ["PNS syndromes", "PROBLEM", 167, 180], ["meningo-)encephalitis", "PROBLEM", 187, 208], ["neuropsychiatric complications", "PROBLEM", 218, 248], ["existing evidenceFirst, ischemic stroke", "PROBLEM", 276, 315], ["CoV", "TEST", 350, 353], ["SARS", "TEST", 363, 367], ["CoV", "TEST", 368, 371], ["cerebrovascular", "ANATOMY", 80, 95], ["disease", "OBSERVATION", 96, 103], ["encephalopathy", "OBSERVATION", 109, 123], ["postinfectious", "OBSERVATION_MODIFIER", 135, 149], ["inflammatory", "OBSERVATION_MODIFIER", 150, 162], ["PNS syndromes", "OBSERVATION", 167, 180], ["encephalitis", "OBSERVATION", 196, 208], ["ischemic", "OBSERVATION_MODIFIER", 300, 308], ["stroke", "OBSERVATION", 309, 315]]], ["41, 53, 66 Presumable underlying factors contributing to CNS hypoxia are a prothrombotic state evidenced by high D-dimer levels, which were observed among intensive care unit patients, 40, 42, 84 disseminated intravascular coagulation (DIC) 85 and/or systemic vasculitis.", [["CNS", "ANATOMY", 57, 60], ["intravascular", "ANATOMY", 209, 222], ["hypoxia", "DISEASE", 61, 68], ["intravascular coagulation", "DISEASE", 209, 234], ["DIC", "DISEASE", 236, 239], ["vasculitis", "DISEASE", 260, 270], ["CNS", "ANATOMICAL_SYSTEM", 57, 60], ["D-dimer", "GENE_OR_GENE_PRODUCT", 113, 120], ["patients", "ORGANISM", 175, 183], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 209, 222], ["patients", "SPECIES", 175, 183], ["underlying factors", "PROBLEM", 22, 40], ["CNS hypoxia", "PROBLEM", 57, 68], ["a prothrombotic state", "PROBLEM", 73, 94], ["high D-dimer levels", "PROBLEM", 108, 127], ["disseminated intravascular coagulation", "TEST", 196, 234], ["DIC", "TEST", 236, 239], ["systemic vasculitis", "PROBLEM", 251, 270], ["CNS", "ANATOMY", 57, 60], ["hypoxia", "OBSERVATION", 61, 68], ["systemic", "ANATOMY", 251, 259], ["vasculitis", "OBSERVATION", 260, 270]]], ["35, 36 Indeed, widespread endotheliitis has recently been demonstrated in several organs in SARS-CoV-2.", [["organs", "ANATOMY", 82, 88], ["endotheliitis", "DISEASE", 26, 39], ["SARS", "DISEASE", 92, 96], ["endotheliitis", "CANCER", 26, 39], ["organs", "ORGAN", 82, 88], ["SARS-CoV-2", "ORGANISM", 92, 102], ["SARS-CoV", "SPECIES", 92, 100], ["widespread endotheliitis", "PROBLEM", 15, 39], ["widespread", "OBSERVATION_MODIFIER", 15, 25], ["endotheliitis", "OBSERVATION", 26, 39]]], ["86 All these conditions facilitate systemic blood clotting.", [["blood", "ANATOMY", 44, 49], ["systemic blood clotting", "DISEASE", 35, 58], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["systemic blood clotting", "PROBLEM", 35, 58], ["clotting", "OBSERVATION", 50, 58]]], ["Furthermore, elderly patients, who were commonly reported being affected by stroke, are more likely to have risk factors for cerebrovascular disease.", [["cerebrovascular", "ANATOMY", 125, 140], ["stroke", "DISEASE", 76, 82], ["cerebrovascular disease", "DISEASE", 125, 148], ["patients", "ORGANISM", 21, 29], ["cerebrovascular", "ANATOMICAL_SYSTEM", 125, 140], ["patients", "SPECIES", 21, 29], ["stroke", "PROBLEM", 76, 82], ["cerebrovascular disease", "PROBLEM", 125, 148], ["stroke", "OBSERVATION", 76, 82], ["cerebrovascular disease", "OBSERVATION", 125, 148]]], ["87 Additionally, exclusively for SARS-CoV-2, intracranial hemorrhages and cerebral microbleeds have been reported, potentially provoked by endothelial damage/dysfunction.", [["intracranial", "ANATOMY", 45, 57], ["cerebral", "ANATOMY", 74, 82], ["endothelial", "ANATOMY", 139, 150], ["intracranial hemorrhages", "DISEASE", 45, 69], ["cerebral microbleeds", "DISEASE", 74, 94], ["intracranial hemorrhages", "PATHOLOGICAL_FORMATION", 45, 69], ["cerebral", "ORGAN", 74, 82], ["endothelial", "TISSUE", 139, 150], ["SARS-CoV", "SPECIES", 33, 41], ["SARS", "PROBLEM", 33, 37], ["CoV", "TEST", 38, 41], ["intracranial hemorrhages", "PROBLEM", 45, 69], ["cerebral microbleeds", "PROBLEM", 74, 94], ["endothelial damage/dysfunction", "PROBLEM", 139, 169], ["intracranial", "ANATOMY", 45, 57], ["hemorrhages", "OBSERVATION", 58, 69], ["cerebral", "ANATOMY", 74, 82], ["microbleeds", "OBSERVATION", 83, 94], ["endothelial damage", "OBSERVATION", 139, 157], ["dysfunction", "OBSERVATION", 158, 169]]], ["53, 64, 77 Second, encephalopathies with clinical features of delirium have been observed among SARS-CoV-2 patients.", [["encephalopathies", "DISEASE", 19, 35], ["delirium", "DISEASE", 62, 70], ["SARS", "DISEASE", 96, 100], ["SARS-CoV-2", "ORGANISM", 96, 106], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["SARS-CoV", "SPECIES", 96, 104], ["encephalopathies", "PROBLEM", 19, 35], ["delirium", "PROBLEM", 62, 70], ["delirium", "OBSERVATION", 62, 70]]], ["53, 66 Many of these patients showed full clinical recovery.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["53 Anecdotal evidence also indicates encephalopathic changes in SARS-CoV-1.", [["SARS", "DISEASE", 64, 68], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 64, 74], ["SARS-CoV-1", "SPECIES", 64, 74], ["encephalopathic changes in SARS", "PROBLEM", 37, 68], ["encephalopathic", "OBSERVATION_MODIFIER", 37, 52]]], ["88 The underlying mechanisms for the encephalopathy is likely multifactorial, resulting from combinatorial effects of sepsis, hypoxia, and immune hyperstimulation (\"cytokine storm\").", [["encephalopathy", "DISEASE", 37, 51], ["sepsis", "DISEASE", 118, 124], ["hypoxia", "DISEASE", 126, 133], ["immune hyperstimulation", "DISEASE", 139, 162], ["cytokine", "PROTEIN", 165, 173], ["the encephalopathy", "PROBLEM", 33, 51], ["sepsis", "PROBLEM", 118, 124], ["hypoxia", "PROBLEM", 126, 133], ["immune hyperstimulation", "PROBLEM", 139, 162], ["encephalopathy", "OBSERVATION", 37, 51], ["sepsis", "OBSERVATION", 118, 124], ["hypoxia", "OBSERVATION", 126, 133], ["immune hyperstimulation", "OBSERVATION", 139, 162]]], ["89 Third, both studies on SARS-CoV-1 and SARS-CoV-2 reported on GBS, an inflammatory demyelinating disease of the PNS.", [["PNS", "ANATOMY", 114, 117], ["SARS", "DISEASE", 26, 30], ["GBS", "DISEASE", 64, 67], ["demyelinating disease of the PNS", "DISEASE", 85, 117], ["SARS-CoV-1", "ORGANISM", 26, 36], ["SARS-CoV-2", "ORGANISM", 41, 51], ["PNS", "CANCER", 114, 117], ["SARS-CoV-1", "SPECIES", 26, 36], ["SARS-CoV", "SPECIES", 41, 49], ["SARS", "TEST", 26, 30], ["CoV", "TEST", 31, 34], ["SARS", "PROBLEM", 41, 45], ["CoV", "TEST", 46, 49], ["GBS", "PROBLEM", 64, 67], ["an inflammatory demyelinating disease of the PNS", "PROBLEM", 69, 117], ["GBS", "OBSERVATION", 64, 67], ["inflammatory", "OBSERVATION_MODIFIER", 72, 84], ["demyelinating disease", "OBSERVATION", 85, 106], ["PNS", "ANATOMY", 114, 117]]], ["65, 90, 91 Additionally, ADEM, an inflammatory demyelinating CNS disease has been reported among SARS-CoV-2 patients.", [["CNS", "ANATOMY", 61, 64], ["ADEM", "DISEASE", 25, 29], ["demyelinating CNS disease", "DISEASE", 47, 72], ["CNS", "ANATOMICAL_SYSTEM", 61, 64], ["SARS-CoV-2", "ORGANISM", 97, 107], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["SARS-CoV", "SPECIES", 97, 105], ["ADEM", "PROBLEM", 25, 29], ["an inflammatory demyelinating CNS disease", "PROBLEM", 31, 72], ["inflammatory", "OBSERVATION_MODIFIER", 34, 46], ["demyelinating CNS disease", "OBSERVATION", 47, 72]]], ["53 Anecdotal evidence also suggests a link of clinically less severe HCoV and MERS-CoV to these diseases.", [["HCoV", "CANCER", 69, 73], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 78, 86], ["HCoV", "SPECIES", 69, 73], ["MERS-CoV", "SPECIES", 78, 86], ["clinically less severe HCoV", "PROBLEM", 46, 73], ["these diseases", "PROBLEM", 90, 104], ["diseases", "OBSERVATION", 96, 104]]], ["They have a presumable autoimmune pathogenesis 92 and are thus less likely to be a direct consequence of neuronal infection by HCoV despite the detection of HCoV RNA in CSF in a few reported cases, but rather represent a para-infectious complication.", [["neuronal", "ANATOMY", 105, 113], ["neuronal infection", "DISEASE", 105, 123], ["neuronal", "CELL", 105, 113], ["HCoV", "CANCER", 127, 131], ["HCoV", "GENE_OR_GENE_PRODUCT", 157, 161], ["CSF", "ORGANISM_SUBSTANCE", 169, 172], ["HCoV RNA", "RNA", 157, 165], ["HCoV", "SPECIES", 127, 131], ["HCoV", "SPECIES", 157, 161], ["a presumable autoimmune pathogenesis", "PROBLEM", 10, 46], ["neuronal infection", "PROBLEM", 105, 123], ["HCoV RNA in CSF", "PROBLEM", 157, 172], ["a para-infectious complication", "PROBLEM", 219, 249], ["presumable", "UNCERTAINTY", 12, 22], ["autoimmune", "OBSERVATION_MODIFIER", 23, 33], ["less likely", "UNCERTAINTY", 63, 74], ["neuronal", "OBSERVATION_MODIFIER", 105, 113], ["infection", "OBSERVATION", 114, 123], ["rather represent", "UNCERTAINTY", 202, 218], ["para-infectious complication", "OBSERVATION", 221, 249]]], ["90 Additionally, other viral infections, such as cytomegaly or EBV, have been associated with GBS.", [["viral infections", "DISEASE", 23, 39], ["cytomegaly", "DISEASE", 49, 59], ["GBS", "DISEASE", 94, 97], ["EBV", "ORGANISM", 63, 66], ["other viral infections", "PROBLEM", 17, 39], ["cytomegaly", "PROBLEM", 49, 59], ["EBV", "PROBLEM", 63, 66], ["GBS", "PROBLEM", 94, 97], ["viral", "OBSERVATION_MODIFIER", 23, 28], ["infections", "OBSERVATION", 29, 39], ["EBV", "OBSERVATION", 63, 66], ["GBS", "OBSERVATION", 94, 97]]], ["92 MS is another autoimmune disease whose potential association with HCoV infection has been substantially investigated.", [["MS", "DISEASE", 3, 5], ["autoimmune disease", "DISEASE", 17, 35], ["HCoV infection", "DISEASE", 69, 83], ["HCoV", "GENE_OR_GENE_PRODUCT", 69, 73], ["HCoV", "SPECIES", 69, 73], ["another autoimmune disease", "PROBLEM", 9, 35], ["HCoV infection", "PROBLEM", 69, 83], ["autoimmune disease", "OBSERVATION", 17, 35], ["infection", "OBSERVATION", 74, 83]]], ["The conflicting results do not allow final conclusions on the role of HCoV in MS pathogenesis, even though the majority of evidence contradicts such an association.", [["MS", "DISEASE", 78, 80], ["HCoV", "GENE_OR_GENE_PRODUCT", 70, 74], ["HCoV", "SPECIES", 70, 74], ["MS pathogenesis", "PROBLEM", 78, 93]]], ["Fourth, exclusively for SARS-CoV-2, few patients with clinical and imaging features of (meningo-)encephalitis have been described (in children anecdotally also for HCoV-229E, HKU1, NL63 and/or OC43).", [["meningo-)encephalitis", "DISEASE", 88, 109], ["patients", "ORGANISM", 40, 48], ["children", "ORGANISM", 134, 142], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 164, 173], ["HKU1", "GENE_OR_GENE_PRODUCT", 175, 179], ["patients", "SPECIES", 40, 48], ["children", "SPECIES", 134, 142], ["SARS-CoV", "SPECIES", 24, 32], ["SARS", "PROBLEM", 24, 28], ["imaging features", "TEST", 67, 83], ["(meningo-)encephalitis", "PROBLEM", 87, 109], ["HCoV", "TEST", 164, 168], ["HKU1", "TEST", 175, 179]]], ["These cases were suggestive for primary HCoV CNS infection.", [["primary HCoV CNS", "ANATOMY", 32, 48], ["primary HCoV CNS infection", "DISEASE", 32, 58], ["HCoV", "SPECIES", 40, 44], ["These cases", "TEST", 0, 11], ["primary HCoV CNS infection", "PROBLEM", 32, 58], ["suggestive for", "UNCERTAINTY", 17, 31], ["CNS", "ANATOMY", 45, 48], ["infection", "OBSERVATION", 49, 58]]], ["64, 66 Yet, SARS-CoV-2 RNA in CSF was only detected in a handful of cases.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 12, 22], ["CSF", "ORGANISM_SUBSTANCE", 30, 33], ["SARS-CoV-2 RNA", "RNA", 12, 26], ["CSF", "PROTEIN", 30, 33], ["SARS", "TEST", 12, 16], ["CoV", "TEST", 17, 20], ["CSF", "ANATOMY", 30, 33]]], ["64, 71 Fifth, a link between neuropsychiatric complications such as psychosis and mood disorders has been described for SARS-CoV-1, SARS-CoV-2, and clinically more benign HCoV.", [["benign HCoV", "ANATOMY", 164, 175], ["neuropsychiatric complications", "DISEASE", 29, 59], ["psychosis", "DISEASE", 68, 77], ["mood disorders", "DISEASE", 82, 96], ["SARS-CoV-1", "ORGANISM", 120, 130], ["SARS-CoV-2", "ORGANISM", 132, 142], ["HCoV", "CANCER", 171, 175], ["SARS-CoV-1", "SPECIES", 120, 130], ["SARS-CoV", "SPECIES", 132, 140], ["HCoV", "SPECIES", 171, 175], ["a link between neuropsychiatric complications", "PROBLEM", 14, 59], ["psychosis", "PROBLEM", 68, 77], ["mood disorders", "PROBLEM", 82, 96], ["SARS", "PROBLEM", 120, 124], ["CoV", "TEST", 125, 128], ["SARS", "PROBLEM", 132, 136], ["CoV", "TEST", 137, 140], ["benign", "OBSERVATION", 164, 170]]], ["However, large cohort studies with adequate control groups are needed to address potential confounders, such as secondary consequences of pandemic lockdown measures.Findings in the context of existing evidenceIt is noteworthy that SARS-CoV-2 RNA could not be retrieved from the CSF in the vast majority of patients from larger case series/cohort studies.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 231, 241], ["CSF", "GENE_OR_GENE_PRODUCT", 278, 281], ["patients", "ORGANISM", 306, 314], ["SARS-CoV-2 RNA", "RNA", 231, 245], ["patients", "SPECIES", 306, 314], ["large cohort studies", "TEST", 9, 29], ["pandemic lockdown measures", "TREATMENT", 138, 164], ["SARS-CoV-2 RNA", "PROBLEM", 231, 245], ["the CSF", "TEST", 274, 281], ["cohort studies", "TEST", 339, 353], ["large", "OBSERVATION_MODIFIER", 9, 14], ["SARS", "OBSERVATION", 231, 235]]], ["Similarly, only few incidences of SARS-CoV-1 RNA detection in CSF have been described.", [["SARS", "DISEASE", 34, 38], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 34, 44], ["CSF", "GENE_OR_GENE_PRODUCT", 62, 65], ["CSF", "PROTEIN", 62, 65], ["SARS", "PROBLEM", 34, 38], ["CoV", "TEST", 39, 42], ["1 RNA detection in CSF", "PROBLEM", 43, 65], ["few", "OBSERVATION_MODIFIER", 16, 19], ["SARS", "OBSERVATION", 34, 38]]], ["93, 94 Neuropathological findings support this notion: only one study reported on electron dense particles in CNS neurons suggestive of SARS-CoV-2, though no RNA was detected in the CSF.", [["CNS neurons", "ANATOMY", 110, 121], ["electron", "SIMPLE_CHEMICAL", 82, 90], ["CNS neurons", "CELL", 110, 121], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 136, 146], ["CSF", "GENE_OR_GENE_PRODUCT", 182, 185], ["CNS neurons", "CELL_TYPE", 110, 121], ["CSF", "PROTEIN", 182, 185], ["SARS-CoV", "SPECIES", 136, 144], ["one study", "TEST", 60, 69], ["electron dense particles in CNS neurons", "PROBLEM", 82, 121], ["SARS", "PROBLEM", 136, 140], ["CoV", "TEST", 141, 144], ["RNA", "PROBLEM", 158, 161], ["CNS neurons", "ANATOMY", 110, 121], ["suggestive of", "UNCERTAINTY", 122, 135], ["SARS", "OBSERVATION", 136, 140], ["no", "UNCERTAINTY", 155, 157], ["RNA", "OBSERVATION", 158, 161], ["CSF", "ANATOMY", 182, 185]]], ["80 Failure to detect SARS-CoV-2 RNA in CSF could depend on different factors: first, the virus could be cell-bound thereby spreading from cellto-cell; second, virus particles have very low levels in CSF or third, endogenous CSF endo-/exonucleases cleave SARS-CoV-2 RNA.", [["cell", "ANATOMY", 104, 108], ["cellto-cell", "ANATOMY", 138, 149], ["SARS", "DISEASE", 21, 25], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 21, 31], ["CSF", "GENE_OR_GENE_PRODUCT", 39, 42], ["cell", "CELL", 104, 108], ["cellto-cell", "CELL", 138, 149], ["CSF", "GENE_OR_GENE_PRODUCT", 199, 202], ["CSF", "GENE_OR_GENE_PRODUCT", 224, 227], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 254, 264], ["SARS-CoV-2 RNA", "RNA", 21, 35], ["CSF", "PROTEIN", 39, 42], ["cellto-cell", "CELL_TYPE", 138, 149], ["CSF", "PROTEIN", 199, 202], ["endogenous CSF endo-/exonucleases", "PROTEIN", 213, 246], ["SARS-CoV-2 RNA", "RNA", 254, 268], ["SARS-CoV", "SPECIES", 21, 29], ["SARS", "PROBLEM", 21, 25], ["CoV", "TEST", 26, 29], ["2 RNA in CSF", "PROBLEM", 30, 42], ["the virus", "PROBLEM", 85, 94], ["cellto", "TEST", 138, 144], ["second, virus particles", "PROBLEM", 151, 174], ["very low levels in CSF", "PROBLEM", 180, 202], ["CSF endo", "TEST", 224, 232], ["exonucleases cleave SARS", "PROBLEM", 234, 258], ["CoV", "TEST", 259, 262], ["low levels", "OBSERVATION_MODIFIER", 185, 195]]], ["95 For the entry of HCoVs into the CNS, two major pathways have been proposed: 96 the hematogenous (via the blood-brain barrier) and neuronal retrograde pathway (via the cribriform plate/olfactory nerve).", [["CNS", "ANATOMY", 35, 38], ["blood-brain barrier", "ANATOMY", 108, 127], ["neuronal", "ANATOMY", 133, 141], ["cribriform plate", "ANATOMY", 170, 186], ["olfactory nerve", "ANATOMY", 187, 202], ["HCoVs", "GENE_OR_GENE_PRODUCT", 20, 25], ["CNS", "ANATOMICAL_SYSTEM", 35, 38], ["blood", "MULTI-TISSUE_STRUCTURE", 108, 113], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 114, 127], ["neuronal", "CELL", 133, 141], ["cribriform plate", "TISSUE", 170, 186], ["olfactory nerve", "MULTI-TISSUE_STRUCTURE", 187, 202], ["HCoVs", "PROTEIN", 20, 25], ["the hematogenous", "PROBLEM", 82, 98], ["the blood-brain barrier", "TREATMENT", 104, 127], ["neuronal retrograde pathway", "TEST", 133, 160], ["CNS", "ANATOMY", 35, 38], ["hematogenous", "OBSERVATION", 86, 98], ["brain", "ANATOMY", 114, 119], ["olfactory nerve", "ANATOMY", 187, 202]]], ["The exact pathway is yet still a matter of debate and more studies are necessary to dissect the specific CNS entry mechanisms of HCoVs.", [["CNS", "ANATOMY", 105, 108], ["CNS", "ANATOMICAL_SYSTEM", 105, 108], ["HCoVs", "GENE_OR_GENE_PRODUCT", 129, 134]]], ["However, the absence of SARS-CoV-2 from the CNS might also indicate that a large share of neurological complications are secondary to the severe systemic manifestations of SARS-CoV-2, that is, from a hyperinflammation syndrome 89 , vasculopathy/coagulopathy, postinfectious auto-inflammation, and the effects of sepsis and hypoxia.", [["CNS", "ANATOMY", 44, 47], ["neurological", "ANATOMY", 90, 102], ["SARS", "DISEASE", 24, 28], ["neurological complications", "DISEASE", 90, 116], ["SARS", "DISEASE", 172, 176], ["hyperinflammation", "DISEASE", 200, 217], ["vasculopathy", "DISEASE", 232, 244], ["coagulopathy", "DISEASE", 245, 257], ["postinfectious auto-inflammation", "DISEASE", 259, 291], ["sepsis", "DISEASE", 312, 318], ["hypoxia", "DISEASE", 323, 330], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 24, 34], ["CNS", "ANATOMICAL_SYSTEM", 44, 47], ["SARS-CoV", "SPECIES", 24, 32], ["SARS-CoV", "SPECIES", 172, 180], ["SARS-CoV", "TEST", 24, 32], ["neurological complications", "PROBLEM", 90, 116], ["the severe systemic manifestations", "PROBLEM", 134, 168], ["SARS", "PROBLEM", 172, 176], ["CoV", "TEST", 177, 180], ["a hyperinflammation syndrome", "PROBLEM", 198, 226], ["vasculopathy", "PROBLEM", 232, 244], ["coagulopathy", "PROBLEM", 245, 257], ["postinfectious auto-inflammation", "PROBLEM", 259, 291], ["sepsis", "PROBLEM", 312, 318], ["hypoxia", "PROBLEM", 323, 330], ["large", "OBSERVATION_MODIFIER", 75, 80], ["neurological complications", "OBSERVATION", 90, 116], ["severe", "OBSERVATION_MODIFIER", 138, 144], ["systemic", "OBSERVATION_MODIFIER", 145, 153], ["SARS", "OBSERVATION", 172, 176], ["hyperinflammation syndrome", "OBSERVATION", 200, 226], ["coagulopathy", "OBSERVATION", 245, 257], ["postinfectious", "OBSERVATION_MODIFIER", 259, 273], ["sepsis", "OBSERVATION", 312, 318], ["hypoxia", "OBSERVATION", 323, 330]]], ["53Recommendations for neuroimagingThe results of the current study highlight the need for adequate neuroimaging protocols in HCoV infections with neurological manifestation to be able to accurately detect encephalitis, leptomeningeal enhancement and vascular complications such as microbleeds, subarachnoid hemorrhage, and infarcts.", [["neurological", "ANATOMY", 146, 158], ["leptomeningeal", "ANATOMY", 219, 233], ["vascular", "ANATOMY", 250, 258], ["subarachnoid", "ANATOMY", 294, 306], ["infarcts", "ANATOMY", 323, 331], ["infections", "DISEASE", 130, 140], ["encephalitis", "DISEASE", 205, 217], ["leptomeningeal enhancement", "DISEASE", 219, 245], ["microbleeds", "DISEASE", 281, 292], ["subarachnoid hemorrhage", "DISEASE", 294, 317], ["infarcts", "DISEASE", 323, 331], ["HCoV", "ORGANISM", 125, 129], ["vascular", "MULTI-TISSUE_STRUCTURE", 250, 258], ["HCoV", "SPECIES", 125, 129], ["neuroimaging", "TEST", 22, 34], ["the current study", "TEST", 49, 66], ["adequate neuroimaging protocols", "TEST", 90, 121], ["HCoV infections", "PROBLEM", 125, 140], ["neurological manifestation", "PROBLEM", 146, 172], ["encephalitis", "PROBLEM", 205, 217], ["leptomeningeal enhancement", "PROBLEM", 219, 245], ["vascular complications", "PROBLEM", 250, 272], ["microbleeds", "PROBLEM", 281, 292], ["subarachnoid hemorrhage", "PROBLEM", 294, 317], ["infarcts", "PROBLEM", 323, 331], ["encephalitis", "OBSERVATION", 205, 217], ["leptomeningeal", "ANATOMY", 219, 233], ["vascular", "ANATOMY", 250, 258], ["complications", "OBSERVATION", 259, 272], ["microbleeds", "OBSERVATION", 281, 292], ["subarachnoid", "ANATOMY", 294, 306], ["hemorrhage", "OBSERVATION", 307, 317], ["infarcts", "OBSERVATION", 323, 331]]], ["Previous studies have mainly relied on CT and MRI without gadolinium-based contrast agents.", [["gadolinium", "CHEMICAL", 58, 68], ["gadolinium", "CHEMICAL", 58, 68], ["gadolinium-based contrast agents", "SIMPLE_CHEMICAL", 58, 90], ["Previous studies", "TEST", 0, 16], ["CT", "TEST", 39, 41], ["MRI", "TEST", 46, 49], ["gadolinium", "TEST", 58, 68]]], ["Cautiousness regarding the use of contrast agents in critically ill patients is naturally warranted, as is the use of ionizing radiation in children.", [["critically ill", "DISEASE", 53, 67], ["patients", "ORGANISM", 68, 76], ["children", "ORGANISM", 140, 148], ["patients", "SPECIES", 68, 76], ["children", "SPECIES", 140, 148], ["contrast agents", "TREATMENT", 34, 49], ["ionizing radiation", "TREATMENT", 118, 136]]], ["For acute deterioration, a non-enhanced head CT scan is likely the most First row: Axial non-enhanced head CT, reported as normal (A) but brain MRI, including susceptibility-weighted imaging (B) revealed numerous microbleeds with a predilection to the corpus callosum and especially the splenium of corpus callosum.", [["head", "ANATOMY", 40, 44], ["head", "ANATOMY", 102, 106], ["brain", "ANATOMY", 138, 143], ["corpus callosum", "ANATOMY", 252, 267], ["splenium", "ANATOMY", 287, 295], ["corpus callosum", "ANATOMY", 299, 314], ["microbleeds", "DISEASE", 213, 224], ["predilection to the corpus callosum", "DISEASE", 232, 267], ["head", "ORGAN", 40, 44], ["head", "ORGAN", 102, 106], ["brain", "ORGAN", 138, 143], ["corpus callosum", "MULTI-TISSUE_STRUCTURE", 252, 267], ["splenium", "ORGAN", 287, 295], ["corpus callosum", "MULTI-TISSUE_STRUCTURE", 299, 314], ["acute deterioration", "PROBLEM", 4, 23], ["a non-enhanced head CT scan", "TEST", 25, 52], ["Axial non-enhanced head CT", "TEST", 83, 109], ["brain MRI", "TEST", 138, 147], ["susceptibility-weighted imaging", "TEST", 159, 190], ["numerous microbleeds", "PROBLEM", 204, 224], ["a predilection to the corpus callosum", "PROBLEM", 230, 267], ["acute", "OBSERVATION_MODIFIER", 4, 9], ["deterioration", "OBSERVATION", 10, 23], ["normal", "OBSERVATION", 123, 129], ["numerous", "OBSERVATION_MODIFIER", 204, 212], ["microbleeds", "OBSERVATION", 213, 224], ["predilection", "OBSERVATION", 232, 244], ["corpus callosum", "ANATOMY", 252, 267], ["splenium", "ANATOMY_MODIFIER", 287, 295], ["corpus callosum", "ANATOMY", 299, 314]]], ["The aforementioned case exemplifies the importance of susceptibility-weighted imaging in the neuroimaging of COVID-19 patients in means of MRI brain examination.", [["brain", "ANATOMY", 143, 148], ["patients", "ORGANISM", 118, 126], ["brain", "ORGAN", 143, 148], ["patients", "SPECIES", 118, 126], ["weighted imaging", "TEST", 69, 85], ["MRI brain examination", "TEST", 139, 160]]], ["Second row: Axial diffusion-weighted imaging, b1000 (C) and ADC map (D) showing a cortical infarct in the right occipital lobe.", [["cortical", "ANATOMY", 82, 90], ["right occipital lobe", "ANATOMY", 106, 126], ["cortical infarct", "DISEASE", 82, 98], ["cortical infarct", "CANCER", 82, 98], ["occipital lobe", "MULTI-TISSUE_STRUCTURE", 112, 126], ["Axial diffusion-weighted imaging", "TEST", 12, 44], ["ADC map (D)", "TEST", 60, 71], ["a cortical infarct in the right occipital lobe", "PROBLEM", 80, 126], ["cortical", "ANATOMY_MODIFIER", 82, 90], ["infarct", "OBSERVATION", 91, 98], ["right occipital lobe", "ANATOMY", 106, 126]]], ["Third row: Axial T 1 -weighted images pre-and post contrast (E and F) depicting a focal enhancement of the right vestibular nerve.", [["right vestibular nerve", "ANATOMY", 107, 129], ["vestibular nerve", "MULTI-TISSUE_STRUCTURE", 113, 129], ["a focal enhancement of the right vestibular nerve", "PROBLEM", 80, 129], ["focal", "OBSERVATION_MODIFIER", 82, 87], ["enhancement", "OBSERVATION", 88, 99], ["right", "ANATOMY_MODIFIER", 107, 112], ["vestibular nerve", "ANATOMY", 113, 129]]], ["Abbreviations: ADC, apparent diffusion coefficient; COVID-19, coronavirus disease 2019. adequate choice, while more subacute symptomatology or further investigation may necessitate a brain and/or spinal cord MRI.", [["brain", "ANATOMY", 183, 188], ["spinal cord", "ANATOMY", 196, 207], ["coronavirus disease", "DISEASE", 62, 81], ["brain", "ORGAN", 183, 188], ["spinal cord", "MULTI-TISSUE_STRUCTURE", 196, 207], ["COVID", "TEST", 52, 57], ["coronavirus disease", "PROBLEM", 62, 81], ["more subacute symptomatology", "PROBLEM", 111, 139], ["further investigation", "TEST", 143, 164], ["a brain and/or spinal cord MRI", "TEST", 181, 211], ["coronavirus disease", "OBSERVATION", 62, 81], ["spinal cord", "ANATOMY", 196, 207]]], ["Based on the findings in this review and our emerging experience with SARS-CoV-2, we recommend the MRI protocols suggested in Table 2 to identify HCoV infection-related neuroradiological manifestations.", [["infection", "DISEASE", 151, 160], ["HCoV", "CANCER", 146, 150], ["SARS-CoV", "SPECIES", 70, 78], ["HCoV", "SPECIES", 146, 150], ["the MRI protocols", "TEST", 95, 112], ["HCoV infection", "PROBLEM", 146, 160], ["neuroradiological manifestations", "PROBLEM", 169, 201], ["infection", "OBSERVATION", 151, 160]]], ["Examples of neuroimaging findings in SARS-CoV-2 from our clinical practice using the recommended protocols can be found in Figures 2 and 3 .LimitationsDue to potential delay in publishing relevant findings, a significant proportion of evidence on SARS-CoV-2 may yet to be published.", [["SARS", "DISEASE", 37, 41], ["SARS", "DISEASE", 247, 251], ["SARS-CoV-2", "ORGANISM", 37, 47], ["neuroimaging findings", "TEST", 12, 33], ["SARS", "PROBLEM", 37, 41], ["the recommended protocols", "TREATMENT", 81, 106], ["potential delay", "PROBLEM", 158, 173], ["SARS", "PROBLEM", 247, 251]]], ["Nevertheless, the available evidence suggests striking similarities of neurological manifestations between SARS-CoV-1 and SARS-CoV-2 patients.ConclusionsOur systematic review provides high level evidence that HCoVs, particularly SARS-CoV-1 and SARS-CoV-2, have a common ground on neurological symptomatology and complications.", [["neurological", "ANATOMY", 71, 83], ["neurological", "ANATOMY", 280, 292], ["SARS", "DISEASE", 107, 111], ["SARS", "DISEASE", 122, 126], ["SARS", "DISEASE", 229, 233], ["neurological symptomatology", "DISEASE", 280, 307], ["SARS-CoV-1", "ORGANISM", 107, 117], ["SARS-CoV-2", "ORGANISM", 122, 132], ["patients", "ORGANISM", 133, 141], ["HCoVs", "CANCER", 209, 214], ["SARS-CoV-1", "ORGANISM", 229, 239], ["SARS-CoV-2", "ORGANISM", 244, 254], ["patients", "SPECIES", 133, 141], ["SARS-CoV-1", "SPECIES", 107, 117], ["SARS-CoV", "SPECIES", 122, 130], ["SARS-CoV-1", "SPECIES", 229, 239], ["SARS-CoV", "SPECIES", 244, 252], ["neurological manifestations", "PROBLEM", 71, 98], ["SARS", "TEST", 107, 111], ["CoV", "TEST", 112, 115], ["Our systematic review", "TEST", 153, 174], ["HCoVs", "PROBLEM", 209, 214], ["SARS", "TEST", 229, 233], ["CoV", "TEST", 234, 237], ["SARS", "TEST", 244, 248], ["CoV", "TEST", 249, 252], ["neurological symptomatology", "PROBLEM", 280, 307], ["complications", "PROBLEM", 312, 325]]], ["Particularly, clinicians treating these patients should be vigilant for at least five classes of neurological complications: (1) Cerebrovascular disorders including ischemic stroke and macro/micro-hemorrhages, (2) encephalopathies, likely caused by combinatorial effects of sepsis, hypoxia, and immune hyperstimulation, (3) para-/postinfectious immune-mediated complications such as GBS and ADEM, (4) (meningo-)encephalitis, potentially with concomitant seizures, and (5) neuropsychiatric complications such as mood disorders or psychosis.", [["neurological", "ANATOMY", 97, 109], ["Cerebrovascular", "ANATOMY", 129, 144], ["neurological complications", "DISEASE", 97, 123], ["Cerebrovascular disorders", "DISEASE", 129, 154], ["ischemic stroke", "DISEASE", 165, 180], ["hemorrhages", "DISEASE", 197, 208], ["encephalopathies", "DISEASE", 214, 230], ["sepsis", "DISEASE", 274, 280], ["hypoxia", "DISEASE", 282, 289], ["immune hyperstimulation", "DISEASE", 295, 318], ["GBS", "DISEASE", 383, 386], ["ADEM", "DISEASE", 391, 395], ["meningo-)encephalitis", "DISEASE", 402, 423], ["seizures", "DISEASE", 454, 462], ["neuropsychiatric complications", "DISEASE", 472, 502], ["mood disorders", "DISEASE", 511, 525], ["psychosis", "DISEASE", 529, 538], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["neurological complications", "PROBLEM", 97, 123], ["Cerebrovascular disorders", "PROBLEM", 129, 154], ["ischemic stroke", "PROBLEM", 165, 180], ["macro/micro-hemorrhages", "PROBLEM", 185, 208], ["encephalopathies", "PROBLEM", 214, 230], ["sepsis", "PROBLEM", 274, 280], ["hypoxia", "PROBLEM", 282, 289], ["immune hyperstimulation", "PROBLEM", 295, 318], ["para", "TEST", 324, 328], ["postinfectious immune", "PROBLEM", 330, 351], ["mediated complications", "PROBLEM", 352, 374], ["GBS", "PROBLEM", 383, 386], ["ADEM", "PROBLEM", 391, 395], ["meningo-)encephalitis", "PROBLEM", 402, 423], ["concomitant seizures", "PROBLEM", 442, 462], ["neuropsychiatric complications", "PROBLEM", 472, 502], ["mood disorders", "PROBLEM", 511, 525], ["psychosis", "PROBLEM", 529, 538], ["Cerebrovascular", "ANATOMY", 129, 144], ["ischemic", "OBSERVATION_MODIFIER", 165, 173], ["stroke", "OBSERVATION", 174, 180], ["hemorrhages", "OBSERVATION", 197, 208], ["likely caused", "UNCERTAINTY", 232, 245], ["sepsis", "OBSERVATION", 274, 280], ["hypoxia", "OBSERVATION", 282, 289], ["immune hyperstimulation", "OBSERVATION", 295, 318], ["postinfectious", "OBSERVATION_MODIFIER", 330, 344], ["ADEM", "OBSERVATION", 391, 395], ["encephalitis", "OBSERVATION", 411, 423], ["seizures", "OBSERVATION", 454, 462]]], ["Thus, the clinical neuroimaging protocol, as herein recommended, should include appropriate MRI sequences for early diagnosis and monitoring of patients.", [["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["the clinical neuroimaging protocol", "TEST", 6, 40], ["appropriate MRI sequences", "TEST", 80, 105], ["early diagnosis", "TEST", 110, 125], ["monitoring", "TEST", 130, 140]]], ["Our results also underscore the need to further research and optimize treatment regarding modulation of the coagulation and immune systems in order to reduce the risk of neurological complications.Author ContributionJesper Almqvist contributed to designed and conceptualized the study, data acquisition, analysis and interpretation, and drafting and revision of the manuscript.", [["neurological", "ANATOMY", 170, 182], ["neurological complications", "DISEASE", 170, 196], ["treatment", "TREATMENT", 70, 79], ["the coagulation", "TEST", 104, 119], ["immune systems", "TREATMENT", 124, 138], ["neurological complications", "PROBLEM", 170, 196], ["the study", "TEST", 275, 284], ["data acquisition", "TEST", 286, 302], ["analysis", "TEST", 304, 312], ["interpretation", "TEST", 317, 331]]], ["Tobias Granberg contributed to designed and conceptualized the study, data acquisition, analysis and interpretation, and drafting and revision of the manuscript.", [["the study", "TEST", 59, 68], ["data acquisition", "TEST", 70, 86], ["analysis", "TEST", 88, 96], ["interpretation", "TEST", 101, 115]]], ["Antonios Tzortzakakis contributed to data interpretation and revision of the manuscript for intellectual content.", [["Antonios Tzortzakakis", "TREATMENT", 0, 21], ["data interpretation", "TEST", 37, 56], ["revision", "TREATMENT", 61, 69], ["intellectual content", "PROBLEM", 92, 112]]], ["Stefanos Klironomos contributed to data interpretation and revision of the manuscript for intellectual content.", [["data interpretation", "TEST", 35, 54], ["revision", "TREATMENT", 59, 67], ["intellectual content", "PROBLEM", 90, 110]]], ["Evangelia Kollia contributed to data interpretation and revision of the manuscript for intellectual content.", [["Evangelia Kollia", "PROBLEM", 0, 16], ["data interpretation", "TEST", 32, 51], ["revision", "TREATMENT", 56, 64], ["intellectual content", "PROBLEM", 87, 107]]], ["Claes \u20ac Ohberg contributed to data interpretation and revision of the manuscript for intellectual content.", [["data interpretation", "TEST", 30, 49], ["revision", "TREATMENT", 54, 62], ["intellectual content", "PROBLEM", 85, 105]]], ["Roland Martin contributed to data interpretation and revision of the manuscript for intellectual content.", [["data interpretation", "TEST", 29, 48], ["revision", "TREATMENT", 53, 61], ["intellectual content", "PROBLEM", 84, 104]]], ["Fredrik Piehl contributed to data interpretation and revision of the manuscript for intellectual content.", [["data interpretation", "TEST", 29, 48], ["revision", "TREATMENT", 53, 61], ["intellectual content", "PROBLEM", 84, 104]]], ["Russell Ouellette contributed to data interpretation and revision of the manuscript for intellectual content.", [["data interpretation", "TEST", 33, 52], ["revision", "TREATMENT", 57, 65], ["intellectual content", "PROBLEM", 88, 108]]], ["Benjamin V. Ineichen contributed to designed and conceptualized the study, data acquisition, analysis and interpretation, and drafting of the manuscript.Conflicts of InterestThis study was supported by the Center for Innovative Medicine (CIMED) and Region Stockholm.", [["the study", "TEST", 64, 73], ["data acquisition", "TEST", 75, 91], ["analysis", "TEST", 93, 101], ["interpretation", "TEST", 106, 120], ["InterestThis study", "TEST", 166, 184], ["Innovative Medicine", "TREATMENT", 217, 236]]], ["Table S2 .", [["S2", "ANATOMY", 6, 8]]], ["Pre-defined criteria Newcastle-Ottawa scale for risk of bias.", [["bias", "PROBLEM", 56, 60]]], ["Risk of bias assessment.", [["bias assessment", "TEST", 8, 23], ["bias", "OBSERVATION", 8, 12]]], ["Summary of studies assessing neurological manifestations and complication in the more clinically mild HCoVs: HCoV-229E, HKU1, NL63 and/or OC43 infections.", [["neurological", "ANATOMY", 29, 41], ["infections", "DISEASE", 143, 153], ["HCoVs", "CANCER", 102, 107], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 109, 118], ["HKU1", "GENE_OR_GENE_PRODUCT", 120, 124], ["NL63", "GENE_OR_GENE_PRODUCT", 126, 130], ["OC43", "GENE_OR_GENE_PRODUCT", 138, 142], ["HCoV-229E", "SPECIES", 109, 118], ["neurological manifestations", "PROBLEM", 29, 56], ["complication", "PROBLEM", 61, 73], ["HCoV", "TEST", 109, 113], ["HKU1", "TEST", 120, 124], ["NL63", "TEST", 126, 130], ["OC43 infections", "PROBLEM", 138, 153], ["OC43", "ANATOMY", 138, 142], ["infections", "OBSERVATION", 143, 153]]], ["Summary of studies assessing neurological manifestations and complication in MERS-CoV infections.", [["neurological", "ANATOMY", 29, 41], ["MERS-CoV infections", "DISEASE", 77, 96], ["MERS-CoV", "ORGANISM", 77, 85], ["MERS-CoV", "SPECIES", 77, 85], ["studies", "TEST", 11, 18], ["neurological manifestations", "PROBLEM", 29, 56], ["complication", "PROBLEM", 61, 73], ["CoV infections", "PROBLEM", 82, 96], ["infections", "OBSERVATION", 86, 96]]], ["Table S6 .", [["S6", "PROTEIN", 6, 8]]], ["Summary of studies assessing neurological manifestations and complication in SARS-CoV-1 infections.", [["neurological", "ANATOMY", 29, 41], ["SARS-CoV-1 infections", "DISEASE", 77, 98], ["SARS-CoV-1", "ORGANISM", 77, 87], ["SARS-CoV-1", "SPECIES", 77, 87], ["studies", "TEST", 11, 18], ["neurological manifestations", "PROBLEM", 29, 56], ["complication", "PROBLEM", 61, 73], ["SARS", "PROBLEM", 77, 81], ["CoV", "PROBLEM", 82, 85], ["1 infections", "PROBLEM", 86, 98], ["infections", "OBSERVATION", 88, 98]]], ["Summary of studies assessing neurological manifestations and complication in SARS-CoV-2 infections.", [["neurological", "ANATOMY", 29, 41], ["SARS-CoV-2 infections", "DISEASE", 77, 98], ["SARS-CoV-2", "ORGANISM", 77, 87], ["SARS-CoV", "SPECIES", 77, 85], ["studies", "TEST", 11, 18], ["neurological manifestations", "PROBLEM", 29, 56], ["complication", "PROBLEM", 61, 73], ["SARS", "PROBLEM", 77, 81], ["CoV", "PROBLEM", 82, 85], ["2 infections", "PROBLEM", 86, 98], ["infections", "OBSERVATION", 88, 98]]], ["Association of coronaviruses with multiple sclerosis.", [["multiple sclerosis", "DISEASE", 34, 52], ["coronaviruses", "ORGANISM", 15, 28], ["coronaviruses", "PROBLEM", 15, 28], ["multiple sclerosis", "PROBLEM", 34, 52], ["coronaviruses", "OBSERVATION", 15, 28], ["multiple", "OBSERVATION_MODIFIER", 34, 42], ["sclerosis", "OBSERVATION", 43, 52]]]], "PMC7419259": [["IntroductionWith the progress of science and technology and the advent of web2.0 era, social software such as Facebook and WeChat have replaced the mode of word of mouth, and which become one of the main tools for interpersonal communication.", [["mouth", "ANATOMY", 164, 169], ["mouth", "ORGANISM_SUBDIVISION", 164, 169], ["mouth", "ANATOMY", 164, 169]]], ["What\u2019s more, some malicious criminals spread rumors on the Internet at will, disturbing public order [1], causing serious bullying [2] and social panic [3].IntroductionTo avoid the harm of rumors, predicting the dynamic behavior of rumors in the virtual digital world has become a hot topic for scholars from all works of life.", [["bullying", "DISEASE", 122, 130], ["panic", "DISEASE", 146, 151], ["rumors", "PROBLEM", 189, 195]]], ["The earliest history of rumor spreading can be traced back to the 1960s.", [["rumor spreading", "PROBLEM", 24, 39]]], ["Delay and Kendall [4] first realized that the social interaction between people was actually based on the Internet, and established a DK network rumor spreading model, which divided people into three categories: ignorant (the people who haven\u2019t heard of rumors), spreaders (the people who have heard and spread rumors) and stiflers (the people who have heard of rumors but don\u2019t spread them).", [["people", "ORGANISM", 73, 79], ["people", "ORGANISM", 182, 188], ["people", "ORGANISM", 226, 232], ["people", "ORGANISM", 278, 284], ["people", "ORGANISM", 337, 343], ["people", "SPECIES", 73, 79], ["people", "SPECIES", 182, 188], ["people", "SPECIES", 226, 232], ["people", "SPECIES", 278, 284], ["people", "SPECIES", 337, 343]]], ["Maki and Thompson [5] improved the defect of DK model in 1973, and extended the reconstructed MK model to the most classical rumor spreading model.", [["the defect of DK model", "PROBLEM", 31, 53], ["defect", "OBSERVATION", 35, 41], ["DK model", "OBSERVATION_MODIFIER", 45, 53]]], ["Since then, most researchers have expanded the spread of rumors on complex networks in different fields.", [["spread", "OBSERVATION_MODIFIER", 47, 53]]], ["In addition, some people are committed to study of non-linear spreading rate of rumors based on individual differences [9], [10], while others were engaged in rumor control to overcome the harm of rumors [11], [12], [13].IntroductionIn view of the individual particularity [14] of rumor spreading group, Huo and Liu et al. [15], [16], [17] believed that the individual activity greatly affects their behavior choices.", [["people", "ORGANISM", 18, 24], ["[12]", "SIMPLE_CHEMICAL", 210, 214], ["[13]", "SIMPLE_CHEMICAL", 216, 220], ["people", "SPECIES", 18, 24], ["non-linear spreading rate of rumors", "PROBLEM", 51, 86], ["rumor spreading group", "PROBLEM", 281, 302], ["Huo", "TEST", 304, 307]]], ["Thus, the activity played a crucial role in the enthusiasm of rumor spreading.", [["rumor spreading", "PROBLEM", 62, 77]]], ["To this end, they have introduced the concept of individual activity into the rumor model and made outstanding contributions in this field.IntroductionHowever, most of the existing literature is limited to the exploration of individual emotion, thinking mode, education level and other internal characteristics.", [["the exploration", "TEST", 206, 221], ["education level", "TEST", 260, 275]]], ["In view of this, Rupp [18] proposed the idea diffusion model containing random effects, and extended the ordinary differential equation model to the stochastic differential equation model.", [["random effects", "OBSERVATION", 72, 86]]], ["Yao et al. [19] proposed a dynamic I2SR model based on rumor spreading with random noise interference and founded that there is a negative correlation between the spreading range of rumors and noise intensity.", [["a dynamic I2SR model", "TEST", 25, 45], ["rumor spreading", "PROBLEM", 55, 70], ["random noise interference", "PROBLEM", 76, 101], ["noise intensity", "PROBLEM", 193, 208]]], ["Coletti et al. [20] explored the sufficient conditions for rumor extinction or survival with a positive probability in an interacting particle system.", [["rumor extinction", "PROBLEM", 59, 75], ["a positive probability", "PROBLEM", 93, 115]]], ["Wang et al. [22] deeply explored the mode of gossip diffusion in social networks when uncertainty exists during users\u2019 decision-making.", [["social networks", "MULTI-TISSUE_STRUCTURE", 65, 80]]], ["Zhu et al. [23] proposed a rumor spreading model which considered the change of connectivity as noise interference.", [["a rumor spreading model", "TREATMENT", 25, 48]]], ["It was found that the peak value of infected individuals was positively correlated with noise intensity, while the rumor life cycle was negatively correlated with noise intensity as a whole.", [["the peak value", "TEST", 18, 32], ["infected individuals", "PROBLEM", 36, 56], ["noise intensity", "PROBLEM", 88, 103], ["infected", "OBSERVATION", 36, 44]]], ["Jia et al. [24], [25], [26] compared and analyzed the threshold difference between deterministic model and stochastic model with white noise fluctuation, and concluded that the basic reproduction number \u211c0 of stochastic model was less than that of deterministic system.", [["white noise fluctuation", "PROBLEM", 129, 152]]], ["Jain et al. [27] introduced the concept of expert interaction into the rumor spreading model to further subdivide the categories of people.", [["people", "ORGANISM", 132, 138], ["people", "SPECIES", 132, 138]]], ["At the same time, Gauss white noise was included in the model as a random factor, and it was explored that noise may be a reason for the persistence of rumors.IntroductionIndividual activity is not only affected by the environment, but also depends on their own interests and personality characteristics to a large extent, so their attitudes towards the same event are quite different.", [["Gauss white noise", "PROBLEM", 18, 35], ["rumors", "PROBLEM", 152, 158], ["large extent", "OBSERVATION_MODIFIER", 309, 321]]], ["Some people are born lively and willing to spread information actively.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11]]], ["Whether it\u2019s rumor or truth, they are all actively spreading.", [["all", "OBSERVATION_MODIFIER", 38, 41], ["actively", "OBSERVATION_MODIFIER", 42, 50], ["spreading", "OBSERVATION_MODIFIER", 51, 60]]], ["On the contrary, other people are naturally indifferent to their surroundings.", [["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29]]], ["From this point of view, people can be divided into two categories: active state and inactive state.", [["people", "ORGANISM", 25, 31], ["people", "SPECIES", 25, 31], ["active", "OBSERVATION", 68, 74]]], ["Thus, we introduce a concept of activity as a criterion to distinguish whether it is active or not.IntroductionWith the advent of the network era, the network content is increasingly rich, the development of self-media has accelerated the information update iteration, the network environment becomes more complex and changeable, microblog hot search or instant information may change people\u2019s views on events at any time, the randomness of the network environment shows increasingly important influence.", [["network", "MULTI-TISSUE_STRUCTURE", 151, 158], ["people", "ORGANISM", 385, 391], ["people", "SPECIES", 385, 391], ["active", "OBSERVATION", 85, 91], ["increasingly", "OBSERVATION_MODIFIER", 170, 182], ["rich", "OBSERVATION_MODIFIER", 183, 187]]], ["With the passage of time, the heat of the event may change dramatically, so does the perception of rumors.", [["rumors", "PROBLEM", 99, 105]]], ["Therefore, the individuals\u2019 activities have great volatility and randomness.", [["volatility", "OBSERVATION_MODIFIER", 50, 60]]], ["In view of this, it is of great practical significance to consider the noise interference of activity in rumor model.", [["the noise interference of activity in rumor model", "PROBLEM", 67, 116]]], ["In Section 4, we discussed the stochastic version of the previous model and deduced the Stratonovich and It\u00f4 transformation equations for the model.", [["the Stratonovich", "TREATMENT", 84, 100]]], ["The existence and uniqueness of positive solutions for stochastic systems were given in Section 5.", [["positive solutions", "TREATMENT", 32, 50], ["stochastic systems", "TREATMENT", 55, 73]]], ["Next, we deduced the global stability condition for the rumor-free equilibrium of stochastic system.", [["the global stability condition", "PROBLEM", 17, 47], ["the rumor", "TEST", 52, 61], ["global stability", "OBSERVATION", 21, 37], ["stochastic system", "OBSERVATION", 82, 99]]], ["Then, some numerical simulations were carried out to prove the analysis results of the two models.", [["some numerical simulations", "TEST", 6, 32], ["the analysis", "TEST", 59, 71]]], ["[15] to consider the impact of active variables on rumor spreading in homogeneous networks In the ISR model, a node can be in active state with a certain probability a and in inactive rate with probability 1\u2212a.", [["node", "ANATOMY", 111, 115], ["networks", "MULTI-TISSUE_STRUCTURE", 82, 90], ["node", "MULTI-TISSUE_STRUCTURE", 111, 115], ["active variables", "PROBLEM", 31, 47], ["a node", "PROBLEM", 109, 115], ["active", "OBSERVATION", 31, 37], ["node", "OBSERVATION", 111, 115], ["active", "OBSERVATION_MODIFIER", 126, 132]]], ["In terms of whether to understand rumors, the total population can be divided into ignorant (people who don\u2019t know rumors), spreaders (people who know and spread rumors), and stiflers (people who know but have no interest in spreading rumors), which are represented by I, S, R, respectively.", [["people", "ORGANISM", 93, 99], ["people", "ORGANISM", 135, 141], ["people", "ORGANISM", 185, 191], ["people", "SPECIES", 93, 99], ["people", "SPECIES", 135, 141], ["people", "SPECIES", 185, 191]]], ["So each node may have six different states at time t and their density is as follows: active ignorant Ia(t), inactive ignorant Id(t), active spreaders Sa(t), inactive spreader Sd(t), active stiflers Ra(t), inactive stiflers Rd(t), in which, the superscript a denotes active state and the superscript d represents inactive state.", [["node", "ANATOMY", 8, 12], ["node", "MULTI-TISSUE_STRUCTURE", 8, 12], ["Ia(t)", "PROTEIN", 102, 107], ["Id(t)", "PROTEIN", 127, 132], ["node", "OBSERVATION", 8, 12]]], ["N(t) denotes the total number of nodes at time t.", [["nodes", "ANATOMY", 33, 38], ["total", "OBSERVATION_MODIFIER", 17, 22], ["number", "OBSERVATION_MODIFIER", 23, 29], ["nodes", "OBSERVATION", 33, 38]]], ["These fractions of different groups satisfy the following condition: Ia(t)+Id(t)+Sa(t)+Sd+Ra(t)+Rd(t)=N(t)", [["Sd", "CHEMICAL", 87, 89], ["Ra(t)+Rd(t)=N(t)", "CHEMICAL", 90, 106], ["Rd(t)=N(t)", "SIMPLE_CHEMICAL", 96, 106], ["Sa", "TEST", 81, 83], ["Ra", "ANATOMY", 90, 92]]]], "PMC7351681": [["IntroductionMulticriteria optimization is a process of simultaneous optimization for two or more conflicting functions within one point [1].", [["IntroductionMulticriteria optimization", "TREATMENT", 0, 38], ["simultaneous optimization", "TREATMENT", 55, 80]]], ["The need to simultaneously optimize different key performance indicators (KPI) exists in both business and industrial production, such as oil refinement facilities.IntroductionOil refinement is an advantageous direction for multicriteria optimization because of its complexity.", [["IntroductionOil refinement", "TREATMENT", 164, 190], ["multicriteria optimization", "TREATMENT", 224, 250]]], ["Optimisation process is preceded by decomposition [2] of the refinement sequence, which is followed by model identification [3].", [["the refinement sequence", "TEST", 57, 80]]], ["Pareto optimality principle [4] is used in conjunction with aforementioned models to build a front of optimal values.IntroductionPart of the refinement process takes place inside a refraction unit (RU).", [["the refinement process", "TREATMENT", 137, 159]]], ["The model got the following KPIs assigned [5]: Quality (matching degree between output and established norms), Performance (output product volume), Efficiency (resource usage potency), Reliability (equipment failures per unit of time), Safety (emergencies per unit of time).IntroductionRectification consists of a wide array of parameters, up to several hundreds of characteristics per one refraction unit.", [["output", "TEST", 80, 86], ["Performance (output product volume)", "TREATMENT", 111, 146], ["a wide array of parameters", "TREATMENT", 312, 338]]], ["These include the splitting section, column head and column plates temperature and pressure.", [["head", "ANATOMY", 44, 48], ["head", "ORGANISM_SUBDIVISION", 44, 48], ["the splitting section", "TEST", 14, 35], ["column head and column plates temperature", "TEST", 37, 78], ["pressure", "TEST", 83, 91], ["column", "ANATOMY", 53, 59], ["pressure", "OBSERVATION_MODIFIER", 83, 91]]], ["Inside and outside of the rectification column both sequential (multi-layered raw oil refinement, raw oil heating, raw oil pumping, etc.) and parallel (vapor condensation) processes take place.", [["oil", "ANATOMY", 102, 105], ["the rectification column", "TREATMENT", 22, 46], ["multi-layered raw oil refinement", "TREATMENT", 64, 96], ["parallel (vapor condensation)", "TREATMENT", 142, 171]]], ["Rectification technology also includes transition products into the process, thus applying an additional, horizontal level of hierarchy between the operations.", [["transition products", "TREATMENT", 39, 58], ["the operations", "TREATMENT", 144, 158]]], ["It is also essential to account for the time delay, added by the inertia of the system itself and enforced by the continuous operating mode.IntroductionConsequently, processes from the highest levels of the hierarchy have unobvious connections with the lower-level processes thus making it impossible to use simple functions like y = f (g, u) to represent dependencies between them.", [["the lower-level processes", "TREATMENT", 249, 274], ["dependencies", "OBSERVATION", 356, 368]]], ["Yet it is essential to influence top-level processes by changing parameters of the low-level processes and vice-versa.IntroductionIn this work the aforementioned problem is resolved by decomposing a complex system (such as refraction unit) down to individual units and processes.", [["the low-level processes", "TREATMENT", 79, 102]]], ["The KPI set takes the top level of the hierarchy.", [["KPI", "DNA", 4, 7], ["KPI", "OBSERVATION", 4, 7], ["top", "OBSERVATION_MODIFIER", 22, 25], ["hierarchy", "ANATOMY_MODIFIER", 39, 48]]], ["Every KPI is divided into several summands of a lower hierarchy levels.", [["KPI", "DNA", 6, 9], ["lower", "ANATOMY_MODIFIER", 48, 53], ["hierarchy levels", "OBSERVATION", 54, 70]]], ["Dependencies are identified using a neural network trained on the RU statistical data archive.", [["neural network", "ANATOMY", 36, 50], ["neural network", "MULTI-TISSUE_STRUCTURE", 36, 50]]], ["Ascending by the hierarchical tree allows to determinate a clean dependency between a KPI and an input parameter from the bottom of the hierarchy.IntroductionHowever, the top-level key performance indicators may directly contradict each other.", [["KPI", "PROTEIN", 86, 89], ["a clean dependency", "PROBLEM", 57, 75], ["a KPI", "TREATMENT", 84, 89], ["an input parameter", "TEST", 94, 112], ["hierarchical tree", "OBSERVATION", 17, 34], ["clean", "OBSERVATION", 59, 64], ["bottom", "ANATOMY_MODIFIER", 122, 128], ["hierarchy", "ANATOMY_MODIFIER", 136, 145]]], ["For instance, raising Performance by forcing aggressive operating parameters will inevitably cause the growth in equipment failures and an overall reduction of Reliability.", [["aggressive operating parameters", "TREATMENT", 45, 76], ["the growth in equipment failures", "PROBLEM", 99, 131], ["growth", "OBSERVATION_MODIFIER", 103, 109], ["reduction", "OBSERVATION_MODIFIER", 147, 156]]], ["Which in turn damages Efficiency of the refraction unit or a refinery as a whole.", [["turn", "OBSERVATION_MODIFIER", 9, 13], ["damages", "OBSERVATION_MODIFIER", 14, 21], ["Efficiency", "OBSERVATION_MODIFIER", 22, 32]]], ["The \u201cGood \u2013 Fast \u2013 Cheap\u201d triangle encourages us to use a multicriteria optimization algorithm to balance out conflicting key performance indicators.IntroductionThe aim of this work is to perform a multicriteria optimization to find a Pareto optimal solution.", [["a multicriteria optimization algorithm", "TREATMENT", 56, 94], ["a multicriteria optimization", "TREATMENT", 196, 224], ["a Pareto optimal solution", "TREATMENT", 233, 258]]], ["It was used to build the graphical representations of dependencies between performance and temperature, characterising the lowest hierarchy level.", [["temperature", "TEST", 91, 102]]], ["To grant it, a dependence model identification has been performed [6].Data IdentificationThe refraction unit consists of an oil pre-heater with a heat-exchange unit, a fractionating column, a refrigerator and a boiler.", [["oil", "ANATOMY", 124, 127], ["oil", "ORGANISM_SUBSTANCE", 124, 127], ["a dependence model identification", "TEST", 13, 46], ["Data Identification", "TEST", 70, 89], ["a heat-exchange unit", "TREATMENT", 144, 164], ["a fractionating column", "TREATMENT", 166, 188], ["a refrigerator", "TREATMENT", 190, 204], ["a boiler", "TREATMENT", 209, 217]]], ["The pre-heated oil is injected into the column feeding zone to be divided into vapour and solid phases.", [["oil", "ANATOMY", 15, 18], ["oil", "ORGANISM_SUBSTANCE", 15, 18], ["The pre-heated oil", "TREATMENT", 0, 18], ["the column feeding zone", "TREATMENT", 36, 59], ["column", "ANATOMY", 40, 46], ["solid phases", "OBSERVATION", 90, 102]]], ["During the rectification process isopentane is extracted from the top part of the column as a fractionator overhead.", [["isopentane", "CHEMICAL", 33, 43], ["isopentane", "SIMPLE_CHEMICAL", 33, 43], ["top", "OBSERVATION_MODIFIER", 66, 69], ["column", "ANATOMY", 82, 88], ["fractionator overhead", "OBSERVATION", 94, 115]]], ["Heavier fractions are taken from the plates in the middle of the rectification column.", [["Heavier fractions", "PROBLEM", 0, 17], ["plates", "OBSERVATION_MODIFIER", 37, 43], ["middle", "ANATOMY_MODIFIER", 51, 57], ["rectification column", "OBSERVATION", 65, 85]]], ["The heaviest part, the long residuum, gets extracted from the bottom part of the column [7].", [["the long residuum", "PROBLEM", 19, 36], ["long residuum", "OBSERVATION_MODIFIER", 23, 36], ["bottom", "ANATOMY_MODIFIER", 62, 68]]], ["A simplified scheme, showing distillation inputs and outputs targeted by this work, is present on Fig. 1.Data IdentificationThe stripper temperature (U4 in Table 1) has been chosen for optimization.", [["A simplified scheme", "PROBLEM", 0, 19], ["Data Identification", "TEST", 105, 124], ["The stripper temperature", "TEST", 124, 148]]], ["Temperature variation was aimed at maximizing fractions 240\u2013300 and 300\u2013350 output volumes (G2 and G3 in Table 1).Data IdentificationTo identify dependencies between the stripper temperature and fraction outputs (see Fig. 1), a neural network (NN) was utilized.", [["neural network", "ANATOMY", 228, 242], ["neural network", "MULTI-TISSUE_STRUCTURE", 228, 242], ["Temperature variation", "TEST", 0, 21], ["output volumes", "TEST", 76, 90], ["fraction outputs", "TEST", 195, 211], ["a neural network (NN)", "TREATMENT", 226, 247]]], ["It was trained on statistical data obtained during 24 h of the prototype column work.Data IdentificationThe neural network consists of 1 input, 1 hidden and 1 output layers.", [["neural network", "ANATOMY", 108, 122], ["neural network", "MULTI-TISSUE_STRUCTURE", 108, 122], ["layers", "TISSUE", 166, 172], ["statistical data", "TEST", 18, 34], ["Data Identification", "TEST", 85, 104]]], ["Input and output layers both contain one neuron, while the hidden layer contains 10.", [["neuron", "ANATOMY", 41, 47], ["Input and output layers", "TEST", 0, 23], ["output", "OBSERVATION_MODIFIER", 10, 16], ["layers", "OBSERVATION_MODIFIER", 17, 23]]], ["The NN was trained by the backward propagation of errors method.", [["errors method", "TREATMENT", 50, 63]]], ["Hidden and output layers use a sigmoid activation function (1):1", [["Hidden and output layers", "PROBLEM", 0, 24], ["output layers", "OBSERVATION", 11, 24], ["sigmoid", "ANATOMY", 31, 38]]]], "PMC7468350": [["IntroductionFor biobanks good governance is key to ensure the protection of the ethically relevant interests of research participants, and at the same time to promote the efficient use of their resources by the scientific community.", [["participants", "SPECIES", 121, 133]]], ["Good governance structures and processes also increase a biobank\u2019s legitimacy and social license to operate, that is, their likelihood that broader publics see their work as socially acceptable and desirable, and aligned with existing norms and societal expectations [1, 2].", [["governance", "OBSERVATION", 5, 15], ["increase", "OBSERVATION_MODIFIER", 46, 54]]], ["Such features are also necessary conditions for trustworthiness [5, 6].", [["trustworthiness", "PROBLEM", 48, 63]]], ["In public management studies, transparency is almost ubiquitously regarded as a positive feature in and of itself.", [["public management studies", "TEST", 3, 28]]], ["Accountability refers to mechanisms through which an organization makes itself answerable for its operations, that is, capable of giving account to stakeholders for the actions it has undertaken [8, 9].", [["its operations", "TREATMENT", 94, 108]]], ["Finally, oversight refers to the procedures and structures that an organization puts in place to monitor its own operations in the interest of affected parties [11, 12].", [["the procedures", "TREATMENT", 29, 43]]], ["Oversight is particularly relevant in biobanking these days, since biobanks handle increasing amounts of research participants\u2019 personal data and biological materials [13].IntroductionExpanding research paradigms like precision medicine and digital health rely on unprecedently large collections of biological samples, genetic and clinical data, as well as data collected through mobile or wearable devices, often by research participants themselves and outside of the research or clinical context [14].", [["samples", "ANATOMY", 310, 317], ["participants", "SPECIES", 114, 126], ["participants", "SPECIES", 426, 438], ["precision medicine", "TREATMENT", 218, 236], ["biological samples", "TEST", 299, 317], ["clinical data", "TEST", 331, 344], ["wearable devices", "TREATMENT", 390, 406]]], ["Moreover, as artificial intelligence emerges as a transformative technology in the quest for extracting medical value from big data, new and still partially unknown regulatory challenges loom large on the horizon [16, 17].", [["big data", "TEST", 123, 131], ["large", "OBSERVATION_MODIFIER", 192, 197]]], ["Biobanks are thus bound to be a key node not only of a rapidly increasing health data ecosystem, but also of an ever-more complex governance network [18].", [["node", "OBSERVATION", 36, 40]]], ["As demonstrated by the failure of initiatives like the NHS England care.data program, securing social license to operate in the domain of large-scale data-driven research is not going to be trivial [19].IntroductionIn response to the increasing and diversifying data volumes in biomedical research, the governance of research biobanks has been attracting considerable academic interest for the last 15 years, especially in areas such as informed consent, privacy, and data management [20].", [["research biobanks", "TREATMENT", 317, 334], ["increasing", "OBSERVATION_MODIFIER", 234, 244]]], ["In particular, biobanks have been studied as a prominent example of post-regulatory governance involving a complex, decentralized network of actors and mechanisms [21] to ensure their alignment with participants\u2019 rights as well as with societal values and expectations [22].IntroductionThe present study contributes to this debate through a comprehensive, empirically-informed analysis of governance mechanisms adopted by biobanks, and discussing how such mechanisms contribute to transparency, accountability, and oversight.", [["participants", "SPECIES", 199, 211], ["The present study", "TEST", 286, 303], ["governance mechanisms", "TREATMENT", 389, 410]]], ["Our analysis shows that most biobanks attempt to be transparent about their governance mechanisms.", [["Our analysis", "TEST", 0, 12]]], ["In particular, we documented considerable efforts on the part of biobanks to earn legitimacy (or social licence).", [["considerable", "OBSERVATION_MODIFIER", 29, 41]]], ["However, more fine-grained information should be provided to inform stakeholders about how governance mechanisms support accountability, as well as about oversight mechanisms adopted to mitigate the risks associated with biobanks\u2019 operations.Ethics ::: MethodsAll data obtained are in the public domain and we do not anticipate any physical, psychological, social or legal risks.Communication ::: ResultsBiobanks employ a variety of strategies to communicate about their structure and activities.", [["biobanks\u2019 operations", "TREATMENT", 221, 241], ["Methods", "TREATMENT", 253, 260], ["All data", "TEST", 260, 268]]], ["Websites and public information stands at associated hospitals are the primary communication channels to inform the scientific community, research participants, and the general public.", [["participants", "SPECIES", 147, 159]]], ["In addition to such information, biobanks at times provide links to external material such as support groups for patients with specific diseases, as in the case of the Alberta Prostate Cancer Registry & Biorepository (Canada) for example [28].", [["Prostate Cancer", "DISEASE", 176, 191], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["specific diseases", "PROBLEM", 127, 144], ["Prostate", "ANATOMY", 176, 184], ["Cancer", "OBSERVATION", 185, 191]]], ["Some biobanks\u2014like the 100,000 Genomes Project, UK [29], for instance\u2014also provide real-life participant stories to explain what motivated participants to donate to the biobank and how they experienced the donation process.", [["participants", "SPECIES", 139, 151]]], ["Similarly, in Austria, the Biobank Graz, maintains a wide portfolio of public relation activities such as open nights, guided tours, and internship programs for pupils [32].Compliance ::: ResultsBiobanks operate under a variety of national as well international legal provisions, ranging from laws ensuring the protection of research subjects, to norms about the use of embryos, germ cells and genetic material [33].", [["embryos", "ANATOMY", 370, 377], ["germ cells", "ANATOMY", 379, 389], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 370, 377], ["germ cells", "CELL", 379, 389], ["germ cells", "CELL_TYPE", 379, 389]]], ["Ethics review of research protocols align the operations of biobanks to such legal rules, but it does not exhaust compliance with complex legislation in areas such as, for instance, data protection.", [["research protocols", "TREATMENT", 17, 35], ["the operations of biobanks", "TREATMENT", 42, 68]]], ["At the European level, a prominent example of such legislation is the General Data Protection Regulation (GDPR) [34].", [["prominent", "OBSERVATION_MODIFIER", 25, 34]]], ["Typically, such committees consist of experts and professionals and they rarely include research participants.", [["participants", "SPECIES", 97, 109]]], ["In other cases, in addition to advisory committees, an independent ethics committee comprised of research and ethics professionals, and sometimes lay members, assesses research protocols and advises on ethical issues.", [["research protocols", "TREATMENT", 168, 186]]], ["For example, at Radboud UMC Biobank, a patient representative is a member of the medical-ethical review board [38].", [["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46]]], ["Some ethics committees also provide ethics advice regarding research strategies and organizational management.", [["research strategies", "TREATMENT", 60, 79], ["organizational management", "TREATMENT", 84, 109]]], ["Such committees are usually comprised of research professionals; participant representatives are rarely part of them.External review ::: ResultsBiobanks receive ethical approval from a research ethics committee prior to their launch.", [["ethical approval", "TREATMENT", 161, 177]]], ["External ethical review is also needed for research projects intending to use a biobank\u2019s resources.", [["a biobank\u2019s resources", "TREATMENT", 78, 99]]], ["This is provided by independent research ethics review committees that are not linked to the biobank.Internal procedures ::: ResultsAll biobanks included in our study collect samples and data following an informed consent process.", [["our study", "TEST", 157, 166]]], ["The description of such policies is generally coupled with information about the IT infrastructure employed for data management.", [["data management", "TREATMENT", 112, 127]]], ["Privacy preserving measures describe how donor privacy is protected including how data are anonymized or pseudonymized.Internal procedures ::: ResultsFlow charts are commonly used tools to explain the organization and the activities of the biobank, or to illustrate relevant processes such as how to inform participants about what to expect from participating in biobank activities, or how to request access to data and samples.", [["participants", "SPECIES", 307, 319], ["Privacy preserving measures", "TREATMENT", 0, 27]]], ["Further, biobanks maintain an active quality system to adhere to international quality standards such as the International Organization for Standardization (ISO) 9000 standards for quality management and the new ISO 20387 standard for biobanking.", [["Standardization (ISO)", "TREATMENT", 140, 161], ["quality management", "TREATMENT", 181, 199], ["active", "OBSERVATION_MODIFIER", 30, 36]]], ["Adherence to such quality standards and quality evaluation by different external organizations is often expected by funding organizations, researchers and partners from industry [47].", [["quality evaluation", "TEST", 40, 58]]], ["For example, Radboud UMC Biobank, the Netherlands, issued a wide range of standard operating procedures regarding sample collection and processing [49].Partnership ::: ResultsOur findings suggest that smaller biobanks often enter into collaboration agreements, or affiliate themselves with other biobanks or research institutions.", [["sample", "ANATOMY", 114, 120], ["standard operating procedures", "TREATMENT", 74, 103], ["sample collection", "TEST", 114, 131]]], ["The aims of such partnerships are multiple.", [["multiple", "OBSERVATION_MODIFIER", 34, 42]]], ["By federating with other organizations, small biobanks can follow more efficient workflows; they can adopt more robust best practices; they can lower costs; and acquire access to bigger repositories of biological material or to larger databases\u2014which is crucial in the case of rare disease for instance [50].Partnership ::: ResultsSome biobanks become members of professional organizations or large networks of biobanks that can increase the value of collected biospecimen.", [["biospecimen", "ANATOMY", 461, 472], ["biospecimen", "CANCER", 461, 472], ["biological material", "TREATMENT", 202, 221], ["rare disease", "PROBLEM", 277, 289]]], ["For example, the Canadian Tissue Repository Network, ensures rigorous quality control on all shared samples and acts as a capacity-building platform for the Canadian biobanking community [51].", [["Tissue", "TISSUE", 26, 32], ["samples", "CANCER", 100, 107]]], ["Analogously, in Europe, BBMRI supports it members in the areas of quality management, data storage and compliance with data protection laws and other relevant regulatory frameworks [52].LimitationsAs this study focuses on European and Canadian biobanks, the findings might not be generalizable beyond these geographical areas.", [["quality management", "TREATMENT", 66, 84], ["this study", "TEST", 200, 210], ["might not be", "UNCERTAINTY", 267, 279]]], ["It is thus possible that other types of biobanks might adopt additional or different governance solutions.", [["biobanks", "TREATMENT", 40, 48], ["different governance solutions", "TREATMENT", 75, 105], ["thus possible", "UNCERTAINTY", 6, 19]]], ["Still verifying the representativeness of our findings exceeds the scope of this study.", [["this study", "TEST", 76, 86]]], ["Hence, these did not contribute to the catalog above.DiscussionThe present study provides insight into the preparedness of biobanks in terms of governance mechanisms and structures for future data intense research.DiscussionAccording to our analysis, all the reviewed biobanks make at least some attempt at being transparent about their governance structures and mechanisms.", [["The present study", "TEST", 63, 80], ["our analysis", "TEST", 237, 249]]], ["However, there is substantial variability in just how much information biobanks provide, both in terms of the number and kind of reported governance mechanisms, and in the amount of detail provided.", [["substantial", "OBSERVATION_MODIFIER", 18, 29], ["variability", "OBSERVATION_MODIFIER", 30, 41]]], ["This finding is consistent with other studies.", [["other studies", "TEST", 32, 45], ["consistent with", "UNCERTAINTY", 16, 31]]], ["A 2005 comparative study taking into account four large-scale population biobanks, shows considerable efforts in establishing legitimacy by means of advisory boards and independent ethical review [3].", [["comparative study", "TEST", 7, 24]]], ["Similarly Salter and Jones, in a paper on the UK Biobank, speak of a \u201cpolitics of legitimation accompanying the emergence of population-based genetic databases\u201d [55].", [["Salter", "OBSERVATION", 10, 16]]], ["Our study shows that this effort extends beyond large-scale biobanks.DiscussionDespite such focus on legitimation-building mechanisms, only scant information is provided about actual accountability mechanisms adopted by the biobanks.", [["Our study", "TEST", 0, 9], ["large-scale biobanks", "TREATMENT", 48, 68]]], ["In this respect, communication activities could offer opportunities to increase accountability in at least two senses: on the one hand, good communication can pre-empt the informational needs of stakeholders, possibly also reducing the need of proper, formal accountability mechanisms themselves; on the other hand, physical presence at information boots (in hospitals, public engagement events or scientific conferences) could enable a biobank to make itself available for questions by interested people.", [["people", "ORGANISM", 498, 504], ["people", "SPECIES", 498, 504]]], ["Internal procedures provide\u2014among other things\u2014information about the governance architecture of biobanks.", [["Internal procedures", "TREATMENT", 0, 19]]], ["This kind of information contributes to accountability directly in that it allows stakeholders to identify who, or which office or committee is responsible for a given activity, for instance, privacy protection or data sharing.", [["privacy protection", "TREATMENT", 192, 210]]], ["However, none of the reviewed biobanks offers clear indications as to how the organization renders account of its operations to interested stakeholders and the public in general.", [["its operations", "TREATMENT", 110, 124]]], ["Similarly, we have not found direct evidence of the translation of legal and compliance regulation into accountability procedures.", [["accountability procedures", "TREATMENT", 104, 129]]], ["Rather we found referencing of legislation or regulation.", [["legislation", "OBSERVATION", 31, 42]]], ["This may reflect a lag between the legal requirements and the scholarly debate on one side, and the implementation of appropriate measures on the other\u2014with the methodological caveat that this may be due to insufficient communication about such mechanisms.DiscussionIn 2016, the Global Alliance for Genomics and Health has issued its accountability policy defyining best practices for stakeholders.", [["a lag between the legal requirements", "PROBLEM", 17, 53], ["may reflect", "UNCERTAINTY", 5, 16], ["lag", "OBSERVATION_MODIFIER", 19, 22]]], ["This policy is intended to promote responsible data sharing and emphasizes oversight mechanisms to ensure effective monitoring and responding to non-complinace [56].", [["effective monitoring", "TEST", 106, 126]]], ["In the near future however, with the anticipated exponential growth of data stored and circulated for research purposes, oversight will arguably have to become a more complex type of activity.", [["research purposes", "TEST", 102, 119], ["more complex", "OBSERVATION_MODIFIER", 162, 174]]], ["With these developments in mind, two of us (AB and EV) have developed a systemic oversight framework that offers high-order principles of adaptive governance to ensure appropriate oversight vis-\u00e0-vis the growing scale and the novel challenges of big data health research [12, 14, 57].", [["adaptive governance", "TREATMENT", 138, 157]]], ["This framework is composed of six principles: adaptation, flexibility, inclusiveness, responsiveness, reflexivity, and monitoring (AFIRRM).", [["inclusiveness", "PROBLEM", 71, 84]]], ["Monitoring refers to the capacity to detect new potential threats and harms in emerging forms of data collection, use and distribution.", [["the capacity", "TEST", 21, 33]]], ["Responsiveness mechanisms aim at repairing or remedying to the extent possible to occurring harms, such as privacy breaches or data misuses.", [["repairing", "TREATMENT", 33, 42]]], ["The long-term objective of AFIRRM is to offer a blueprint for the development of a variety of oversight mechanisms fostering the emergence of an adaptive approach to the governance of big data health research.DiscussionBiobanks are one of the central actors in the rapidly evolving field of large-scale, data-driven health research.", [["an adaptive approach", "TREATMENT", 142, 162], ["long-term", "OBSERVATION_MODIFIER", 4, 13], ["large", "OBSERVATION_MODIFIER", 291, 296]]], ["We also stressed, however, that there is room for improving biobank governance especially in making accountability mechanisms more visible and adopting a systemic approach to oversight activities.", [["a systemic approach", "TREATMENT", 152, 171]]]], "302a8847f2878b3d8d28e5a9a15e8cbd5e21aaab": [["as well as different protocols around release from the workplace to be quarantined.", [["different protocols", "TREATMENT", 11, 30]]]]}